
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="us-ascii"?-->

  <!-- XBRL Document Created with XML Edge from P3 Data Systems -->
  
    <title>HUMANIGEN, INC</title>
    <meta content="text/html" http-equiv="Content-Type">
  
  
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2020-12-31" unitref="Usd" id="fact-identifier-0" xsi:nil="true" inside-table="false" data-original-id="Fact_0000000000619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>
          <span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2021-12-31" unitref="Usd" id="fact-identifier-1" xsi:nil="true" inside-table="false" data-original-id="Fact_0000000000620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>
          <span><ix:nonnumeric name="dei:EntityCentralIndexKey" contextref="From2021-01-01to2021-12-31" id="fact-identifier-2" inside-table="false" data-original-id="Fact_0000000000621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001293310</ix:nonnumeric></span>
          <span><ix:nonnumeric name="dei:AmendmentFlag" contextref="From2021-01-01to2021-12-31" id="fact-identifier-3" inside-table="false" data-original-id="Fact_0000000000622" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
          <span><ix:nonnumeric name="dei:DocumentFiscalPeriodFocus" contextref="From2021-01-01to2021-12-31" id="fact-identifier-4" inside-table="false" data-original-id="Fact_0000000000623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
          <ix:nonnumeric id="Fact_0000000000586">2022-12-31</ix:nonnumeric>
          <ix:nonnumeric id="Fact_0000000000587">2037-12-31</ix:nonnumeric>
          <ix:nonnumeric id="Fact_0000000000589">2028-12-31</ix:nonnumeric>
          <ix:nonnumeric id="Fact_0000000000590">2041-12-31</ix:nonnumeric>
          <ix:nonnumeric id="Fact_0000000000593">2022-12-31</ix:nonnumeric>
          <ix:nonnumeric id="Fact_0000000000594">2035-12-31</ix:nonnumeric>
        </ix:hidden>
        <ix:references>
          <xbrll:schemaref xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="hgen-20211231.xsd" xlink:type="simple"></xbrll:schemaref>
        </ix:references>
        <ix:resources>
          <i:context id="AsOf2016-06-30_custom_SavantWarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">hgen:SavantWarrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2016-06-30</i:instant>
            </i:period>
          </i:context>
          <i:unit id="Shares">
            <i:measure>i:shares</i:measure>
          </i:unit>
          <i:context id="AsOf2013-06-19_us-gaap_WarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2013-06-19</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2015-12-04_us-gaap_WarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2015-12-04</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-07-30_custom_SavantWarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">hgen:SavantWarrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-07-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-04-22_us-gaap_WarrantMember_custom_InvestorRelationServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:InvestorRelationServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-04-22</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-05-20_us-gaap_WarrantMember_custom_InvestorRelationServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:InvestorRelationServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-05-20</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-05-20_us-gaap_WarrantMember_custom_ManufacturingConsultingServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:ManufacturingConsultingServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-05-20</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-09-14_us-gaap_WarrantMember_custom_InvestorRelationServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:InvestorRelationServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-09-14</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-09-11">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2020-09-11</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-09-11_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-09-11</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-09-11_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-09-11</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:unit id="Usd">
            <i:measure>iso4217:USD</i:measure>
          </i:unit>
          <i:context id="From2021-01-01to2021-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ControlledEquityOfferingSmSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:ControlledEquityOfferingSmSalesAgreementMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">hgen:CantorFitzgeraldAndCoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2022-01-01to2022-02-28_custom_ControlledEquityOfferingSmSalesAgreementMember_us-gaap_SubsequentEventMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:ControlledEquityOfferingSmSalesAgreementMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2022-01-01</i:startdate>
              <i:enddate>2022-02-28</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-06-01to2020-06-30_us-gaap_PrivatePlacementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-06-01</i:startdate>
              <i:enddate>2020-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:unit id="Usdpershares">
            <i:divide>
              <i:unitnumerator>
                <i:measure>iso4217:USD</i:measure>
              </i:unitnumerator>
              <i:unitdenominator>
                <i:measure>i:shares</i:measure>
              </i:unitdenominator>
            </i:divide>
          </i:unit>
          <i:context id="AsOf2020-06-02_us-gaap_PrivatePlacementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-06-02</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2018-09-20to2020-06-30_us-gaap_ConvertibleNotesPayableMember_custom_NonQualifiedFinancingMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:NonQualifiedFinancingMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2018-09-20</i:startdate>
              <i:enddate>2020-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2019-04-24to2020-04-30_custom_ConvertibleNotesPayableTwoMember_custom_NonQualifiedFinancingMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:NonQualifiedFinancingMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2019-04-24</i:startdate>
              <i:enddate>2020-04-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-04-01to2020-04-02_custom_ConvertibleNotesPayableTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-04-01</i:startdate>
              <i:enddate>2020-04-02</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2016-06-30_us-gaap_NotesPayableOtherPayablesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2016-06-30</i:instant>
            </i:period>
          </i:context>
          <i:unit id="Pure">
            <i:measure>i:pure</i:measure>
          </i:unit>
          <i:context id="AsOf2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-11-12</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-04-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-09-19_custom_ConvertiblePromissoryNoteMember_custom_BlackHorseCapitalLPMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:ConvertiblePromissoryNoteMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BlackHorseCapitalLPMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-09-19</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-08-31_us-gaap_NotesPayableOtherPayablesMember_custom_BridgeNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-08-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-04-23_custom_ConvertibleNotesPayableTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-04-23</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-06-28_custom_BridgeNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-06-28</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-06-28_custom_BridgeNotesMember_custom_NomisBayLtdMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:NomisBayLtdMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-06-28</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-06-28_custom_BridgeNotesMember_custom_CameronDurrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:CameronDurrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-06-28</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-06-28_custom_BridgeNotesMember_srt_ChiefExecutiveOfficerMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-06-28</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_CameronDurrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">hgen:CameronDurrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-11-12</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_ChevalHoldingsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hgen:ChevalHoldingsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-11-12</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_ChevalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">hgen:ChevalMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-04-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_NomisBayMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">hgen:NomisBayMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-04-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-03-10</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_LicenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_LicenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-03-01</i:startdate>
              <i:enddate>2021-03-10</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-03-01</i:startdate>
              <i:enddate>2021-03-10</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-04-01to2020-04-22_us-gaap_WarrantMember_custom_InvestorRelationServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:InvestorRelationServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-04-01</i:startdate>
              <i:enddate>2020-04-22</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-05-01to2020-05-20_us-gaap_WarrantMember_custom_InvestorRelationServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:InvestorRelationServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-05-01</i:startdate>
              <i:enddate>2020-05-20</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-09-01to2020-09-14_us-gaap_WarrantMember_custom_InvestorRelationServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:InvestorRelationServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-09-01</i:startdate>
              <i:enddate>2020-09-14</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_EmployeeAndNonemployeeStockOptionsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hgen:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_WarrantsToPurchaseCommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hgen:WarrantsToPurchaseCommonStockMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_EmployeeAndNonemployeeStockOptionsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hgen:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_WarrantsToPurchaseCommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">hgen:WarrantsToPurchaseCommonStockMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_ConvertibleDebtMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_KpmAndTelconMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">hgen:KpmAndTelconMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-03-19_custom_ConvertibleNotesPayableThreeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-03-19</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2018-09-01to2018-09-19_custom_ConvertiblePromissoryNoteMember_custom_BlackHorseCapitalLPMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:ConvertiblePromissoryNoteMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BlackHorseCapitalLPMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2018-09-01</i:startdate>
              <i:enddate>2018-09-19</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2019-04-24to2020-04-30_custom_ConvertibleNotesPayableTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2019-04-24</i:startdate>
              <i:enddate>2020-04-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-03-14to2020-06-30_custom_ConvertibleNotesPayableThreeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-03-14</i:startdate>
              <i:enddate>2020-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_BridgeNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-06-01to2020-06-30_custom_BridgeNotesMember_custom_BonaFideFinancingTransactionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:BonaFideFinancingTransactionMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-06-01</i:startdate>
              <i:enddate>2020-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2018-09-20to2020-04-30_custom_BridgeNotesMember_custom_BonaFideFinancingMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:BonaFideFinancingMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2018-09-20</i:startdate>
              <i:enddate>2020-04-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-04-01to2020-04-30_custom_AdvanceNotesMember_custom_ConvertibleNotesPayables2018Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:AdvanceNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayables2018Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-04-01</i:startdate>
              <i:enddate>2020-04-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-04-01to2020-04-30_custom_AdvanceNotesMember_custom_ConvertibleNotesPayableTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:AdvanceNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-04-01</i:startdate>
              <i:enddate>2020-04-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_AdvanceNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:AdvanceNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_ConvertibleNotesPayableThreeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_SecuredTermLoanFacilityMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_NotesPayableOtherPayablesMember_us-gaap_ConvertibleNotesPayableMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_ConvertibleNotesPayableTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-04-30_us-gaap_ConvertibleNotesPayableMember_custom_NonQualifiedFinancingMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:NonQualifiedFinancingMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-04-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-04-30_custom_ConvertibleNotesPayableTwoMember_custom_NonQualifiedFinancingMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:NonQualifiedFinancingMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-04-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-04-01to2020-04-02_custom_ConvertibleNotesPayableTwoMember_custom_ChevalDrDaleChappellMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">hgen:ChevalDrDaleChappellMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-04-01</i:startdate>
              <i:enddate>2020-04-02</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2019-11-01to2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2019-11-01</i:startdate>
              <i:enddate>2019-11-12</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-03-01to2020-03-13_custom_ConvertibleNotesPayableThreeMember_custom_TrancheOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:VestingAxis">hgen:TrancheOneMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-03-01</i:startdate>
              <i:enddate>2020-03-13</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-03-01to2020-03-19_custom_ConvertibleNotesPayableThreeMember_custom_TrancheTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:VestingAxis">hgen:TrancheTwoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-03-01</i:startdate>
              <i:enddate>2020-03-19</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-04-01to2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:BridgeNotesMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">hgen:NovemberBridgeNotesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-04-01</i:startdate>
              <i:enddate>2020-04-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-03-13_custom_ConvertibleNotesPayableThreeMember_custom_TrancheOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:VestingAxis">hgen:TrancheOneMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-03-13</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-03-19_custom_ConvertibleNotesPayableThreeMember_custom_TrancheTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:VestingAxis">hgen:TrancheTwoMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-03-19</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ConvertibleNotesPayableThreeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ConvertibleNotesPayableThreeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">hgen:ConvertibleNotesPayableThreeMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2016-06-01to2016-06-30_custom_SavantWarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">hgen:SavantWarrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2016-06-01</i:startdate>
              <i:enddate>2016-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_EquityIncentivePlanTwentyTwentyMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">hgen:EquityIncentivePlanTwentyTwentyMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-05-01to2020-05-20_us-gaap_WarrantMember_custom_ManufacturingConsultingServicesMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">hgen:ManufacturingConsultingServicesMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-05-01</i:startdate>
              <i:enddate>2020-05-20</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-06-30">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2021-06-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2022-02-16">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2022-02-16</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_KpmAndTelconMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">hgen:KpmAndTelconMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-10-01to2020-12-31_custom_KpmAndTelconMember_custom_KpmAndTelconMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">hgen:KpmAndTelconMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-10-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-04-01to2021-06-30_custom_KpmAndTelconMember_custom_KpmAndTelconMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">hgen:KpmAndTelconMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-04-01</i:startdate>
              <i:enddate>2021-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-03-29_custom_SecuredTermLoanFacilityMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-03-29</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember_custom_SecondTrancheMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:SecondTrancheMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-03-10</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember_custom_SecondTrancheMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:SecondTrancheMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-03-10</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember_custom_ThirdTrancheMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">hgen:ThirdTrancheMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-03-10</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-03-01</i:startdate>
              <i:enddate>2021-03-10</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_SecuredTermLoanFacilityMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">hgen:SecuredTermLoanFacilityMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-04-01to2021-09-30_custom_EversanaAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:LitigationCaseAxis">hgen:EversanaAgreementMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-04-01</i:startdate>
              <i:enddate>2021-09-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-12-01to2021-12-17_custom_AvidArbitrationMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">hgen:AvidArbitrationMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-12-01</i:startdate>
              <i:enddate>2021-12-17</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-09-11_custom_EquityPlan2020Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">hgen:EquityPlan2020Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-09-11</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-07-27_custom_EquityPlan2020Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">hgen:EquityPlan2020Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-07-27</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_EquityPlan2020Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">hgen:EquityPlan2020Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-09-01to2020-09-17_custom_UnderwrittenPublicOffering2020Member_custom_JPMorganSecuritiesLlcAndJefferiesLlcMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:UnderwrittenPublicOffering2020Member</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">hgen:JPMorganSecuritiesLlcAndJefferiesLlcMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-09-01</i:startdate>
              <i:enddate>2020-09-17</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-03-01to2021-03-30_custom_UnderwrittenPublicOffering2021Member_custom_JefferiesLlcMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:UnderwrittenPublicOffering2021Member</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">hgen:JefferiesLlcMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-03-01</i:startdate>
              <i:enddate>2021-03-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-09-01to2020-09-17_custom_PartialUnderwrittenPublicOffering2020Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:PartialUnderwrittenPublicOffering2020Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-09-01</i:startdate>
              <i:enddate>2020-09-17</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-03-01to2021-05-03_custom_UnderwrittenPublicOffering2021Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:UnderwrittenPublicOffering2021Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-03-01</i:startdate>
              <i:enddate>2021-05-03</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_EquityIncentivePlanTwentyTwelveMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">hgen:EquityIncentivePlanTwentyTwelveMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_EquityIncentivePlanTwentyTwentyMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">hgen:EquityIncentivePlanTwentyTwentyMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000440" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000448" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000458" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000442" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000450" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000444" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000452" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000454" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000446" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000456" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000462" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000466" torefs="FN_619b843e2c08a27c7fd81efc"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000460" torefs="FN_621627d1c1256b3ad4a9b4a2"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000464" torefs="FN_621627d1c1256b3ad4a9b4a2"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000468" torefs="FN_621627d1c1256b3ad4a9b4a2"></ix:relationship>
          <i:context id="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars16.90To16.90Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars1.90To2.25Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars3.33Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeDollars3.33Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars3.50To9.65Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars16.07Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeDollars16.07Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars16.90To20.00Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars20.68Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeDollars20.68Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars16.90To16.90Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars1.90To2.25Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ExercisePriceRangeDollars3.33Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeDollars3.33Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars3.50To9.65Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ExercisePriceRangeDollars16.07Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeDollars16.07Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeFromDollars16.90To20.00Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ExercisePriceRangeDollars20.68Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">hgen:ExercisePriceRangeDollars20.68Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-12-31_us-gaap_InternalRevenueServiceIRSMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_InternalRevenueServiceIRSMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_InternalRevenueServiceIRSMember_us-gaap_ResearchMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_StateAndLocalJurisdictionMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_StateAndLocalJurisdictionMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_us-gaap_ResearchMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_us-gaap_ResearchMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_KiteAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">hgen:KiteAgreementMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_KiteAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">hgen:KiteAgreementMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-06-30_custom_MayoAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">hgen:MayoAgreementMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-09-01to2021-09-30">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:startdate>2021-09-01</i:startdate>
              <i:enddate>2021-09-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-09-01to2020-09-30">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
            </i:entity>
            <i:period>
              <i:startdate>2020-09-01</i:startdate>
              <i:enddate>2020-09-30</i:enddate>
            </i:period>
          </i:context>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000255" torefs="FN_621627d1c1256b3ad4a9b49f"></ix:relationship>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkrole="http://www.xbrl.org/2003/role/link" order="1" fromrefs="Fact_0000000000258" torefs="FN_621627d1c1256b3ad4a9b49d"></ix:relationship>
          <i:context id="From2022-02-01to2022-02-24_custom_AllianceTexasHoldingCaseMember_custom_TwoPlaintiffsMember_us-gaap_SubsequentEventMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:LitigationCaseAxis">hgen:AllianceTexasHoldingCaseMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">hgen:TwoPlaintiffsMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2022-02-01</i:startdate>
              <i:enddate>2022-02-24</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2022-02-01to2022-02-24_custom_AllianceTexasHoldingCaseMember_srt_MinimumMember_custom_TwoPlaintiffsMember_us-gaap_SubsequentEventMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="srt:LitigationCaseAxis">hgen:AllianceTexasHoldingCaseMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">hgen:TwoPlaintiffsMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2022-02-01</i:startdate>
              <i:enddate>2022-02-24</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-03-31_custom_KpmAndTelconMember_custom_KpmAndTelconMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">hgen:KpmAndTelconMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-03-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ControlledEquityOfferingSmSalesAgreementMember_custom_CantorFitzgeraldAndCoMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:ControlledEquityOfferingSmSalesAgreementMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">hgen:CantorFitzgeraldAndCoMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-01-01</i:startdate>
              <i:enddate>2021-12-31</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-06-01to2021-06-30_custom_SavantWarrantMember_us-gaap_SubsequentEventMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">hgen:SavantWarrantMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-06-01</i:startdate>
              <i:enddate>2021-06-30</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-09-11_custom_EquityPlan2020Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">hgen:EquityPlan2020Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2020-01-01</i:startdate>
              <i:enddate>2020-09-11</i:enddate>
            </i:period>
          </i:context>
          <i:context id="From2021-05-01to2021-05-03_custom_UnderwrittenPublicOffering2021Member">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:UnderwrittenPublicOffering2021Member</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startdate>2021-05-01</i:startdate>
              <i:enddate>2021-05-03</i:enddate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ControlledEquityOfferingSmSalesAgreementMember_custom_CantorFitzgeraldAndCoMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001293310</i:identifier>
              <i:segment>
                <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">hgen:ControlledEquityOfferingSmSalesAgreementMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">hgen:CantorFitzgeraldAndCoMember</xbrldi:explicitmember>
                <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
        </ix:resources>
      </ix:header>
    </div>
    <div> <div style="width:100%; clear:both;"> <hr style="border-top:2pt solid #000000; width:100%; margin-left:0pt; text-align:left; "><hr style="border-top:1pt solid #000000; width:100%; margin-top:-5pt; margin-left:0pt; text-align:left; ">
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; "></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:14pt; text-align:center; margin-top:-10pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">UNITED STATES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:14pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">SECURITIES AND EXCHANGE COMMISSION</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">WASHINGTON, D.C. 20549</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td style="width:100%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:18pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">FORM </span><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-5" contextref="From2021-01-01to2021-12-31" name="dei:DocumentType" inside-table="true" data-original-id="Fact_0000000000001" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span> </p> </td> </tr> <tr class="even" style=""> <td style="width:100%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-12pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td colspan="2" style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(Mark One)</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-6" contextref="From2021-01-01to2021-12-31" name="dei:DocumentAnnualReport" format="ixt:booleantrue" inside-table="true" data-original-id="Fact_0000000000002" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span> </p> </td> <td style="width:94%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p> </td> </tr> <tr class="odd" style=""> <td colspan="2" style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">For the Fiscal Year Ended </span><span style="font-weight:bold; "><span style="font-weight:bold; "><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-7" contextref="From2021-01-01to2021-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" inside-table="true" data-original-id="Fact_0000000000005" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric id="fact-identifier-8" contextref="From2021-01-01to2021-12-31" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen" inside-table="true" data-original-id="Fact_0000000000003" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span>, <span><ix:nonnumeric id="fact-identifier-9" contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus" inside-table="true" data-original-id="Fact_0000000000004" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span></ix:nonnumeric></span></span></span></span> </p> </td> </tr> <tr class="even" style=""> <td colspan="2" style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Or</span> </p> </td> </tr> <tr class="odd" style=""> <td style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-10" contextref="From2021-01-01to2021-12-31" name="dei:DocumentTransitionReport" format="ixt:booleanfalse" inside-table="true" data-original-id="Fact_0000000000006" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span> </p> </td> <td style="width:94%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p> </td> </tr> <tr class="even" style=""> <td colspan="2" style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Commission File Number: </span><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-11" contextref="From2021-01-01to2021-12-31" name="dei:EntityFileNumber" inside-table="true" data-original-id="Fact_0000000000007" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-35798</ix:nonnumeric></span></span> </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td style="width:100%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:24pt; text-align:center; margin-top:2pt; margin-bottom:0pt; "><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-12" contextref="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName" inside-table="true" data-original-id="Fact_0000000000008" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">HUMANIGEN, INC</ix:nonnumeric></span></span><span style="font-weight:bold; ">.</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:100%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(Exact name of registrant as specified in its charter) </p> </td> </tr> <tr class="odd" style=""> <td style="width:100%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-3pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style=""> <td style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-18pt; text-indent:36pt; margin-bottom:0pt; "><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-13" contextref="From2021-01-01to2021-12-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" inside-table="true" data-original-id="Fact_0000000000009" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span> </p> </td> <td style="width:14%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-9pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-18pt; text-indent:36pt; margin-bottom:0pt; "><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-14" contextref="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber" inside-table="true" data-original-id="Fact_0000000000010" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77-0557236</ix:nonnumeric></span></span> </p> </td> </tr> <tr class="even" style=""> <td style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-10pt; text-indent:36pt; margin-bottom:0pt; ">(State or other jurisdiction of </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; ">incorporation or organization) </p> </td> <td style="width:14%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-5pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-10pt; text-indent:36pt; margin-bottom:0pt; ">(I.R.S. Employer</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; ">Identification No.) </p> </td> </tr> <tr class="odd" style=""> <td colspan="3" style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; text-indent:36pt; margin-bottom:0pt; "><span style="font-weight:bold; "><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-15" contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1" inside-table="true" data-original-id="Fact_0000000000011" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">830 Morris Turnpike, 4<sup><span style="font-weight:bold; ">th</span></sup> Floor</ix:nonnumeric></span></span></span> </p> </td> </tr> <tr class="even" style=""> <td colspan="3" style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-16" contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown" inside-table="true" data-original-id="Fact_0000000000012" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Short Hills</ix:nonnumeric></span></span><span style="font-weight:bold; ">, </span><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-17" contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressStateOrProvince" inside-table="true" data-original-id="Fact_0000000000013" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NJ</ix:nonnumeric></span></span><span style="font-weight:bold; "></span><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-18" contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode" inside-table="true" data-original-id="Fact_0000000000014" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">07078</ix:nonnumeric></span></span> </p> </td> </tr> <tr class="odd" style=""> <td colspan="3" style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(Address of Principal Executive Offices) (Zip Code) </p> </td> </tr> <tr class="even" style=""> <td colspan="3" style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(</span><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-19" contextref="From2021-01-01to2021-12-31" name="dei:CityAreaCode" inside-table="true" data-original-id="Fact_0000000000015" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">973</ix:nonnumeric></span></span><span style="font-weight:bold; ">) </span><span style="font-weight:bold; "><span><ix:nonnumeric id="fact-identifier-20" contextref="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber" inside-table="true" data-original-id="Fact_0000000000016" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200-3100</ix:nonnumeric></span></span> </p> </td> </tr> <tr class="odd" style=""> <td colspan="3" style="width:43%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(Registrants Telephone Number, Including Area Code)</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Securities registered pursuant to Section 12(b) of the Act: </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-3pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; font-weight:bold; ">Title of each class</span> </p> </td> <td style="width:20%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-3pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; font-weight:bold; ">Trading Symbol(s)</span> </p> </td> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-3pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; font-weight:bold; ">Name of each exchange on which registered</span> </p> </td> </tr> <tr class="even" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-21" contextref="From2021-01-01to2021-12-31" name="dei:Security12bTitle" inside-table="true" data-original-id="Fact_0000000000017" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock</ix:nonnumeric></span> </p> </td> <td style="width:20%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-22" contextref="From2021-01-01to2021-12-31" name="dei:TradingSymbol" inside-table="true" data-original-id="Fact_0000000000018" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">HGEN</ix:nonnumeric></span> </p> </td> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">The <span><ix:nonnumeric id="fact-identifier-23" contextref="From2021-01-01to2021-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" inside-table="true" data-original-id="Fact_0000000000019" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nasdaq</ix:nonnumeric></span> Stock Market LLC </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; ">Securities registered pursuant to Section 12(g) of the Act: None</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  <span><ix:nonnumeric id="fact-identifier-24" contextref="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" data-original-id="Fact_0000000000020" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  <span><ix:nonnumeric id="fact-identifier-25" contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers" inside-table="false" data-original-id="Fact_0000000000021" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span><ix:nonnumeric id="fact-identifier-26" contextref="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus" inside-table="false" data-original-id="Fact_0000000000022" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>  No </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span><ix:nonnumeric id="fact-identifier-27" contextref="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent" inside-table="false" data-original-id="Fact_0000000000023" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>  No </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company" in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style=""> <td style="width:20%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-28" contextref="From2021-01-01to2021-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" inside-table="true" data-original-id="Fact_0000000000024" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Large accelerated filer</ix:nonnumeric></span>  </p> </td> <td style="width:1%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accelerated filer  </p> </td> <td style="width:1%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:18%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Non-accelerated filer  </p> </td> <td style="width:1%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:22%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Smaller reporting company <span><ix:nonnumeric id="fact-identifier-29" contextref="From2021-01-01to2021-12-31" name="dei:EntitySmallBusiness" format="ixt:booleantrue" inside-table="true" data-original-id="Fact_0000000000025" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:22%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Emerging growth company <span><ix:nonnumeric id="fact-identifier-30" contextref="From2021-01-01to2021-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt:booleanfalse" inside-table="true" data-original-id="Fact_0000000000026" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span> </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant has filed a report on and attestation to its managements assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes  No <span><ix:nonnumeric id="fact-identifier-31" contextref="From2021-01-01to2021-12-31" name="dei:IcfrAuditorAttestationFlag" format="ixt:booleanfalse" inside-table="false" data-original-id="Fact_0000000000027" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No <span><ix:nonnumeric id="fact-identifier-32" contextref="From2021-01-01to2021-12-31" name="dei:EntityShellCompany" format="ixt:booleanfalse" inside-table="false" data-original-id="Fact_0000000000028" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">The aggregate market value of the registrants voting stock held by non-affiliates as of June 30, 2021, was approximately $<span><ix:nonfraction id="fact-identifier-33" contextref="AsOf2021-06-30" name="dei:EntityPublicFloat" unitref="Usd" decimals="0" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000029" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">710,884,199</ix:nonfraction></span> based on the closing price of $17.38 of the Common Stock of the registrant as reported on the Nasdaq Capital Market on such date. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the Registrant have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes. As of February 16, 2022, there were <span><ix:nonfraction id="fact-identifier-34" contextref="AsOf2022-02-16" name="dei:EntityCommonStockSharesOutstanding" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000030" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,329,177</ix:nonfraction></span> shares of the registrants Common Stock, par value $0.001 per share, outstanding. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; ">DOCUMENTS INCORPORATED BY REFERENCE</p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-35" contextref="From2021-01-01to2021-12-31" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000031" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> The definitive proxy statement relating to the registrants Annual Meeting of Stockholders to be held on June 9, 2022, is incorporated by reference in Part III to the extent described therein. </p></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;"> <hr style="border-top:1pt solid #000000; width:100%; margin-left:0pt; text-align:left; "><hr style="border-top:2pt solid #000000; width:100%; margin-top:-5pt; margin-left:0pt; text-align:left; ">
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; "></p> </div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Unless the context indicates otherwise, the terms Humanigen, we, us and our refer to Humanigen, Inc., and its consolidated subsidiaries. This report also may include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this report are the property of their respective owners. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">This Annual Report on Form 10-K contains statements that discuss future events or expectations, projections of results of operations or financial condition, trends in our business, business prospects and strategies and other forward-looking information. In some cases, you can identify forward-looking statements by words like may, will, should, expects, plans, anticipates, believes, estimates, predicts, intends, potential, alignment or continue or the negative of those words and other comparable words. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. These forward-looking statements may relate to, among other things, our expectations regarding: our beliefs as to the potential benefits of lenzilumab as a treatment for hospitalized COVID-19 patients; the timeline for announcement of release of topline results from the ACTIV-5/BET-B study being conducted by the National Institutes of Health; our efforts and potential timeline to make future regulatory submissions in respect of potential emergency use authorization or other marketing authorization or approval from applicable regulatory agencies in the United States, United Kingdom, European Union and other foreign jurisdictions for commercial use of lenzilumab in COVID-19 patients; our other plans to initiate or participate in planned clinical trials and otherwise explore the effectiveness of lenzilumab and our other product candidates in our development portfolio as therapies for other inflammation and immune-oncology indications our opportunity to benefit from various regulatory incentives; expectations for our financial results, revenue, operating expenses and other financial measures in future periods; and the availability and adequacy of our sources of liquidity to satisfy our working capital needs, capital expenditures, and other liquidity requirements and continue as a going concern. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals (including EUA in the United States and CMA in the United Kingdom and European Union) and launch of any new pharmaceutical product; challenges associated with manufacturing and commercializing a biologic such as lenzilumab; and the outcome of pending or future litigation or arbitrations to which we are a party. These are only some of the factors that may affect the forward-looking statements contained in this Annual Report on Form 10-K. For a discussion identifying additional important factors that could cause actual results to vary materially from those anticipated in the forward-looking statements, see Managements Discussion and Analysis of Financial Condition and Results of Operations and Risk Factors in this Annual Report on Form 10-K. You should review these risk factors for a more complete understanding of the risks associated with an investment in our securities. However, we operate in a competitive and rapidly changing environment and new risks and uncertainties emerge, are identified or become apparent from time to time. It is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K. You should be aware that the forward-looking statements contained in this Annual Report on Form 10-K are based on our current views and assumptions. We undertake no obligation to revise or update any forward-looking statements made in this Annual Report on Form 10-K to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" id="toc" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:94%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:-12pt; margin-bottom:0pt; ">&nbsp;</p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; background-color:#FFFFFF; "> <td style="width:94%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; margin-bottom:0pt; ">&nbsp;</p> </td> <td style="width:6%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; margin-bottom:0pt; ">&nbsp;</p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </div>
<!-- Field: Include-Text; File: hgen_part2.htm; Date: 2022%2D02%2D28T20:53:10; Size: 0x000A7566; Options: XMLPreprocess -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">&nbsp;</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt">&nbsp;</span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="toc1"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Humanigen,&nbsp;Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form&nbsp;10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Index</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="width: 9%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 71%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 14%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Page</b></span></td>
    <td>&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Summary of Principal Risk Factors</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Part&nbsp;I&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;1.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p1i1" tabindex="18">Business</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;1A.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p1i1a" tabindex="18">Risk Factors</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;1B.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p1i1b" tabindex="18">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;2.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p1i2" tabindex="18">Properties</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;3.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p1i3" tabindex="18">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;4.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p1i4" tabindex="18">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Part&nbsp;II&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;5.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i5" tabindex="18">Market for the Companys Common
        Equity, Related Stockholder Matters and Issuer <br> Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;6.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i6" tabindex="18">Reserved</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;7.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i7" tabindex="18">Managements Discussion and
        Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;7A.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i7a" tabindex="18">Quantitative and Qualitative Disclosures
        About Market Risk</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;8.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i8" tabindex="18">Financial Statements and Supplementary
        Data</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;9.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i9" tabindex="18">Changes in and Disagreements with
        Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;9A.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i9a" tabindex="18">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;9B.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i9b" tabindex="18">Other Information</a> </span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item&nbsp;9C.&nbsp;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p2i9c" tabindex="18">Disclosure Regarding Foreign Jurisdictions
        that Prevent Inspections</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Part&nbsp;III</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;10.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p3i10" tabindex="18">Directors, Executive Officers and
        Corporate Governance</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;11.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p3i11" tabindex="18">Executive Compensation</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;12.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p3i12" tabindex="18">Security Ownership of Certain Beneficial
        Owners and Management and Related <br> Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;13.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p3i13" tabindex="18">Certain Relationships and Related
        Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;14.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p3i14" tabindex="18">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Part&nbsp;IV&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;15.&nbsp;</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p3i15" tabindex="18">Exhibits and Financial Statement
        Schedules</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Item&nbsp;16.</span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#p3i16" tabindex="18">Form 10-K Summary</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">69</span></td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#sig" tabindex="18">Signatures</a></span></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top; text-align: right">69</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>SUMMARY OF PRINCIPAL RISK FACTORS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>This summary briefly states the principal
risks and uncertainties facing our business that could affect our common stock, which are only a select portion of those risks. A more
complete statement of those risks and uncertainties is set forth in Part I, Item 1A - Risk Factors of this report. This
summary is qualified in its entirety by that more complete statement. You should carefully read the entire statement and Risk Factors
when considering the risks and uncertainties as part of your evaluation of an investment in our common stock.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">The U.S. Food and Drug Administration (FDA) declined our initial
        request for Emergency Use Authorization (EUA) for lenzilumab as a therapy for hospitalized patients with COVID-19. The Medicines
        and Healthcare Products Regulatory Agency (MHRA) also has not approved our application for marketing authorization of lenzilumab
        in this indication. We are continuing to pursue an authorization or approval for lenzilumabs use in hospitalized patients with
        COVID-19 in the United States (U.S.), United Kingdom (UK) and European Union (EU) but may not
        obtain one. </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Results from the ACTIV-5/BET-B (as defined below) trial will be critically important
        for the future viability of our development program of lenzilumab as a therapy for hospitalized patients with COVID-19. If the results
        from such trial are not confirmatory of the findings of the C-reactive protein level (CRP) subgroup from the LIVE-AIR study
        (as defined below), we would either conduct a new clinical trial of our own or abandon this development program altogether. Even if the
        results of such trial are favorable and are included in an amendment to our initial EUA application, there can be no assurance that FDA
        will agree with our efficacy claim or that we will obtain EUA.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We need to obtain additional financing to fund our operations and, if we are
        unable to obtain such financing, we may be unable to continue as a going concern. We expect the results of the ACTIV-5/BET-B (as defined
        below) trial to be important to investors in evaluating future financings we may undertake. If the results from such trial are not confirmatory
        of the findings of the CRP subgroup from the LIVE-AIR study (as defined below), our ability to obtain financing may be further impaired.
        </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Our commercial opportunity in COVID-19 or other indications may be reduced or
        eliminated if competing products for the same segment of patients that lenzilumab targets are authorized or approved.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Manufacturing efforts in respect of lenzilumab have been extremely costly and
        inefficient in producing treatments for use in our clinical development program or potential sale. We are subject to a multitude of manufacturing
        risks and rely completely on third parties to manufacture drug product and supply drug substance. We may not be able to obtain materials
        or supplies necessary to conduct clinical trials or, following requisite regulatory authorizations or approvals, to manufacture and sell
        our products.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Interim, top-line or preliminary data from our clinical trials that we announce
        may change as more patient data become available and are subject to audit and verification procedures that could result in material changes
        in the final data. Disclosure of such data by us, including data from the ACTIV-5/BET-B (as defined below) trial, or by our competitors
        could result in volatility in the price of shares of our common stock and dramatic spikes in trading volume.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">If an authorization or approval is granted for lenzilumab, we may be unable to
        accurately predict demand for lenzilumab or to produce sufficient quantities on a timely basis to meet demand.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">There can be no assurance that lenzilumab, even if approved or authorized, would
        ever become profitable, due to government or healthcare provider or payer interest and public perception regarding vaccines and treatments
        for COVID-19 related complications. </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We currently have no internal sales and marketing capabilities and will rely
        on third parties to market and sell lenzilumab if we attain authorization or approval for its commercialization, and any product candidates
        we may successfully develop. We or they may not be able to effectively market and sell any such product candidates.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We have a history of operating losses and we may never become profitable.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">The adoption of chimeric antigen receptor T-cell (CAR-T) therapies
        as the potential standard of care for treatment of certain cancers is uncertain, and dependent on the efforts of a limited number of market
        entrants, and if not adopted as anticipated, the market for lenzilumab or next-generation gene-edited CAR-T therapies may be limited or
        not develop.&nbsp;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Our business could target benefits from various regulatory incentives, such as
        orphan drug exclusivity, breakthrough therapy designation, fast track designation, and priority review, but we may not ultimately qualify
        for or benefit from these incentives. </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">There is a limited amount of information about us upon which investors can evaluate
        our product candidates and business.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">If our current and any future collaborators cease development efforts under our
        collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products,
        and we may never receive milestone payments or future royalties under these agreements.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We may experience delays in commencing or conducting our planned or contemplated
        clinical trials, which may render us unable to complete the development and commercialization of our product candidates. </span></td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Our product candidates are subject to extensive regulation, compliance with which
        is costly and time consuming, may cause unanticipated delays, and may prevent the receipt of the required approvals to commercialize our
        product candidates.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">If we fail to attract and retain key management and clinical development personnel,
        or if the attention of such personnel is diverted, we may be unable to successfully manage our business.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We may encounter difficulties in managing our growth and expanding our operations
        successfully, including internationally if lenzilumab is authorized or approved in any foreign country or market.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Currently pending, threatened or future litigation, arbitration, governmental
        proceedings or inquiries could result in material adverse consequences, including judgments or settlements.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We may not be able to obtain, maintain, enforce or protect our intellectual property
        rights in the U.S. and throughout the world.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Our insurance policies are expensive and protect us only from some business risks,
        which leaves us exposed to significant uninsured liabilities. </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Our executive officers, directors and principal stockholders, if they choose
        to act together, will continue to have the ability to significantly influence all matters submitted to stockholders for approval.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Raising additional funds by issuing equity securities will cause dilution to
        our existing stockholders.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="p1i1"></span>ITEM 1.&nbsp;&nbsp;BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><b>&nbsp;</b>We are a clinical stage biopharmaceutical
company, developing our portfolio of proprietary Humaneered<sup></sup> anti-inflammatory immunology and immuno-oncology monoclonal
antibodies. Our proprietary, patented Humaneered technology platform is a method for converting existing antibodies (typically murine)
into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. We have
developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied our Humaneered technology
to optimize them. Our lead product candidate, lenzilumab, and our other two product candidates, ifabotuzumab (iFab) and
HGEN005, are Humaneered monoclonal antibodies. Our Humaneered antibodies are closer to human antibodies than chimeric or conventionally
humanized antibodies and have a high affinity for their target. In addition, we believe our Humaneered antibodies offer further important
advantages, such as high potency, a slow off-rate and a lower likelihood to induce an inappropriate immune response or infusion related
reaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are focusing our efforts on the development
of our lead product candidate, lenzilumab. Lenzilumab is a monoclonal antibody that has been demonstrated to neutralize human granulocyte-macrophage
colony-stimulating factor (GM-CSF), a cytokine that we believe is of critical importance in the hyperinflammatory cascade,
sometimes referred to as cytokine release syndrome (CRS) or cytokine storm, associated with COVID-19, chimeric antigen receptor
T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD) associated with bone marrow transplants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Pipeline</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our product candidates are in the clinical stage
of development and require substantial time, resources, research and development, and regulatory approval prior to commercialization.
Our current pipeline is depicted below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image1.jpg" src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image1.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Lenzilumab</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">We are developing
lenzilumab for potential commercial use in several indications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td><span style="background-color: white">as a therapeutic for patients newly hospitalized with COVID-19;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td><span style="background-color: white">as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T)
        programs;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td><span style="background-color: white"><span style="background-color: white">for the prevention and/or treatment of acute graft versus
        host disease (aGvHD) associated with bone marrow transfers; and</span></span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td><span style="background-color: white">as a therapeutic for chronic myelomonocytic leukemia (CMML).</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our development programs in COVID-19, CAR-T and
aGvHD are complementary in that all are focused on preventing or reducing cytokine storm in those disease states. It is possible that
results observed from the Phase 3 trials in COVID-19 described below may be predictive of results in these other settings, which are also
characterized by cytokine storm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="background-color: white"><b><i>Lenzilumab
in COVID-19</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white"><i>Scientific
Rationale</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the emergence of the SARS-CoV-2 virus
that leads to the condition referred to as COVID-19, scientific literature suggested that GM-CSF is critical for the initiation of the
hyperinflammatory cascade experienced by many hospitalized patients characterized in the later and sometimes fatal stages by lung dysfunction
and, in many patients, multi-organ impairment. Multiple publications have pointed to GM-CSF as being a signature cytokine in this process,
with elevated GM-CSF levels correlated to poorer outcomes, including ventilator use, Intensive Care Unit (ICU) admission,
and mortality.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The severe clinical features associated with some
COVID-19 infections result from an inflammation-induced lung injury which may require supplemental oxygen through a nasal cannula, non-invasive
or invasive mechanical ventilation or Extra Corporeal Mechanical Oxygenation (ECMO) and sometimes ICU care. This lung injury
is a result of a hyperinflammatory dysregulation of the immune system and associated with cytokine storm. The lung injury that leads to
death is not directly related to the virus but appears to be a result of a hyper-reactive immune response to the virus triggering a cytokine
storm that can continue even after viral titers remain stable or even begin to fall.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">CRS is characterized
by an elevation of inflammatory cytokines resulting in fever, hypotension, capillary leak syndrome, pulmonary edema, disseminated intravascular
coagulation, respiratory failure, and Acute Respiratory Distress Syndrome (ARDS). The development of CRS as a direct result
of immune hyper-stimulation has been previously described in patients with autoimmune and lymphoproliferative diseases, as well as in
patients with B-cell malignancies receiving CAR-T therapy. Over the last several years, preclinical studies and correlative science from
clinical trials in CAR-T therapy have shed light on the pathophysiology, development, characterization, and management of CRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">CRS is also
characterized by activation of myeloid cells and release of inflammatory cytokines, including GM-CSF, monocyte chemoattractant protein-1
(MCP-1), macrophage inflammatory protein 1 (MIP-1), interferon gamma-induced protein 10 (IP-10), interleukin-6 (IL-6), and
interleukin-1 (IL-1). The cascade, once initiated, can quickly evolve into a cytokine storm, resulting in further activation, expansion
and trafficking of myeloid cells, leading to abnormal endothelial activation, increased vascular permeability, and disseminated intravascular
coagulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Data from <i>National
Scientific Review</i> (2020, Vol. 7, No. 6) titled Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in
severe COVID-19 patients, supports the hypothesis that GM-CSF induced cytokine storm immune mechanisms have contributed to patient
mortality with the current pandemic strain. We believe that there is increasing acceptance that this pathophysiology may be responsible
for worsening of clinical status and poor outcomes. The authors noted that steroid treatment in such cases has been disappointing in terms
of outcome but suggested that a monoclonal antibody that targets GM-CSF may prevent or curb the hyper-active immune response caused by
COVID-19 in this setting. Several publications point to GM-CSF as a so-called signature cytokine including the largest inflammatory
marker study in over 600 patients from a multicenter study in the UK. (Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients
with COVID-19 ARDS,&nbsp;deProst et al, <i>AJRCCM</i> Articles in Press., American Thoracic Society, August 31, 2020, 10.1164/rccm.202005-1885OC)
(The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome, Blot et al. <i>J Transl Med</i>
(2020) 18:457) (<span style="color: #131313">Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19, Openshaw
et al, <i>MedRxIV</i>, doi). In March 2021, </span><span style="color: #212121; background-color: white">Thwaites RS et al and several,
ISARIC4C (</span><span style="font-size: 10pt; color: #4D5156; background-color: white">Coronavirus Clinical Characterisation Consortium)</span>
<span style="color: #212121; background-color: white">investigators published Inflammatory profiles across the spectrum of disease
reveal a distinct role for GM-CSF in severe COVID-19, in <i>Science Immunology</i>, further confirming elevated GM-CSF levels are
correlated with COVID-19 mortality (doi: 10.1126/sciimmunol.abg9873. PMID: 33692097; PMCID: PMC8128298).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white"><i>Our Development
Program</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">In response
to the scientific literature, we designed and conducted a Phase 3 clinical trial of lenzilumab in newly hospitalized COVID-19 patients,
which we refer to as the LIVE-AIR study, to examine whether lenzilumabs neutralization of human GM-CSF could prevent
or reduce poor outcomes associated with COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The LIVE-AIR study enrolled 520 patients in 35
sites in the U.S. and Brazil who were at least 18 years of age; experienced blood oxygen saturation (SpO<sub>2</sub>) of
less than or equal to 94%; or required low-flow supplemental oxygen, or high-flow oxygen support, or non-invasive positive pressure ventilation;
and were hospitalized but did not require invasive mechanical ventilation (IMV). Following enrollment, subjects were randomized
to receive three infusions of either lenzilumab or placebo, with each infusion separated by eight hours over a 24-hour period. The primary
objective was to assess whether lenzilumab, in addition to standard of care, which included dexamethasone (or other steroids) and/or remdesivir,
could prevent or alleviate the immune-mediated cytokine storm and improve survival without ventilation (SWOV) (sometimes
referred to as ventilator-free survival). SWOV is a composite endpoint of time to death and time to IMV and SWOV is an important
composite clinical endpoint that measures mortality, mechanical ventilation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The LIVE-AIR Phase 3 randomized, double-blind,
placebo-controlled trial investigated the efficacy and safety of lenzilumab to assess the potential for lenzilumab to improve the likelihood
of SWOV, beyond standard supportive care, in hospitalized subjects with severe COVID-19. Subjects with COVID-19 (n=520), &gt;18 years,
and 94% oxygen saturation on room air and/or requiring supplemental oxygen, but not invasive mechanical ventilation, were randomized
to receive lenzilumab (600 mg, n=261) or placebo (n=259) via three intravenous infusions administered 8 hours apart. Subjects were followed
through Day 28 following treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white"><span style="background-color: white">In
March 2021, we announced results from our LIVE-AIR study. </span>Baseline demographics were comparable between the two modified intention-to-treat
(mITT) populations: male, 65%; mean age, 61 years; mean BMI, 33 kg/m<sup>2</sup>; median CRP, 79 mg/L; CRP was &lt;150 mg/L
in 77.9% of subjects. The most common comorbidities were hypertension (66%), obesity (55%), diabetes (53%), chronic kidney disease (14%),
and coronary artery disease (14%). Subjects received steroids (94%), remdesivir (72%), or both (69%). Lenzilumab improved the likelihood
of SWOV by 54% in the mITT population (HR: 1.54; 95%CI: 1.02-2.32, p=0.040) compared to placebo. SWOV also relatively improved by 82%
in subjects who received both corticosteroids and remdesivir (1.82; 1.16-2.86, nominal p=0.0092); by 3.04-fold in subjects with CRP&lt;150
mg/L and age &lt;85 years (3.04; 1.685.51, nominal p=0.0003). Survival was improved by 2.22-fold in subjects with CRP&lt;150 mg/L
and age &lt;85 years (2.22; 1.07-4.67, nominal p=0.034).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Lenzilumab improved SWOV in hospitalized, hypoxic
subjects with COVID-19 pneumonia over and above treatment with remdesivir and/or corticosteroids. Subjects with C-reactive protein level
(CRP)&lt;150 mg/L and age &lt;85 years demonstrated an improvement in survival and had the greatest benefit from lenzilumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following completion of the LIVE-AIR study, we
commenced a series of efforts to attain authorization to commercialize lenzilumab for use in hospitalized COVID-19 patients in the United
States and other territories. We filed an application for Emergency Use Authorization (EUA) with U.S. Food and Drug Administration
(FDA) at the end of May 2021. We also submitted an application for marketing authorization of lenzilumab in hospitalized
COVID-19 patients to Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom and conducted a series
of exploratory discussions with representatives of European Medicines Agency (EMA) regarding our potential submission of
lenzilumab for marketing authorization in the European Union. In addition, we commenced significant manufacturing efforts in support of
potential commercialization, as described below under Manufacturing and Raw Materials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 8, 2021, FDA declined our EUA request,
stating in its letter that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential
risks of its use as a treatment for COVID-19. In addition to raising similar concerns around efficacy, MHRA requested further information
related to clinical, manufacturing and quality processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The results from the LIVE-AIR study were published
in the peer-reviewed journal, <i>The Lancet Respiratory Medicine (The Lancet)</i>, on December 1, 2021. Per the Lancet paper,
the implication from all the available evidence is that Lenzilumab significantly improved survival without invasive mechanical
ventilation in hospitalized patients with COVID-19 who were treated concurrently with other available therapies. The Lancet paper
concluded that LIVE-AIR showed that lenzilumab treatment of hospitalized patients with COVID-19 can improve the likelihood of survival
without the need for mechanical ventilation, with a safety profile similar to that of placebo. As a result, we continue to believe
in the potential therapeutic benefits of lenzilumab and remain committed to our efforts to develop lenzilumab for patients hospitalized
with COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The next anticipated step in our development program
for lenzilumab in COVID-19 is the release of results from the Accelerating COVID-19 Therapeutic Interventions and Vaccines-5 (ACTIV-5)
and Big Effect Trial, in the B arm of the trial (BET-B), referred to as the <span style="color: #201F1E; background-color: white">ACTIV-5/BET-B
trial,</span> which is sponsored and funded by the National Institutes of Health (NIH). This study is evaluating lenzilumab
in combination with remdesivir, compared to placebo and remdesivir, in hospitalized COVID-19 patients as described more fully below. We
provided lenzilumab for the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A retrospective analysis of the LIVE-AIR study
suggested that patients under the age of 85 and with a baseline CRP below 150 mg/L (the CRP subgroup) appeared to derive
the greatest benefit from lenzilumab, therefore, the ACTIV-5/BET-B study protocol was modified to include baseline CRP below 150 mg/L
as the primary analysis population. The ACTIV-5/BET-B study has reached its target enrollment with over 400 patients enrolled that met
this criterion. Topline results from ACTIV-5/BET-B are expected to be released late in the first quarter or early in the second quarter
of 2022. If confirmatory of the results of the findings of the CRP subgroup from the LIVE-AIR study, we plan to include the results from
ACTIV-5/BET-B in an amendment to our EUA submission, and to include these results in a responsive submission to MHRA along with certain
performance process qualification (PPQ) data around drug product batches, in the second quarter of 2022. In addition, as
a result of feedback received from representatives of EMA, if the ACTIV-5/BET-B data are confirmatory of the results of the findings of
the CRP subgroup from the LIVE-AIR study, we intend to submit a Conditional Marketing Authorization (CMA) for lenzilumab
with an Accelerated Approval request to EMA later in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Through partners in Australia, we have also initiated
a study of lenzilumab in cancer patients with COVID-19. The trial, known as C-SMART (COVID-19 Prevention and Treatment in <span style="text-decoration: underline">C</span>ancer;
a <span style="text-decoration: underline">S</span>equential <span style="text-decoration: underline">M</span>ultiple <span style="text-decoration: underline">A</span>ssignment
<span style="text-decoration: underline">R</span>andomized <span style="text-decoration: underline">T</span>rial), is <span style="background-color: white">a
multi-center, four arm trial, which aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19
in the cancer population. </span>C-SMART will include 2,282 cancer patients&nbsp;at risk of, or known positive for, COVID-19 infection.
The study contemplates prophylaxis of 957 patients with IFN-alpha, 957 patients on placebo; post-exposure prophylaxis of 85 patients with
IFN-alpha, 85 patients on placebo; 63 COVID-19 hospitalized patients on selinexor, 85 patients on placebo; 36 COVID-19 hospitalized pneumonia
on lenzilumab and 36 patients on placebo. The C-SMART study is led by the National Centre for Infections in Cancer at the Peter MacCallum
Cancer Centre and will be conducted at five Australian sites&nbsp;in Melbourne and&nbsp;Sydney.&nbsp;The study is supported by a grant
from the Australian Government's Medical Research Future Fund.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, our partners in South Korea are conducting
a Phase 1 bridging study in 20 healthy volunteers. This Phase 1 clinical study is being conducted to explore the safety, tolerability,
and pharmacokinetic (PK) properties of lenzilumab and compare it between Koreans and Caucasians.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Our Commercial Opportunity</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an EUA in the U.S. or equivalent marketing authorization
in the EU or UK were granted, we intend to commercialize lenzilumab for COVID-19. Our goal would be to position lenzilumab as a front-line
therapeutic for use in hypoxic COVID-19 patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Lenzilumab is intended to be used in patients hospitalized
for COVID-19 with oxygen saturation levels below 94%. Since the beginning of the pandemic through January 31, 2022 over 4.3 million patients
have been hospitalized and the current number of hospitalized patients is estimated by the CDC to be over 120,000. As of the end of January
2022, the vaccination rate in the United States is over 80%; however, given the emergence of new variants, waning protection from vaccinations
and boosters, lack of efficacy from neutralizing monoclonals primarily due to emerging variants and potential limited efficacy of some
oral anti-virals, and the 20% of people that remain unvaccinated, we believe patients infected with COVID-19 will continue to be admitted
to the hospital for treatment, particularly immunocompromised populations. Scientists and experts have stated beliefs that the COVID-19
pandemic will become endemic. Hospitalization rates due to influenza over the past decade have ranged from 140,000 to 800,000 per year.
We believe the commercial opportunity to treat COVID-19 hospitalized patients with lenzilumab will continue to exceed 100,000 patients
in the U.S. on an annual basis in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Lenzilumab in CAR-T</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Scientific Rationale</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">FDA-approved
CAR-T therapies have demonstrated the effectiveness of using targeted immuno-cellular engineering to cause a patients own T-cells
to fight certain cancers that have not responded to standard therapies. T-cells are often called the workhorses of the immune
system because of their role in coordinating the immune response and killing cells infected by pathogens and cancer cells. As depicted
below, each of the FDA-approved CAR-T therapies are currently a one-time treatment that involves</span> multiple steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Harvesting white blood cells from the patients blood, also known as apheresis;&nbsp;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Engineering T-cells within this population to express cancer-specific receptors;&nbsp;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Increasing and purifying the number of genetically re-engineered T-cells; and</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Infusing the functional cancer-specific T-cells back into the patient to allow for expansion and targeting the cancer cells.&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image2.jpg" src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image2.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">As of the
date of this filing, five CAR-T therapies have been approved by FDA: Gilead/Kites Yescarta, and Tecartus, Novartiss Kymriah,
Bristol Myers Squibbs </span>Breyanzi&nbsp; <span style="background-color: white">and <span style="color: #333333">Abecma, which
</span>seek to treat forms of B-cell cancers such as various types of NHL, including DLBCL, Follicular Lymphoma (FL) Mantle
Cell Lymphoma (MCL) and adult acute lymphoblastic leukemia (ALL) that are refractory or in second or later
stage relapse. Although patients suffering from these aggressive cancers frequently undergo multiple treatments, including chemotherapy,
radiation and targeted therapy including stem cell transplants, the five-year survival rate has been severely limited and patients who
do not respond to, or have relapsed following at least two courses of standard treatment, have no other treatment options and a very poor
outcome. According to U.S. governmental sources, including the Surveillance, Epidemiology, and End Results (SEER) program
of the National Cancer Institute, which is a source of epidemiologic information on the incidence and survival rates of cancer in the
U.S., based on incidence data, we estimate that there are 21,000 patients per year in the U.S. with B-cell DLBCL and FL (Yescarta) and
7,000 with MCL and ALL (Tecartus). The number of patients eligible for Yescarta and Tecartus will be lower than the incidence rate as
only patients who have failed at least two prior systemic therapies are currently eligible for CAR-T therapy. In addition, both Yescarta
and Breyanzi have reported positive data in second line therapy for (r/r) B-cell NHL. If CAR-T therapy is approved as a second line option
versus stem cell transplantation, additional patients may be eligible for treatment. </span>Moreover, there are multiple B-cell maturation
antigen (BCMA) targeted CAR-T therapies in Phase 2 development for relapsed or refractory multiple myeloma and several other
novel CAR-T therapies targeting various antigens and neo-antigens in development for a number of hematologic and solid cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The five FDA-approved CAR-T therapies have significant
limitations. Despite the exciting prospects for treating patients with limited options, significant and potentially life-threatening side-effects
are associated with CAR-T therapy, including Immune Effector Cell Associated Neurotoxicity (ICANS) and CRS. While there
may be individual differences between CAR-T therapy products, the overall toxicity profile is generally consistent with that reported
for Yescarta and Tescartus, and it is known that various development-stage BCMA and other CAR-T therapies are hampered by the emergence
of cytokine storm, ICANS and other serious and potentially fatal side-effects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Both CRS and ICANS are caused by a large-scale
release of pro-inflammatory cytokines and chemokines induced by the CAR-T therapy and remain significant unmet needs that must be addressed.
<span style="background-color: white">Because ICANS and CRS can be life-threatening and have proven fatal in many instances, and because
each product bears a Boxed Warning from FDA (the strictest FDA warning label intended to alert patients and providers about
serious and life-threatening risks associated with a particular drug), patients seeking to benefit from Yescarta and Tescartus, generally
may only do so if the treatment center is in compliance with the Risk Evaluation and Mitigation Strategy (REMS) program
required by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">REMS is a drug safety&nbsp;program&nbsp;that FDA
requires certain medications with serious safety concerns to adhere to strict on-going monitoring and reporting and is intended to assist
and train certified treatment centers on the management of these serious side-effects. For example, each hospital and its associated clinics
are required to have a minimum of two doses of tocilizumab available on-site for each patient for the potential treatment of moderate
to severe cases of CRS. We believe the REMS requirement may have adversely impacted both market uptake and usage to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">According
to the original package inserts for Yescarta </span>and Tecartus, 81% (NHL), 81% (MCL), 87% (ALL) of patients treated in the clinical
trial setting experienced ICANS (with up to 35% of cases being severe, or grade <span style="text-decoration: underline">&gt;</span>3).
The package insert for Yescarta was recently updated to include the use of prophylactic corticosteroids across all approved indications.
The update was based on the safety update from Cohort 6 of the ZUMA-1 study which showed that in 39 patients, prophylactic or early use
of corticosteroids resulted in neurological events (Grade 3) in 13% or patients and 0% of the patients had CRS. These original
rates may be more prevalent in practice, despite the availability and utilization of tocilizumab and corticosteroids. Moreover, b<span style="background-color: white">ased
on feedback from leading treatment centers in the U.S., approximately 30% to 60% of patients receiving CAR-T therapy require admission
to the ICU and in some cases require an extended stay, with multiple interventions, including ventilator support and other supportive
measures, to be urgently administered to manage these side-effects. </span>Some patients can suffer seizures, coma, brain swelling, heart
arrhythmias, organ failure and serious and life-threatening clotting disorders, not only causing more complex and potentially fatal medical
consequences, but significantly adding to cost of patient care. These can be particularly challenging and concerning issues, especially
in younger and pediatric patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Our Development Program</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">There are currently no FDA-approved products for
the prevention of CAR-T therapy-related side effects, nor are there any approved therapies for the treatment of CAR-T therapy related
ICANS. Tocilizumab, among other indications, is approved for the treatment of CAR-T induced severe CRS. We believe lenzilumab has the
potential to improve the efficacy and safety of CAR-T therapy and that the use of lenzilumab may minimize or eradicate the incidence,
frequency, duration and/or severity of ICANS and/or CRS that frequently appear in CAR-T patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Accordingly, we are developing lenzilumab as a
treatment for cytokine storm associated with ICANS and CRS in certain CD19-targeted CAR-T cell therapies. Further, GM-CSF neutralization
may enhance CAR-T proliferation and effector functions and potentially confer additional benefits in terms of durable efficacy and healthcare
resource utilization. Preclinical data generated in collaboration with the Mayo Clinic, which was published in <i>Blood</i>, a premier
journal in hematology, indicates that the use of lenzilumab in combination with CAR-T therapy may also enhance the proliferation and improve
the efficacy of CAR-T therapy. This may also result in durable, or longer term, responses in CAR-T therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Lenzilumab has been studied in a multi-center
Phase 1b trial as a sequenced therapy with Yescarta to prevent CRS and ICANS in patients with relapsed or refractory diffuse large B-cell
lymphoma (DLBCL) (NCT04314843), for which we announced positive results in April 2021. We intend to initiate a randomized,
placebo-controlled, double-blind, registrational, Phase 3 study to evaluate the efficacy and safety of lenzilumab combined with Yescarta
and Tecartus CAR-T therapies in non-Hodgkin lymphoma in 2022. This study is known as SHIELD (<b>S</b>tudy on <span style="text-decoration: underline">H</span>ow
to <span style="text-decoration: underline">I</span>mprove <span style="text-decoration: underline">E</span>fficacy and toxicity with
<span style="text-decoration: underline">L</span>enzilumab in <span style="text-decoration: underline">D</span>LBCL and other NHL patients
treated with CAR-T therapy). We have alignment with FDA on the design of the Phase 3 study. <span style="background-color: white">Following
a dose run-in period in approximately 25 patients,</span> we currently plan to enroll more than 150 patients in the study. SHIELD will
study lenzilumab for the prevention of CAR-T therapy-related toxicities including ICANS and CRS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><i>Our Commercial Opportunity</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Revenues from the sales of the five approved CAR-T
therapies exceeded $1.7 billion in 2021. We estimate that over 3,000 patients were treated with CAR-T therapy in 2021. Analysts predict
that Yescarta only will reach peak sales in excess of $1.5 billion as additional patients become eligible for treatment. We believe we
have the ability to transform CAR-T therapy and potentially a broad range of other T-cell engaging therapies, including both autologous
and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening
toxicities, including ICANS and CRS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that our GM-CSF pathway science, assets
and expertise create two technology platforms to assist in the development of next-generation CAR-T therapies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>Lenzilumab has the potential to be used in combination with any FDA-approved or development stage T-cell therapy, including CAR-T therapy,
        as well as in combination with other cell therapies such as allogeneic HSCT such as bone marrow transplants, to make these treatments
        safer and more effective.</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>In addition, our GM-CSF knockout gene-editing CAR-T platform has the potential to create next-generation CAR-T therapies that may inherently
        avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while reducing or altogether avoiding
        its serious and potentially life-threatening side-effects.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Lenzilumab in Acute GvHD</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Scientific Rationale</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">Allogeneic
</span>hematopoietic stem cell therapy (<span style="background-color: white">HSCT), </span>a potentially curative therapy
for patients with hematological cancers, <span style="background-color: white">involves transferring stem cells from a healthy donor to
the patient. HSCT has demonstrated effectiveness in treating these cancers. As depicted below, allogeneic HSCT involves</span> multiple
steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Collecting blood from a healthy donor;&nbsp;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Processing the donors blood to remove the stem cells before returning the rest of the donors blood back to the donor;&nbsp;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Pre-conditioning the patient with high-dose chemotherapy and/or radiation; and&nbsp;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.75in"></td>
    <td style="width: 0.25in"></td>
    <td>Infusing the donors stem cells into the patient to allow for the production of new blood cells.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image3.jpg" src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image3.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although a potentially life-saving treatment for
patients suffering from hematological cancers, between 40-60% of patients receiving HSCT treatments experience acute or chronic aGvHD,
which together carries a 50% mortality rate. After being transplanted into the patient, donor-derived T cells are responsible for mediating
the beneficial graft versus leukemia (GvL) effect. In many cases, however, donor-derived T cells that remain within the
graft itself have also been linked to destruction of healthy tissue in the patient (the host), with particular risk of destroying cells
in the patients skin, gut, and liver, resulting in aGvHD. Although depleting donor grafts of T cells can prevent or reduce the
risk of aGvHD, this results in a reduced GvL effect, thereby having a detrimental impact on the efficacy of the allogeneic HSCT treatment
itself and leading to increased relapse rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Despite new therapies, there remains a significant
unmet medical need for an agent that can uncouple the beneficial GvL effect from harmful aGvHD. The FDA has recently approved Orencia
(abatacept) from <span style="background-color: white">Bristol Myers Squibb</span> for the prevention of aGvHD and in 2019 Jakafi (ruxolitinib)
from Incyte Corporation was approved for steroid-refractory aGvHD. Other treatments include pre-conditioning regimens for HSCT treatments
that can vary significantly by treatment centers, including by unapproved, or off-label, use of agents that have been approved
by FDA for other uses only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that cytokine storm may be responsible,
at least in part, for the emergence of GvHD in this setting. We believe that GM-CSF neutralization with lenzilumab has the potential to
prevent or treat GvHD without compromising, and potentially improving, the beneficial GvL effect in patients undergoing allogeneic HSCT,
thereby making allogeneic HSCT safer. The technology was featured in a November 2018 research article published in <i>Science Translational
Medicine</i>, where the authors demonstrated in a murine model of GvHD, that donor T cell-derived GM-CSF drives GvHD through activation,
expansion, and trafficking of myeloid cells but has no effect on the GvL response. Neutralization of GM-CSF (either using a neutralizing
antibody or through GM-CSF gene knock-out) was able to uncouple the myeloid-mediated immunopathology resulting in GvHD from the T cell-mediated
control of leukemic cells. This discovery provides a mechanistic proof-of-concept for neutralizing GM-CSF to prevent GvHD without compromising,
and potentially improving, the GvL effect in patients undergoing allogeneic HSCT. Corroborating data related to the critical effect GM-CSF
has on GvHD development in HSCT was published in <i>blood advances</i> in October 2019 by Gartlan et al.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Our Development Program</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that GM-CSF neutralization using lenzilumab
has the potential to make allogeneic HSCT safer and more effective. Similar to GM-CSF neutralization with lenzilumab breaking the efficacy/toxicity
linkage with CAR-T therapy, GM-CSF neutralization has demonstrated potential to attenuate acute GvHD while maintaining the beneficial
GvL effect in patients undergoing allogeneic HSCT. Accordingly, we aim to position lenzilumab as a must have companion product
to any allogeneic HSCT and as a part of the standard pre-conditioning that all patients receiving allogeneic HSCT should receive or as
an early treatment option in patients identified as high risk for GvHD. We believe lenzilumab has potential to prevent or reduce aGvHD
in allogeneic HSCT, thereby making allogeneic HSCT safer as a potentially curative therapy for patients with hematological cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to study lenzilumab as a companion to allogeneic
HSCT for patients with hematological cancers. We plan to commence a Phase 2/3 potentially registrational trial for lenzilumab to treat
patients who have undergone allogeneic HSCT who are at high and intermediate risk for aGvHD, known as the RATinG study. The study will
be conducted by the IMPACT Partnership, a collection of 22 stem cell transplant centers located in the United Kingdom and is expected
to begin enrollment in the first half of 2022. We will provide lenzilumab for the study including the cost of import, labeling and distribution
of the study drug, and support certain laboratory tests related to the study, but the majority of the study costs will be borne by the
IMPACT Partnership. The goal of the trial, as it is currently contemplated, would be to determine the efficacy and safety of lenzilumab
in reducing non-relapse mortality at six months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><i>Our Commercial Opportunity</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The overall number of allogeneic HSCT treatments
continues to increase annually in the U.S. and abroad. According to the Center for International Blood &amp; Bone Marrow Transplant Research
(CIBMTR), in 2019, approximately 10,000 allogeneic HSCT treatments were expected to be performed in the U.S., with similar
trends expected in Europe (Phelan, et al Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides
2020).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Lenzilumab in CMML</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><i>Scientific Rationale</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that lenzilumab also holds promise in
CMML, a rare form of hematologic cancer with no FDA-approved treatment options and a three-year overall survival rate of 20% and median
overall survival of 20 months. CMML is a clonal stem cell disorder of which monocytosis is a key feature. Approximately 40% of CMML patients
carry NRAS/KRAS/CBL mutations which are associated with GM-CSF hypersensitivity. CMML has features of myelodysplastic syndrome (MDS),
including abnormal, dysplastic bone marrow cells; cytopenia; transfusion dependence; and of myeloproliferative neoplasms, including overproduction
of white blood cells, organomegaly (e.g., splenomegaly and hepatomegaly) and extramedullary disease. About 15 to 20% of CMML cases progress
to acute myeloid leukemia, or AML. According to the American Cancer Society, approximately 1,100 individuals in the United States are
newly diagnosed annually with CMML, with the majority of these new patients being age 60 or older. These patients are typically unsuitable
for stem cell transplants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><i>Our Development Program</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In a Phase 1 study, 3 of 6 patients with NRAS/KRAS/CBL
mutations demonstrated a clinical response to lenzilumab by the MDS/MPN International Working Group criteria. The Phase 1 clinical trial
in patients with CMML identified the Maximum Tolerated Dose (MTD) or recommended Phase 2 dose of lenzilumab, and assessed
lenzilumabs safety, pharmacokinetics, and clinical activity. Final results of this study were presented at the 2019 ASH Annual
Meeting and published in <i>blood</i>. Building on this successful Phase 1 study in CMML, we are running a Phase 2 study in combination
with azacitidine in newly diagnosed CMML patients who express NRAS/KRAS/CBL mutations which are known to be hypersensitive to GM-CSF and
therefore may lend themselves to responsiveness to lenzilumab treatment. The Phase 2 study, known as PREcision Approach to Chronic
Myelomonocytic Leukemia or PREACH-M, is being conducted in partnership with the South Australian Health &amp; Medical
Research Institute (SAHMRI) and the University of Adelaide. The study has begun enrollment at five sites in Australia and
the first patient has been dosed. We will provide lenzilumab for this study and the majority of the study costs will be borne by the partner
and funded by a grant from the Medical Research Futures Fund, a research fund set up by the Australian Government.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given our interest in developing lenzilumab to
prevent CRS/cytokine storm in COVID-19 as well as in the treatment of rare cancers and other orphan conditions such as aGvHD and CMML,
we believe that we have the opportunity to benefit from various regulatory and commercial incentives, such as orphan drug exclusivity,
breakthrough therapy designation, fast track designation, priority review and accelerated approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<b><i>Ifabotuzumab</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ifabotuzumab is a Humaneered monoclonal antibody,
formerly referred to as KB004, which targets the EphA3 receptor, and in which the antibody carbohydrate chains lack fucose, thereby enhancing
the targeted cell-killing activity of the antibody. We believe that ifabotuzumab as part of an antibody drug conjugate has the potential
for treating solid tumors. In 2006, we entered into a license agreement with Ludwig Institute of Cancer Research (LICR)
pursuant to which LICR granted certain exclusive rights to the ifabotuzumab prototype (referred to as IIIA4) as well as EphA3 intellectual
property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ifabotuzumab binds to EphA3, which plays an important
role in cell positioning and tissue organization during fetal development but is not thought to be expressed nor play a significant role
in healthy adults. EphA3 is a tyrosine kinase receptor, aberrantly expressed on the tumor vasculature and tumor stroma in several solid
tumors including melanoma, breast cancer, small and non-small cell lung cancer (SCLC and NSCLC), colorectal
cancer, gastric cancer, renal cancer, glioblastoma multiforme (GBM), and prostate cancer, making it an attractive target
for a range of cancers. Publications related to certain cancers have indicated that EphA3 tumor cell expression correlates with cancer
growth and a poor prognosis. EphA3 appears to be critically involved in maintaining tumor cells in a less differentiated state by modulating
mitogen-activated protein kinase signaling. EphA3 knockdown or depletion of EphA3-positive tumor cells may reduce tumorigenic potential
to a degree comparable to treatment with a therapeutic radiolabeled EphA3-specific monoclonal antibody. We believe EphA3 is a functional,
targetable receptor in solid tumors. A study published in December 2018 in Cancers showed that an antibody drug conjugate
(ADC) comprising IIIA4 (a predecessor monoclonal antibody and prototype for ifabotuzumab) showed significant survival benefit
in mice with GBM.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Anti-EphA3 treatment has shown encouraging preclinical
results in multiple experiment types, including patient primary tumor cell assays, colony forming assays, and xenograft mouse models.
Upon binding to EphA3, ifabotuzumab causes cell killing to occur either through antibody-dependent, cell-mediated cytotoxicity or through
direct apoptosis, and in the case of tumor neovasculature, through cell rounding and blood vessel disruption. Given the expression pattern
of EphA3 in multiple tumor types, ifabotuzumab may have the potential to kill cancer cells and the tumor stem cell microenvironment, providing
for long-term responses while sparing normal cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 10, 2021, we presented top-line results
from the Phase 1 safety and bioimaging trial of ifabotuzumab in patients with GBM at the American Association for Cancer Research 2021
Annual Meeting. The Phase 1 study primarily sought to determine the safety and recommended Phase 2 dose of ifabotuzumab in patients with
GBM, the most frequent and lethal primary brain neoplasm, with 5-year survival rates of 10%. There were no dose-limiting toxicities observed
and all adverse events were readily manageable. Additional studies are being planned to evaluate ifabotuzumab as an ADC in patients with
solid tumors, such as, colon, breast, prostate, and pancreatic cancer. These studies include the Olivia Newton-John Cancer Research Institute
which plans to conduct a Phase 1b dose-escalation and imaging study in non-CNS solid tumors that is scheduled to begin in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>HGEN005</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HGEN005 is a Humaneered monoclonal antibody, formerly
referred to as KB005, which selectively targets the eosinophil receptor EMR1. HGEN005 is being explored as a potential treatment for a
range of eosinophilic diseases including eosinophilic leukemia both as an optimized naked antibody and as the backbone for a novel CAR-T
construct.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A major limitation of current eosinophil-targeted
therapies is incomplete depletion of tissue eosinophils and/or lack of cell selectivity. Eosinophils are a type of white blood cell. If
too many eosinophils are produced in the body, chronic inflammation and tissue and organ damage may result. The origin and development
of eosinophilic disorders is mostly due to eosinophils infiltrating tissue. EMR1 is expressed exclusively on eosinophils, making it an
ideal target for the treatment of eosinophilic disorders. Regardless of the eosinophilic disorder, mature eosinophils express EMR1 in
tissue, blood and bone marrow in patients with eosinophilia. We believe that because of its high selectivity, HGEN005 has significant
potential to treat serious eosinophil diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In preclinical work, HGEN005s anti-EMR1
activity resulted in dramatically enhanced Natural Killer (NK) of eosinophils from normal and eosinophilic donors and also
induced a rapid and sustained depletion of eosinophils in a non-human primate model without any clinically significant adverse events.
The development of HGEN005 is on hold while we focus on lenzilumab and ifabotuzumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #222222">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Intellectual property
is an important part of our strategy and has been a key focus area for Humanigen. We have and continue to file aggressively on our own
inventions and in-license intellectual property and technology as it relates to our therapeutic interests. We believe that we are a leader
in the field of GM-CSF neutralization to ameliorate cytokine storm as it relates to COVID-19, CAR-T and GvHD.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Licensing and Collaborations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The Mayo Foundation for Medical Education and Research</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 19, 2019, we entered into the Mayo Agreement
with the Mayo Foundation. Under the Mayo Agreement, we have in-licensed certain technologies that we believe may be used to create CAR-T
cells lacking <span style="background-color: white">GM-CSF </span>expression through various gene-editing tools including CRISPR-Cas9.
The license covers various patent applications and know-how developed by Mayo Foundation in collaboration with us. These licensed technologies
complement and broaden our position in the GM-CSF neutralization space and expand our discovery platform aimed at improving CAR-T to include
gene-edited CAR-T cells. The Mayo Agreement requires the payment of milestones and royalties upon the achievement of certain regulatory
and commercialization milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term of the Mayo Agreement runs from May 29,
2019 until the later of: (i) the expiration date of the last to expire of the patent rights granted; or (ii) the conclusion of a period
of ten (10) years from the date of the first commercial sale, subject to termination rights specified in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The University of Zurich</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 19, 2019, we entered into an exclusive
worldwide license agreement (the Zurich Agreement) with the University of Zurich (UZH). Under the Zurich Agreement,
we have in-licensed certain technologies that we believe may be used to prevent GvHD through GM-CSF neutralization. The Zurich Agreement
covers various patent applications filed by UZH which complement and broaden our position in the application of GM-CSF neutralization
and expands our development platform to include improving allogeneic HSCT.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Zurich Agreement required an initial one-time
payment of $100,000, which we paid to UZH on July 29, 2019. The Zurich Agreement also requires the payment of annual license maintenance
fees, as well as milestones and royalties upon the achievement of certain regulatory and commercialization milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term of the Zurich Agreement runs from July
19, 2019 until the expiration date of the longest-lived patent right, subject to termination rights specified in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Clinical Trial Agreement with the National Institute of Allergy
and Infectious Diseases</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 24, 2020, we entered into a clinical trial
agreement (the Clinical Trial Agreement) with NIAID, part of the National Institutes of Health, which is part of the United
States Government Department of Health and Human Services, as represented by the Division of Microbiology and Infectious Diseases. Pursuant
to the Clinical Trial Agreement, lenzilumab is being evaluated in the NIAID-sponsored ACTIV-5/ BET in hospitalized patients with COVID-19.
The ACTIV-5/BET-B study protocol was modified to include baseline CRP below 150 mg/L (the CRP subgroup) as the primary analysis population.
The ACTIV-5/BET-B study has reached its target enrollment with over 400 patients enrolled that met this criterion and we anticipate top-line
data in late first quarter or early second quarter of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;Pursuant to the Clinical Trial Agreement,
NIAID serves as sponsor and is responsible for supervising and overseeing ACTIV-5/BET-B. We provided lenzilumab to NIAID without charge
and in quantities to ensure a sufficient supply of lenzilumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;The Ludwig Institute for Cancer Research</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2004, we entered into a license agreement with
the Ludwig Institute for Cancer Research (LICR) pursuant to which LICR granted to us an exclusive license for intellectual
property rights and materials related to chimeric anti-GM-CSF antibodies that formed the basis for lenzilumab. Under the agreement, we
were granted an exclusive license to develop antibodies related to LICRs antibodies against GM-CSF. We are responsible for using
commercially reasonable efforts to research, develop, and sell lenzilumab. We pay LICR a quarterly license fee and are obligated to pay
to LICR a royalty from 1.5% to 3% of net sales of licensed products, subject to certain potential offsets and deductions. Our royalty
obligation applies on a country-by-country and licensed product-by-licensed product basis, and will begin on the first commercial sale
of a licensed product in a given country and end on the later of the expiration of the last to expire patent covering a licensed product
in a given country (which in the U.S. is currently expected in 2029 for the composition of matter and 2038 for methods of use in CAR-T)
or 10 years from first commercial sale of such licensed product in the country. We must also pay to LICR a certain percentage of sublicensing
revenue received by us. Payments made to LICR under this license for each of the twelve months ended December 31, 2021 and 2020 were $0.1
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Other License Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>LICR and ifabotuzumab</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2006, we entered into a license agreement with
LICR pursuant to which LICR granted to us certain exclusive rights to the ifabotuzumab prototype (IIIA4) which targets EphA3 and EphA3-related
intellectual property. Under the agreement, we obtained rights to develop and commercialize products made through use of licensed patents
and any improvements thereto, including human or Humaneered antibodies that bind to or modulate EphA3. We paid LICR an upfront option
fee of $0.05 million and a further $0.05 million upon our exercise of the option for the exclusive license outlined above. We are responsible
for contingent milestone payments of less than $2.5 million and royalties of 3% of net sales subject to certain potential offsets and
deductions. In addition, we are obligated to pay to LICR a percentage of certain payments we receive from any sublicensee in consideration
for a sublicense. Our royalty obligation exists on a country-by-country and licensed product-by-licensed product basis, which will begin
on the first commercial sale and end on the later of the expiration of the last to expire patent covering such licensed product in such
country, which in the U.S. is currently expected in 2031, or 10 years from first commercial sale of such licensed product in such country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>BioWa and Lonza</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2010, we entered into a license agreement with
BioWa, Inc. (BioWa), and Lonza Sales AG (Lonza) pursuant to which BioWa and Lonza granted us a non-exclusive,
royalty-bearing, sub-licensable license under certain know-how and patents related to antibody expression and antibody-dependent cellular
cytotoxicity enhancing technology using BioWa and Lonzas Potelligent<sup></sup> CHOK1SV technology. This technology is used
to enhance the cell killing capabilities of antibodies and is currently used by us in connection with our development of ifabotuzumab.
Under this agreement, we owe annual license fees, milestone payments in connection with certain regulatory and sales milestones and royalties
in the low single digits on net sales of products developed under the agreement. The agreement expires upon the expiration of royalty
payment obligations under the agreement, is terminable at will by us upon written notice, is terminable by BioWa and Lonza if we challenge
or otherwise oppose any licensed patents under the agreement and is terminable by either party upon the occurrence of an uncured material
breach or insolvency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Patents and Trade Secrets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We use a combination of patent, trade secret and
other intellectual property protections to protect our product candidates and platforms. We will be able to protect our product candidates
from unauthorized use by third parties only to the extent they are covered by valid and enforceable patents or to the extent our technology
is effectively maintained as trade secrets. Intellectual property is an important part of our strategy. We have and continue to file aggressively
on our own inventions and in-license intellectual property and technology as it relates to our therapeutic interests. Our success will
depend in part on our ability to obtain, maintain, defend and enforce patent rights for and to extend the life of patents covering lenzilumab,
ifabotuzumab, HGEN005, our Humaneered technology, and our GM-CSF gene-editing CAR-T platform technologies, to preserve trade secrets and
proprietary know how, and to operate without infringing the patents and proprietary rights of third parties. We actively seek patent protection,
if available, in the U.S. and select foreign countries for the technology we develop. We have 131 registered patents, including 16 registered
in the U.S. and 115 registered in foreign countries. Of the 131 registered patents, 107 are owned by us, 9 are owned jointly with a third
party and 15 are exclusively licensed from a third party. We also have 79 patent applications pending globally, of which 33 are owned
by us, 20 are owned jointly with a third party and 26 are exclusively licensed from a third party.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Using our Humaneered technology, we have developed
and own two composition of matter U.S. patents covering lenzilumab and related anti-GM-CSF antibodies that provide patent protection through
April 2029, a granted composition of matter patent in 15 European countries and certain foreign countries, and have four U.S. patents
and nine additional pending patent applications in the U.S., 21 foreign patent applications, and one PCT international patent application
covering various methods of treatment, including in the CAR-T space covering a broad and comprehensive range of approaches to neutralizing
GM-CSF, including the use of GM-CSF k/o CAR-T cells, which, if granted, are expected to confer protection to at least September 2039.
We also have one currently pending foreign patent application that is jointly owned with a third party for anti-EphA3 antibodies and their
use, and we developed and own an issued U.S. composition of matter patent covering ifabotuzumab and related anti-EphA3 antibodies, which
is currently expected to expire in 2031, and own 22 foreign patents to anti-EphA3 antibodies and therapeutic uses, in addition to owning
four U.S. patents to therapeutic methods using anti-EphA3 antibodies, one European patent to be validated in 19 countries, and seven foreign
patents owned jointly with a third party covering methods of treatment with anti-EphA3 antibodies. The two U.S. and 45 foreign patents
to our Humaneered technology cover methods of producing human antibodies that are very specific for target antigens using only a small
region from mouse antibodies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing and Raw Materials</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We outsource all development activities, including
the development of formulation prototypes. We do not have, nor do we plan to have, any manufacturing facilities. Instead, we have adopted
a manufacturing strategy of contracting with third party contract manufacturing organizations (CMOs) for the manufacture
of bulk drug substance (BDS) and fill, finish, labeling, packaging and distribution work for our product candidates. We
believe our outsourcing approach allows us to maintain a leaner staff and a more flexible infrastructure, allowing us to focus our expertise
on developing our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The successful execution of our manufacturing strategy
is a key component of our overall business strategy, as we believe that our ability to obtain regulatory approval for lenzilumab to be
used commercially depends at least in part on our ability to demonstrate to regulators that we will be able to scale the manufacturing
to produce a sufficient quantity of dosages to address the potential demand for the product. Our experience has been that the overall
time to manufacture a 2-to-4-thousand-liter batch of lenzilumab BDS at an existing CMO and to complete the fill, finish, labeling and
packaging of the vials is approximately 6 to 9 months. Accordingly, our reliance on CMOs requires us to carefully plan the availability
of manufacturing slots and the availability of drug for investigation in preclinical and clinical trials and, potential commercialization.
Further, our current agreements with CMOs represent large financial commitments, including upfront amounts prior to commencement of manufacturing
and progress payments through the course of the manufacturing process and include payments for the initial technology transfer, which
takes several months in advance of any manufacturing taking place. For a description of risks related to our manufacturing strategy, including
our complete reliance on CMOs, see Item 1A. Risk Factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2020 and the first half of 2021, we were aggressive
in pursuing manufacturing slots for lenzilumab in contemplation of its potential commercialization under an EUA in the U.S. or an equivalent
authorization in the UK and EU. Please refer to Part II, Item 7. Managements Discussion and Analysis for a further
discussion of the costs we incurred in these efforts. Our production efforts were less successful than we had anticipated, as we experienced
shortages of raw materials and critical components necessary for our manufacturing processes, delays in production and availability of
manufacturing slots and failures in production at the BDS and DP level resulting in lower than anticipated yields. Further, certain of
our CMOs had difficulties in producing BDS within specifications or were unable to produce BDS on a timely basis due to challenges in
the supply of materials used in the production process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, MHRA in the UK has advised us that
it requires certain validation work to be conducted related to production of lenzilumab prior to potential approval for sale. Guidance
from FDA is that validation is not required for materials produced for sale under EUA, that validation could be completed and submitted
as part of the subsequent regulatory process and that lenzilumab made prior to validation may be available for sale under an EUA, if FDA
were to grant such an authorization. For lenzilumab for which no validation is planned, FDA would rely on a comparability report to ensure
lenzilumab would be available for sale under an EUA. As of February 15, 2022, lenzilumab treatments for approximately 67,000 patients
were in various stages of the validation process and another approximately 24,000 lenzilumab treatments had been produced, or were in
process of being produced, for which we do not plan to complete validation. Another 41,000 treatments are in production at one of our
CMOs for which material has not yet been released, and which may require reprocessing prior to release. At this time, it is not possible
to predict if these 41,000 treatments would be released and available for sale if authorization or approval for lenzilumab were to be
attained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have sought to mitigate our financial commitments
while continuing to position lenzilumab for a future authorization or approval in the U.S., EU and UK. Our mitigation efforts included
the amendment or in some cases cancelation of certain of our agreements with CMOs for future manufacturing work, some of which were contingent
on EUA, in an effort to reduce our future spending. We incurred cancellation fees for several of these modifications. We also have disputed
several invoices for cancellation fees and for production batches for lenzilumab that had been submitted by CMOs that failed to produce
BDS within our stated release specifications, but our mitigation efforts may not be successful to recoup any such loss of lenzilumab BDS
or DP. See Item 3. To this Annual Report on Form 10-K and Note 11 to the Consolidated Financial Statements included in this Annual Report
on Form 10-K for more information on these disputes. In the event of authorization by MHRA, EMA, or FDA, we anticipate that the demand
for commercial product could exceed the in process and planned production of lenzilumab through 2022. We intend to seek additional manufacturing
capacity if authorization is obtained. We expect to use a portion of the revenues generated from commercial sale of lenzilumab following
receipt of a regulatory authorization to support our efforts to expand production capacity in 2023 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sales and Marketing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to outsource our sales and marketing
infrastructure necessary to market and sell our products, if authorized or approved. As our drug candidates progress, we may also seek
strategic alliances and partnerships with third parties including those with existing infrastructure and with government bodies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We compete in an industry characterized by rapidly
advancing technologies, intense competition, a changing regulatory and legislative landscape and a strong emphasis on the benefits of
intellectual property protection and regulatory exclusivities. Our competitors include pharmaceutical companies, other biotechnology companies,
academic institutions, government agencies and other private and public research organizations. We compete with these parties to develop
potential biologic therapies to treat COVID-19, to make CAR-T therapy and allogeneic HSCT safer and more effective and to develop a potential
treatment for hematologic cancers, in addition to recruiting highly qualified personnel. Our product candidates, if successfully developed
and approved, may compete with established therapies, with new treatments that may be introduced by our competitors, including competitors
relying to a large extent on our drug approvals or on our biologics approvals, or with generic copies of our product approved by FDA,
as bio-similars, referencing our drug products. Many of our potential competitors have substantially greater scientific, research, and
product development capabilities, as well as greater financial, marketing, sales and human resources capabilities than we do. In addition,
many specialized biotechnology firms have formed collaborations with large, established companies to support the research, development
and commercialization of products that may be competitive with ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The current standard of care for aGvHD is daily
systemic steroids, with a patient response rate of approximately 50%. CMML is currently treated via stem cell transplant, surgery or chemotherapy,
typically azacytidine or decitabine. Competition for the treatment of solid tumors varies by tumor type. Surgery and/or radiation treatment
is typically the first-line therapy, followed by chemotherapy. Chemotherapy may be used as front-line treatment in the case of inoperable
tumors and targeted therapies may be used as second-line therapy for specific solid tumors that exhibit certain mutations. There are currently
no known therapies that target EpAh3 antigen.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Lenzilumab and COVID-19 competition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are currently no FDA-approved immunomodulators
for the prevention of the hyperinflammatory state associated with COVID-19; however, Emergency Use Authorization has been granted to tocilizumab
and baricitinib, two compounds that are approved for certain inflammatory conditions. The NIH treatment guidelines for therapeutic management
of hospitalized adults with COVID-19 (as of December 2021) are shown below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image4.jpg" src="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/image4.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Lenzilumab and CAR-T-related toxicities competition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">There are
currently no FDA-approved products for the prevention or treatment of ICANS or for the prevention of CRS associated with CAR-T therapy.
Medicines used to manage ICANS and CRS, such as tocilizumab and corticosteroids, have not adequately controlled the side-effects, and
steroids may have a detrimental impact on the efficacy of the CAR-T therapy itself while tocilizumab may increase the risk of CAR-T therapy
induced ICANS and is correlated with an increased risk of infections, including severe infections. Further, these medicines have not undergone
prospective clinical trials for use in this patient population. Tocilizumab is only approved for the treatment of severe cases of CRS,
but is not approved for prevention of CRS, nor is it approved for either prevention or treatment of ICANS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other experimental approaches being explored include
development of next-generation, CAR-T constructs, including introducing suicide genes into CAR-T cells using herpes simplex virus thymidine
kinase (HSV-TK) or inducible caspase-9 (iCasp9) genes with on / off switches, incorporating
a co-stimulatory molecule into T-cells, using RNA-guided DNA targeting technology or other epitope-based / gene-editing technology. While
it is possible that some of these approaches could result in lower rates of ICANS and/or CRS, preliminary data suggests that improvements
in the safety profile are associated with lower rates of efficacy and durable response. This is not surprising given the linkage that
has been shown to exist between CAR-T cell expansion, efficacy and toxicity. There are also several other anti-GM-CSF compounds that are
in various stages of development, however the focus of these compounds appears to be in chronic autoimmune disorders such as rheumatoid
arthritis, ankylosing spondylitis, giant cell arteritis and related disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Government Regulation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Drug Development and Approval in the U.S.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a biopharmaceutical company operating in the
U.S., we are subject to extensive regulation by FDA and by other federal, state, and local regulatory agencies. FDA regulates biological
products such as our product candidates under the U.S. Federal Food and Cosmetic Act (FDCA), the Public Health Service Act
(PHSA) and their implementing regulations. These laws and regulations set forth, among other things, requirements for preclinical
and clinical testing, development, approval, labeling, manufacture, storage, record keeping, reporting, distribution, import, export,
advertising, and promotion of our products and product candidates. Under the PHSA, in most circumstances an FDA-approved BLA is required
to market a biological product, or biologic, in the U.S. Biologics receive 12 years market exclusivity from first licensure. During the
COVID-19 public health emergency, however, FDA has certain authority, under the FDCA and The Pandemic and All Hazards Preparedness Reauthorization
Act of 2013, to bypass the BLA pathway and issue an EUA for certain medical products, including biologics, intended for use during the
emergency. An EUA, once issued for a biologic, lasts only for a limited amount of time, after which a BLA will be required for continued
marketing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Emergency Use Authorization</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FDAs EUA authority allows the agency to
facilitate greater availability and use of medical countermeasures, including biologics, when the Secretary of Health and Human Services
(HHS) has declared that circumstances exist that justify such authorization. Under such circumstances, companies may request
an EUA to permit the marketing and use of a product before that product has received FDA approval, or to permit the otherwise unapproved
use of an approved product. FDA may only issue an EUA if it concludes that: the chemical, biological, radiological or nuclear agent referred
to in the HHS Secretarys public health emergency declaration is capable of causing a serious or life-threatening disease; the product
at issue may be effective to prevent, diagnose, or treat serious or life-threatening diseases or conditions that can be
caused by that agent or to mitigate a disease or condition caused by an FDA-regulated product used to diagnose, treat, or prevent a disease
or condition caused by that agent; and that there are no adequate, approved, and available alternatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The EUA may be effective standard
requires a lower level of evidence than the effectiveness standard required for a BLA. FDA assesses the potential effectiveness
of a possible EUA product on a case-by-case basis using a risk-benefit analysis. In deciding whether to authorize emergency use, FDA will
evaluate whether the known and potential benefits of the product outweigh the known and potential risks, taking into account the totality
of the scientific evidence. Such evidence may include clinical trial data, in vivo efficacy data from animal models, and in vitro data.
Even where a product may be effective, FDA may only issue an EUA if there is no adequate, approved, and available alternative
to the candidate product, either because there is no alternative product at all or because of, for example, an insufficient supply of
an approved alternative to meet the emergency need; contraindications for use of an approved product in certain populations or circumstances;
or the agent at issue in the public health emergency is resistant to approved and available products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When an EUA is issued, FDA will typically limit
or restrict the amount of promotional activity that may be conducted for the medical product granted an EUA and may reissue an EUA to
change the terms based on a change in circumstances, such as the emergence of new clinical trial data that change the risk-versus-benefit
analysis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An EUA is not a permanent marketing authorization.
Rather, an EUA may be terminated once the Secretary of HHS declares that the public health emergency is terminated; when a product that
is marketed under an EUA obtains full marketing approval (for example, under a BLA); or when circumstances change (such as, for example,
new data emerge that change the risk-benefit calculation). As a practical matter, where the HHS Secretary declares an end to the public
health emergency that gave rise to FDAs EUA authority, the Secretary must provide advance notice that allows for disposition of
an unapproved product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Applications Relying on the Applicants Clinical Data</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The approval process for a BLA under the PHSA requires
the conduct of extensive studies and the submission of large amounts of data by the applicant. The biologic development process for these
applications will generally include the following phases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Preclinical Testing</i>. Before testing any
new biologic in human subjects in the U.S., a company must generate extensive preclinical data. Preclinical testing generally includes
laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species
to assess the quality and safety of the product. Animal studies must be performed in compliance with FDAs Good Laboratory Practice
(GLP) regulations and the U.S. Department of Agricultures Animal Welfare Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>IND Application</i>. Human clinical trials in
the U.S. cannot commence until an IND application is submitted and becomes effective. A company must submit preclinical testing results
to FDA as part of the IND application, and FDA must evaluate whether there is an adequate basis for testing the product in initial clinical
studies in human volunteers. Unless FDA raises concerns, the IND application becomes effective 30 days following its receipt by FDA. Once
human clinical trials have commenced, FDA may stop the clinical trials by placing them on clinical hold because of concerns
about the safety of the product being tested, or for other reasons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Clinical Trials</i>. Clinical trials involve
the administration of the product to healthy human volunteers or to patients, under the supervision of a qualified investigator. The conduct
of clinical trials is subject to extensive regulation, including compliance with FDAs bioresearch monitoring regulations and Good
Clinical Practice (GCP) requirements, which establish standards for conducting, recording data from, and reporting the results
of clinical trials. GCP requirements are intended to assure that the data and reported results are credible and accurate, and that the
rights, safety, and well-being of study participants are protected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical trials must be conducted under protocols
that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol
is submitted to FDA as part of the IND application. In addition, each clinical trial must be reviewed, approved, and conducted under the
auspices of an Institutional Review Board (IRB), at the institution conducting the clinical trial. Companies sponsoring
the clinical trials, investigators, and IRBs also must comply with regulations and guidelines for obtaining informed consent from the
study subjects, complying with the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of
adverse events. Foreign studies conducted under an IND application must meet the same requirements that apply to studies being conducted
in the U.S. Data from a foreign study not conducted under an IND application may be submitted in support of a BLA if the study was conducted
in accordance with GCP and FDA is able to validate the data. A study sponsor is required to publicly post certain details about active
clinical trials and clinical trial results on the government website clinicaltrials.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Human clinical trials are typically conducted in
three sequential phases, although the phases may overlap with one another and, notably, in the CAR-T setting, FDA has granted approval
to all five currently marketed CAR-T therapies (Gilead/Kites Yescarta, and Tecartus, Novartiss Kymriah and Bristol Myers
Squibbs Breyanzi and Abecma) based on Phase 2 data and to tocilizumab without any prospective data in the CAR-T setting:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"></td>
    <td>Phase 1 clinical trials include the initial administration of the investigational product to humans, typically to a small group of healthy
        human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase I clinical trials generally are intended
        to determine the metabolism and pharmacologic actions of the product, the side-effects associated with increasing doses, and, if possible,
        to gain early evidence of effectiveness.</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"></td>
    <td>Phase 2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population and
        are designed to develop data regarding the products effectiveness, to determine dose response and the optimal dose range, and to
        gather additional information relating to safety and potential adverse effects.</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"></td>
    <td>Phase 3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained and are intended to gather additional
        information about safety and effectiveness necessary to evaluate the products overall risk-benefit profile, and to provide a basis
        for physician labeling. Generally, Phase 3 clinical development programs consist of expanded, large-scale studies of patients with the
        target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen, or with
        the safety, purity, and potency of a biological product.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"></td>
    <td>FDA does not always require every approved therapy to complete Phase 1 through 3 studies to secure approval. Approval through expedited
        routes is at the discretion of FDA.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The sponsoring company, FDA, or the IRB may suspend
or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable
health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from
clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit, or prevent regulatory
approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>BLA Submission and Review</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After completing clinical testing of an investigational
biologic product, a sponsor must prepare and submit a BLA for review and approval by FDA. A BLA is a comprehensive, multi-volume application
that must include, among other things, sufficient data establishing the safety, purity and potency of the proposed biological product
for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the products chemistry,
manufacturing, controls and proposed labeling. When a BLA is submitted, FDA conducts a preliminary review to determine whether the application
is sufficiently complete to be accepted for filing. If it is not, FDA may refuse to accept the application for filing and may request
additional information, in which case the application must be resubmitted with the supplemental information and review of the application
is delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FDA performance goals, which are target dates and
other aspirational measures of agency performance to which the agency, Congressional representatives, and industry agree through negotiations
that occur every five years, generally provide for action BLA applications within 10 months of submission or 10 months from acceptance
for filing for an original BLA. FDA is not expected to meet those target dates for all applications, however, and the deadline may be
extended in certain circumstances, such as when the applicant submits new data late in the review period. In practice, the review process
is often significantly extended by FDA requests for additional information or clarification. In some circumstances, FDA can expedite the
review of new biologics deemed to qualify for priority review, such as those intended to treat serious or life-threatening conditions
that demonstrate the potential to address unmet medical needs. In those cases, the targeted action date is six months from submission,
or for biologics constituting original biological products, six months from the date that FDA accepts the application for filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of its review, FDA may refer a BLA to an
advisory committee for evaluation and a recommendation as to whether the application should be approved. Although FDA is not bound by
the recommendation of an advisory committee, the agency usually has followed such recommendations. FDA may also determine that a REMS
program is necessary to ensure that the benefits of a new product outweigh its risks, and that the product can therefore be approved.
A REMS program may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe
or dispense the product, depending on what FDA considers necessary for the safe use of the product. Under the Pediatric Research Equity
Act, a BLA must include an assessment, generally based on clinical study data, of the safety and effectiveness of the subject drug or
biological product in relevant pediatric populations, unless the requirement is waived or deferred. Receiving orphan drug designation
from FDA is one situation where such a requirement may be waived.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After review of a BLA, FDA may determine that the
product cannot be approved, or may determine that it can only be approved if the applicant cures deficiencies in the application, in which
case the agency endeavors to provide the applicant with a complete list of the deficiencies in correspondence known as a Complete Response
Letter (CRL). A CRL may request additional information, including additional preclinical or clinical data. Even if such
additional information and data are submitted, FDA may decide that the BLA still does not meet the standards for approval. Data from clinical
trials are not always conclusive and FDA may interpret data differently than the sponsor interprets them. Additionally, as a condition
of approval, FDA may impose restrictions that could affect the commercial success of a drug or require post-approval commitments, including
the completion within a specified time period of additional clinical studies, which often are referred to as Phase IV studies
or post-marketing requirements. Obtaining regulatory approval often takes several years, involves the expenditure of substantial
resources, and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments,
and the risks and benefits demonstrated in clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Post-approval modifications to the drug or biologic
product, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional
data or conduct additional preclinical or clinical trials. The proposed changes would need to be submitted in a new or supplemental BLA,
which would then require FDA approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Regulatory Exclusivities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Biologics Price Competition and Innovation Act</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2010, the <i>Biologics Price Competition and
Innovation Act</i> (BPCIA) was enacted, creating an abbreviated approval pathway for biologic products that are biosimilar
to, and possibly interchangeable with, reference biological products licensed under a BLA. The BPCIA also provides innovator manufacturers
of original reference biological products 12 years of exclusive use from first licensure before biosimilar versions can be licensed in
the U.S. This means that FDA may not approve an application for a biosimilar version of a reference biological product until 12 years
after the date of first licensure of the reference biological product (with a potential six-month extension of exclusivity if certain
pediatric studies are conducted and the results reported to FDA), although a biosimilar application may be submitted four years after
the date of first licensure of the reference biological product. Additionally, the BPCIA establishes procedures by which the biosimilar
applicant must provide information about its application and product to the reference product sponsor, and by which information about
potentially relevant patents is shared and litigation over patents may proceed in advance of approval of the biosimilar product, although
the interpretation of those procedures has been subject to litigation and appears to continue to evolve. The BPCIA also provides a period
of exclusivity for the first biosimilar to be determined by FDA to be interchangeable with the reference product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FDA approved the first biosimilar product under
the BPCIA in 2015, and the agency continues to refine the procedures and standards it will apply in implementing this approval pathway.
FDA has released guidance documents interpreting specific aspects of the BPCIA in the years since. We would expect lenzilumab, ifabotuzumab
and HGEN005, as biologics, to each receive at least 12 years exclusivity from first licensure if they are approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Pediatric Studies and Exclusivity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the <i>Pediatric Research Equity Act</i>,
a BLA must contain data adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.
Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric
study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information
required by regulation. The applicant, FDA, and FDAs internal review committee must then review the information submitted, consult
with each other and agree upon a final plan. FDA or the applicant may request an amendment to the plan at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For products intended to treat a serious or life-threatening
disease or condition, FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to
discuss deferral or waiver of pediatric assessments. In addition, FDA will meet early in the development process to discuss pediatric
study plans with sponsors and FDA must meet with sponsors by no later than the end-of-Phase I meeting for serious or life-threatening
diseases and by no later than ninety (90) days after FDAs receipt of the study plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FDA may, on its own initiative or at the request
of the applicant, grant deferrals for submission of some or all pediatric data until after licensing of the product for use in adults,
or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests
and requests for extension of deferrals are contained in <i>Food and Drug Administration Safety and Innovation Act </i>(FDASIA).
Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA Reauthorization Act of 2017 established
new requirements to govern certain molecularly targeted cancer indications. Any company that submits a BLA three years after the date
of enactment of that statute must submit pediatric assessments with the BLA if the biologic is intended for the treatment of an adult
cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric
cancer. The investigation must be designed to yield clinically meaningful pediatric study data regarding the dosing, safety and preliminary
potency to inform pediatric labeling for the product. Deferrals and waivers as described above are also available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pediatric exclusivity is another type of exclusivity
in the U.S. and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing
regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits
pediatric data that fairly respond to a written request from FDA for such data. The data do not need to show the product to be effective
in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to FDAs request, the additional
protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits,
whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by a further six months. This
is not a patent term extension, but it effectively extends the regulatory period during which FDA cannot license another application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Orphan Drug Designation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Orphan Drug Act provides incentives for the
development of therapeutic products intended to treat rare diseases or conditions. Rare diseases and conditions generally are those affecting
less than 200,000 individuals in the U.S., but also include diseases or conditions affecting more than 200,000 individuals in the U.S.
if there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for such disease or condition
will be recovered from sales in the U.S. of such product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a sponsor demonstrates that a therapeutic product,
including a biological product, is intended to treat a rare disease or condition, and meets certain other criteria, FDA grants orphan
drug designation to the product for that use. FDA may grant multiple orphan designations to different companies developing the same product
for the same indication, until the one company is the first to be able to secure successful approval for that product. The first product
approved with an orphan drug designated indication is granted seven years of orphan drug exclusivity from the date of approval for that
indication. During that period, FDA generally may not approve any other application for the same product for the same indication, although
there are exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. FDA can
also revoke a products orphan drug exclusivity under certain circumstances, including when the holder of the approved orphan drug
application is unable to assure the availability of sufficient quantities of the product to meet patient needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A sponsor of a product application that has received
an orphan drug designation is also granted tax incentives for clinical research undertaken to support the application. In addition, FDA
will typically coordinate with the sponsor on research study design for an orphan drug and may exercise its discretion to grant marketing
approval based on more limited product safety and efficacy data than would ordinarily be required, based on the limited size of the applicable
patient population.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Expedited Programs for Serious Conditions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FDA has implemented a number of expedited programs
to help ensure that therapies for serious or life-threatening conditions, and for which there is unmet medical need, are approved and
available to patients as soon as it can be concluded that the therapies benefits justify their risks. Among these programs are
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Fast Track Designation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FDA may designate a product for fast-track review
if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening
disease or condition and where non-clinical or clinical data demonstrates the potential to address unmet medical need for such a disease
or condition. A product can also receive fast track review if it receives breakthrough therapy designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For fast-track products, sponsors may have greater
interactions with FDA and FDA may initiate review of sections of a fast-track products application before the application is complete,
also referred to as a rolling review. This rolling review may be available if FDA determines, after preliminary evaluation
of clinical data submitted by the sponsor, that a fast-track product may be effective. The sponsor must also provide, and FDA must approve,
a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Furthermore, FDAs time
period goal for reviewing a fast-track application does not begin until the last section of the complete application is submitted. Finally,
the fast-track designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the
clinical trial process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Breakthrough Therapy Designation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A product may be designated as a breakthrough therapy
if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition
and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or
more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes
all of the features of fast-track designation, as well as more intensive FDA interaction and guidance. FDA may take certain actions with
respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice
to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary
project lead for the review team; and taking other steps to design efficient clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accelerated Approval</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the accelerated approval pathway, FDA may
approve a drug or biologic based on a surrogate endpoint that is reasonably likely to predict clinical benefit; qualifying products must
target a serious or life-threatening illness and provide meaningful therapeutic benefit to patients over existing treatments. In clinical
trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct
measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than
clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including
the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required
post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow FDA to withdraw the product from the
market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior
review by FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Priority Review</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FDA may designate a product for priority review
if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness.
FDA generally determines, on a case-by-case basis, whether the proposed product represents a significant improvement in safety and effectiveness
when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the
treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient
compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority
designation is intended to direct overall attention and resources to the evaluation of such applications and will shorten FDAs
goal for acting on a marketing application from the standard targeted ten months to a target of six months review.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Created in 2012 under the FDASIA and extended with
the <i>21<sup>st</sup> Century Cures Act</i> in 2016, FDA is authorized under section 529 of the FDCA to grant a PRV to BLA sponsors receiving
FDA approval for a product to treat a rare pediatric disease, defined as a disease that affects fewer than 200,000 individuals in the
U.S., and where more than 50% of the patients affected are aged from birth to 18 years. We believe that our product candidates which may
assist with the treatment of rare pediatric cancers or other rare pediatric diseases may qualify for a PRV under this program, depending
on the indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The PRV program allows the voucher holder to obtain
priority review for a product application that would otherwise not receive priority review, shortening FDAs target review period
to a targeted six months following acceptance of filing of an NDA or BLA, or four months shorter than the standard review period. The
voucher may be used by the sponsor who receives it, or it may be sold to another sponsor for use in that sponsors own marketing
application. The sponsor who uses the voucher is required to pay additional user fees on top of the standard user fee for reviewing an
NDA or BLA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We anticipate submitting applications for one or
more of these expedited programs and the targeted therapeutic indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Regenerative Medicine Advanced Therapy Designation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Recently, through the <i>21st Century Cures Act
</i>(the Cures Act), Congress also established another expedited program, called a RMAT designation. The Cures Act directs
FDA to facilitate an efficient development program for and expedite review of RMATs. To qualify for this program, the product must be
a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or a combination of such products, and not a product
solely regulated as a human cell and tissue product. The product must be intended to treat, modify, reverse, or cure a serious or life-threatening
disease or condition, and preliminary clinical evidence must indicate that the product has the potential to address an unmet need for
such disease or condition. Advantages of the RMAT designation include all the benefits of the fast track and breakthrough therapy designation
programs, including early interactions with FDA. These early interactions may be used to discuss potential surrogate or intermediate endpoints
to support accelerated approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Post-Licensing Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once a BLA is approved and a product marketed,
a sponsor will be required to comply with all regular post-licensing regulatory requirements as well as any post-licensing requirements
that FDA may have imposed as part of the licensing process. The sponsor will be required to report, among other things, certain adverse
reactions and manufacturing problems to FDA, provide updated safety and potency or efficacy information and comply with requirements concerning
advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments
with FDA and certain state agencies and are subject to periodic unannounced inspections by FDA and certain state agencies for compliance
with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon
manufacturers. Changes to the manufacturing processes are strictly regulated and often require prior FDA approval before being implemented.
Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production
and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the distribution of prescription pharmaceutical
products is subject to the <i>Prescription Drug Marketing Act</i> (PDMA) and its implementing regulations, as well as the
<i>Drug Supply Chain Security Act</i> (DSCA), which regulate the distribution and tracing of prescription drug samples at
the federal level and set minimum standards for the regulation of distributors by the states. The PDMA, its implementing regulations and
state laws limit the distribution of prescription pharmaceutical product samples, and the DSCA imposes requirements to ensure accountability
in distribution and to identify and remove counterfeit and other illegitimate products from the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Drug Development and Approval in the European Union and United
Kingdom</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">In order to market a drug
product outside of the United States, a company must comply with a variety of foreign regulatory requirements governing clinical studies,
product approval, and commercial sale and distribution of the product. Regardless of whether a company obtains FDA approval for the product,
it must obtain any necessary approvals from foreign regulatory authorities prior to commencing clinical trials or marketing the product
in the relevant countries. The approval process and regulatory requirements vary significantly across jurisdictions, and the time to approval
and marketing may be longer or shorter than that required for FDA approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>European Union </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The process governing
approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory
completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product
for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application,
or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU. As in the
United States, the EU also has a standard marketing authorization approval process and a conditional authorization process that can be
used to bring medicine to the market more quickly during a public health emergency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
EUs Clinical Trials Regulation (CTR) went into effect on January 31, 2022. The CTR repeals the Clinical Trials Directive
(CTD) and national implementing legislation in EU Member States, which previously regulated clinical trials in the EU. The
evaluation, authorization, and supervision of&nbsp;clinical trials&nbsp;are the responsibilities of EU Member States and European Economic
Area (EEA) countries. Prior to the CTR, clinical trial sponsors had to submit clinical trial applications separately to regulatory authorities
in each country to gain regulatory approval to conduct clinical trials. The new CTR aims to harmonize the process for assessment and supervision
of clinical trials by enabling sponsors to submit a single online application for approval to run a clinical trial in several European
countries, making it more efficient to carry out such multinational trials. A three-year phased-in transition period has been established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Traditional marketing
authorization in the EU may be obtained under a centralized procedure, a decentralized procedure, or a mutual recognition procedure. The
data requirements and standards governing drug authorization are the same in the EU regardless of the authorization route.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The centralized procedure
provides for a grant of a single marketing authorization that is valid for all EU Member States. Under the centralized procedure, drug
companies submit a single marketing authorization application to European Medicines Agency (EMA). EMAs <span style="background-color: white">Committee
for Medicinal Products for Human Use (CMPH) </span>will carry out a scientific assessment of the application and recommend
whether or not the drug should be marketed. The European Commission will then make a legally binding decision based on the CMPH recommendation.
Once granted by the European Commission, the centralized marketing authorization is valid in all EU Member States and in European Economic
Area countries, although decisions about pricing and reimbursement will take place at the national and regional level before a medicine
will be made available in a particular EU country. The centralized procedure is mandatory for drugs that contain a new active substance
to treat certain condition (such as cancer); drugs derived from biotechnology processes, such as genetic engineering; advanced-therapy
medicines, such as gene-therapy; orphan medicines for rare diseases; and some veterinary medicines. It is optional for other drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The decentralized procedure
allows an applicant to apply for simultaneous authorization by more than one EU Member State where a drug product has not yet been authorized
by any EU Member State and does not fall within the mandatory scope of the centralized procedure. Under the decentralized procedure, <span style="background-color: white">one
of the proposed EU Member States is asked by the applicant to act as a Reference Member State (RMS). The RMS conducts the
initial evaluation of the product and issues a draft assessment report and related materials. The assessment report is submitted to the
other Concerned Member States (CMS) who must decide whether to approve the report and related materials or
to ask further questions and/or raise objections. If all issues are resolved and the application is successful, each Member State will
then issue a Marketing Authorization for the product permitting it to be marketed in their country. If a CMS cannot approve the assessment
report and related materials due to concerns regarding potential serious risk to public health, disputed elements may be referred to the
European Commission, whose decision is binding on all Member States. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, the Mutual Recognition Procedure must
be used when a product has already been authorized in at least one Member State on a national basis and the Marketing Authorization Holder
wishes to obtain a marketing authorization for the same product in at least one other Member State. The Member State that has already
authorized the product (known as the RMS) submits its evaluation of the product to one or more other Concerned Member States, which are
then asked to mutually recognize the marketing authorization of the RMS. If the application it successful, the Concerned Member State(s)
will then issue a marketing authorization permitting the marketing of the product in their country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.05pt; background-color: white">As in the U.S., companies
may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the application for
marketing authorization is made. Orphan drugs in Europe enjoy economic and marketing benefits, including up to 11 years of exclusivity
for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior
to the orphan-designated product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.05pt; background-color: white">In the EU, companies
developing a new medicinal product must agree to a Pediatric Investigation Plan (PIP) with EMA and must conduct pediatric
clinical trials in accordance with that PIP, unless a deferral or waiver applies, (e.g., because the relevant disease or condition occurs
only in adults). The marketing authorization application for the product must include the results of pediatric clinical trials conducted
in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must
be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted
in accordance with the PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (if any
is in effect at the time of approval) or, in the case of orphan medicinal products, a two-year extension of the orphan market exclusivity.
This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed
and submitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i><span style="text-decoration: underline">European
Union  Conditional Marketing Authorization</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The EMA may grant a conditional marketing authorization
for medicines that address unmet needs, on the basis of less comprehensive clinical data than normally required, where the benefit of
immediate availability of the medicine outweighs the risk inherent in the fact that additional data are still required. Drugs for human
use, including orphan drugs, are eligible for conditional marketing authorization if they are intended to treat, prevent, or diagnose
serious debilitating or life-threatening diseases, if: (1) the risk-benefit balance of the product is positive; (2) it is likely that
the applicant will be in a position to provide the required comprehensive clinical study data; (3) unmet medical needs will be fulfilled;
and (4) the benefit to the public health of the immediate availability on the market of the product outweighs the risk inherent in the
need for additional data. Conditional marketing authorization, which may specify additional requirements regarding completion of ongoing
or new studies and collection of pharmacovigilance data, is valid for one year, and may be renewed annually if the risk-benefit balance
remains positive, and after assessment of the need for additional or modified conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the COVID-19 pandemic, EMA is using the
conditional marketing authorization procedure to expedite the approval of safe and effective COVID-19 treatments and vaccines in the EU.
In a public health emergency such as the pandemic, the conditional marketing authorization procedure can be combined with a rolling review
of data during the development of a promising medication to further expedite evaluation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>The United Kingdom</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.75pt; background-color: white">Since the exit of the
UK from the European Union, Great Britain (England, Scotland, and Wales) is no longer covered by EU procedures for the grant of marketing
authorizations and a separate marketing authorization will be required to market drugs (Northern Ireland is covered by the centralized
authorization procedure and can be covered under the decentralized or mutual recognition procedures). It will be necessary for applicants
to make a separate application to the UK Medicines and Healthcare products Regulatory Agency ("MHRA") for a UK marketing authorization.
For a period of two years from January 1, 2021, MHRA may rely on a decision taken by the European Commission on the approval of a new
marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate
application, however, is still required. There is currently no procedure for mutual EU/UK recognition of new medicinal products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.75pt; background-color: white; color: #0B0C0C">MHRA
has introduced a national conditional marketing authorization scheme for new drugs in Great Britain. This scheme has the same eligibility
criteria as theEUscheme and is intended for drugs that fulfill an unmet medical need, such as drugs for serious and life-threatening
diseases where no satisfactory treatment methods are available or where the product offers a major therapeutic advantage. MHRA&nbsp;may
grant a&nbsp;conditional marketing authorization where comprehensive clinical data is not yet complete, but it is judged that such data
will become available soon. The marketing authorization application must still contain adequate evidence of safety and efficacy to enable
MHRA to conclude that the risk-benefit balance of the drug is positive. MHRA may take into account the designation by EMA (or another
jurisdiction) of a drug as eligible for conditional marketing authorization, but MHRA will make the final decision on eligibility of the
product under the Great Britain framework. Conditional marketing authorizations will be valid for one year and will be renewable annually.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">With the exit of the UK
from the European Union, the UK will not be implementing the CTR and the UK provisions implementing the current law as set out in the
CTD will continue to apply until amended by the UK.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Data exclusivity periods
in the United Kingdom are currently in line with those in the European Union; however, the Trade and Cooperation Agreement that outlines
the future trading relationship between the UK and EU provides that the periods for both data and market exclusivity are to be determined
by domestic law; therefore, exclusivity periods in the two jurisdictions could diverge in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Gaining orphan drug designation
in Great Britain following Brexit is based on the prevalence of the condition in Great Britain (rather than in the EU). It is, therefore,
possible that conditions that are currently designated as orphan conditions in Great Britain will no longer be and that conditions that
are not currently designated as orphan conditions in the EU will be designated as such in Great Britain. Unlike in the EU, applications
for orphan drug designation in Great Britain are reviewed in parallel with the corresponding marketing authorization application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees and Human Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2021, we employed 11 full-time
employees, and no part-time employees, the majority of whom work remotely in various locations throughout the United States and the world.
In addition, we contract with several part-time independent consultants performing manufacturing, supply chain, quality assurance and
control, regulatory and clinical development, intellectual property, public relations, investor relations, commercial, and finance and
accounting functions. None of our employees are subject to a collective bargaining agreement. We consider our relationship with our employees
to be good.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Information about our Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">The following
sets forth the names, ages and current positions of our executive officers as of February 16, 2022</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white"><i>Cameron
Durrant, M.D., MBA</i>, <i>age 61</i>, has served as our Chairman of our Board since January 2016, and as our Chief Executive Officer
since March 2016. In addition, Dr. Durrant served as our Interim Chief Financial Officer from July 1, 2019 to July 31, 2020. From May
2014 to January 2016, Dr. Durrant served as Founder and Director of Taran Pharma Limited, a private semi-virtual specialty pharma company
developing and registering treatments in Europe for orphan conditions. Dr. Durrant served as President and Chief Executive Officer of
ECR Pharmaceuticals Co., Inc., a subsidiary of Hi-Tech Pharmacal Co., Inc., from September 2012 to April 2014 until its acquisition by
Akorn. He previously has been a senior executive at Johnson and Johnson, Pharmacia Corporation, GSK and Merck. Dr. Durrant was a director
of Immune Pharmaceuticals Inc. from July 2014 to September 2018 and serves on the boards of directors of two privately held healthcare
companies. Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College
of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, and his MBA from
Henley Management College, Oxford, UK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white"><i>Timothy
Morris, CPA, age 60, </i>joined Humanigen as Chief Operating and Financial Officer on August 1, 2020. Prior to assuming his position as
a Humanigen officer, Mr. Morris served as a member of our Board since June 2016. </span>Mr. Morris served as the Chief Financial Officer
of Iovance Biotherapeutics, Inc., a biopharmaceutical company, from August 2017 until June 2020. From March&nbsp;2014 to June 2017, Mr.
Morris served as Chief Financial Officer and Head of Business Development of AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical
company. From November 2004 to December 2013, Mr.&nbsp;Morris served as Senior Vice President Finance and Global Corporate Development,
Chief Financial Officer of VIVUS, Inc. a biopharmaceutical company. Mr.&nbsp;Morris received his BS in Business with an emphasis in Accounting
from California State University, Chico, and is a Certified Public Accountant (Inactive).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Dale Chappell, M.D., MBA, age 51,</i>&nbsp;was
appointed as our Chief Scientific Officer on July 6, 2020. Dr. Chappell is the managing member of BH Management, a private investment
manager that specializes in biopharmaceuticals and a significant stockholder, a position he has held since 2002. Since April 2015, Dr.
Chappell has served as CEO, President and CFO of Cheval U.S. Holdings, Inc., a private investment company with holdings in the hospitality
industry. Previously, Dr. Chappell was an associate with Chilton Investment Company, covering healthcare, and an analyst at W.P. Carey
&amp; Company. Dr. Chappell, who received his MD from Dartmouth Medical School and his MBA from Harvard Business School, began his career
as a Howard Hughes Medical Institute fellow at the National Cancer Institute where he studied tumor immunology, worked as a researcher
in the labs of Dr. Steven A. Rosenberg (widely thought of as one of the pioneers in CAR-T therapy) and Dr. Nicholas P. Restifo (a leading
researcher in the field of immunology) and is published in the field of GM-CSF. Dr. Chappell served as a member of the Board from June
2016 to November 2017. Prior to joining Humanigen in a full-time role as our Chief Scientific Officer, Dr. Chappell advised and consulted
with management as our ex-officio chief scientific officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Edward P. Jordan, MBA, age 54,</i> was appointed
as our Chief Commercial Officer on August 24, 2020. Mr. Jordan has more than two decades of commercial operations experience at leading
biotechnology and pharmaceutical companies, having launched over a dozen products and developed new therapeutic markets in the U.S. and
abroad. From 2016 until joining Humanigen, Mr. Jordan served as Senior Vice President of DBV Technologies, where he built the North American
commercial organization in preparation for the launch of a lifesaving pediatric biologic. Prior to DBV Technologies, from January 2014
to July 2015, Mr. Jordan was the Senior Vice President, Hematology and Oncology Sales and Marketing at AMAG Pharmaceuticals. Prior to
AMAG Pharmaceuticals, Mr. Jordan served in executive roles at Teva Pharmaceuticals. Mr. Jordan began his career at Schering-Plough, prior
to the acquisition by Merck, and spent 18 years in sales and marketing leadership positions. Mr. Jordan received dual undergraduate degrees
from The University of Rhode Island and an MBA from Southern New Hampshire University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Adrian Kilcoyne, MD, MBA, MPH, age 51,</i> was
appointed as our Chief Medical Officer on April 21, 2021. Dr. Kilcoyne has significant global pharmaceutical and biotechnology industry
experience and an extensive clinical background. From June 2019 until joining Humanigen, Dr. Kilcoyne served as Vice President of Oncology
Global Medical Affairs, AstraZeneca most recently as Head of Evidence Generation and External Alliances, where he oversaw the global evidence
strategy across the companys entire oncology portfolio. Previously, Dr. Kilcoyne held several leadership positions at Celgene Corporation
including Executive Medical Director, Global Lymphoma Program Lead, Clinical Research and Development, overseeing the development of lenalidomide
in DLBCL and worked closely on the development of Breyanzi. Dr. Kilcoyne graduated from Trinity College, Dublin and holds a MSc in Public
Health from the London School of Hygiene and Tropical Medicine, along with a MSc in Business Administration from the Warwick Business
School.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were incorporated on March 15, 2000 in California
and reincorporated as a Delaware corporation in September 2001. Effective August 7, 2017, we changed our legal name to Humanigen, Inc.
Our principal executive offices are located at 830 Morris Turnpike, 4<sup>th</sup> Floor, Short Hills, NJ 07078 and our telephone number
is (973) 200-3010. Our website address is www.humanigen.com. Our common stock is currently listed on the Nasdaq Capital Market under the
symbol HGEN. We operate in a single segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our website and the information contained on, or
that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this
Annual Report on Form 10-K. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments
to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free
of charge on the Investor Relations portion of our website as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the SEC. In addition, the SEC maintains an internet site that contains the reports, proxy and information statements,
and other information we electronically file with or furnish to the SEC, located at www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="p1i1a"></span>ITEM 1A.&nbsp;&nbsp;RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business faces significant risks and uncertainties.
Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should
carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors,
in its entirety, in addition to other information contained in or incorporated by reference into this Annual Report on Form 10-K and our
other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect
our business, prospects, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Business and Industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.2pt"><b><i>Risks Related to Our Efforts to Develop
Lenzilumab for COVID-19</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.2pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>FDA declined our initial request for emergency use authorization
for lenzilumab as a therapy for hospitalized patients with COVID-19. The MHRA also has not approved our application for marketing authorization
of lenzilumab in this indication. We are continuing to pursue an authorization or approval for lenzilumabs use in hospitalized
patients with COVID-19 in the U.S., UK and EU, but may not obtain one.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">On September 8, 2021, FDA informed us that it
had declined to issue an EUA for lenzilumab for patients hospitalized with COVID-19. FDA has advised us that we will need to submit further
safety and efficacy data in an amended application for EUA. Likewise, MHRA raised a number of questions in its review of our application
for marketing authorization, including around efficacy, to which we need to respond. It is possible, but not assured, that the results
from the Accelerating COVID-19 Therapeutic Interventions and Vaccines-5 (ACTIV-5) and Big Effect Trial, in the B
arm of the trial (BET-B), referred to as the <span style="color: #201F1E; background-color: white">ACTIV-5/BET-B trial,</span>
being conducted by NIH, if confirmatory of the findings of the CRP subgroup from the LIVE-AIR study, may support our efficacy claim in
such a way as to support an amendment to the EUA application and our response to MHRA. In addition, if the results from ACTIV-5/BET-B
are not confirmatory of the results of the findings of the CRP subgroup from the LIVE-AIR study, we would either conduct a new clinical
trial of our own or abandon this development program altogether. Unfavorable results likely would have a material and adverse impact on
our stock price and ability to obtain future financing needed to continue as a going concern, as well.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If ACTIV-5/BET-B results confirm our findings
from the CRP subgroup from the LIVE-AIR study, we may be required to obtain and submit additional information related to the Chemistry
Manufacturing and Control (CMC) aspects of lenzilumab production before we attain EUA or any other authorization or approval.
We are in the process of obtaining additional CMC information but there is no assurance as to exactly when or if we will generate sufficient
information to satisfy regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">More broadly, in the context of EUA or any other
request for a conditional marketing authorization or approval, there is no requirement that FDA or any regulatory body reach a favorable
conclusion about our submissions. A myriad of factors, including the regulators assessment of the urgency of the need for a therapeutic
such as lenzilumab; the efficacy of lenzilumab in new or different variants that have emerged or may evolve; and other factors such as
the development of more efficacious vaccines or therapies, may influence a regulators decision on any submissions we may make.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Furthermore, if an EUA is granted to permit lenzilumab
to be commercialized for use in the treatment of COVID-19, the authorization would only remain in effect while a Public Health
Emergency is underway and might be expressly conditioned or limited by FDA. An EUA, if granted, could also be terminated if, in
the future, there are changes in available data that bear on the risk-benefit analysis, or if alternative approved products become available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; color: #262524">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Accordingly, it is possible that FDA and other
regulatory authorities may not authorize or approve lenzilumab for the treatment of COVID-19, or that any such authorization or approval,
if granted, may have significant limitations on its use or subsequently be rescinded or terminated. We may never successfully commercialize
lenzilumab for use in COVID-19 patients or realize a return on our significant investment in the development, supply, and commercialization
of lenzilumab for this purpose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We need to obtain additional financing to fund our operations
and, if we are unable to obtain such financing, we may be unable to continue to operate as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">During 2021, we incurred significant costs associated
with our development program for lenzilumab in COVID-19 without attaining a regulatory authorization or approval to commercialize it.
Our liquidity position is highly constrained as a result. We need to obtain additional financing to pursue the development of lenzilumab
and our other product candidates pending our ability to commence commercialization and begin generating revenues from product sales if
lenzilumab were to be authorized or approved by a regulatory agency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until we can generate a sufficient amount of revenue,
we intend to attempt to finance future cash needs through our at-the-market offering program or other public or private equity offerings,
license agreements, grant financing and support from governmental agencies, convertible debt, other debt financings, collaborations, strategic
alliances, extending and managing amounts owed to vendors and marketing, supply, distribution or licensing arrangements. Additional funds
may not be available when we need them on terms that are acceptable to us, or at all. We expect that the results of the ACTIV-5/BET-B
trial will be important to potential investors in evaluating an investment in our company. Accordingly, our ability to raise capital on
favorable terms in the future is linked closely to the success of that trial, which we cannot assure. Unfavorable results likely would
have a material and adverse impact on our stock price and ability to obtain future financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unsuccessful in efforts to raise additional
capital, based on our current levels of operating expenses, our current capital is not expected to be sufficient to fund our operations
for the next twelve months. These conditions raise substantial doubt about our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements for the year
ended December 31, 2021 were prepared on the basis of a going concern, which contemplates that we will be able to realize our assets and
discharge liabilities in the normal course of business. The financial statements do not include any adjustments that might be necessary
if we are unable to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the presence of the explanatory paragraph
about our ability to continue as a going concern in our financial statements, could also make it more difficult to raise the capital necessary
to address our current needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our commercial opportunity in COVID-19 may be reduced or eliminated
if competing products for the same segment of patients that lenzilumab targets are authorized or approved.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We may not be successful in attaining any authorization
or approval for lenzilumab in hospitalized COVID-19 patients before competitors receive authorization or approval of competitive therapeutics.
In addition, vaccines, neutralizing antibodies, and oral antivirals which have been granted EUA and/or FDA approval to prevent COVID-19
may indirectly compete for the same patients by preventing hospitalization. As discussed in greater detail under Item 1. BusinessLenzilumab
and COVID-19 Competition, several neutralizing antibodies have been approved to prevent progression in the early stages of infection,
multiple vaccines and boosters have been authorized by FDA and other regulatory agencies, and there are numerous other companies working
on therapies and/or vaccines to treat COVID-19. If additional competing therapies and/or vaccines are approved, such approval could have
a material adverse impact on our ability to attain regulatory approvals needed to commercialize lenzilumab as a therapy for COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Manufacturing efforts relating to our lenzilumab program in COVID-19
have been extremely costly and inefficient in producing treatments for use in our clinical development program or potential sale. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our complete reliance on third-party manufacturers
to produce lenzilumab subjects us to a number of risks, as described in more detail under Other Risks Related to Our Business
and Industry below. We believe that our ability to obtain the requisite regulatory authorizations or approvals to permit lenzilumab
to be used commercially for hospitalized patients with COVID-19 depends at least in part on our ability to demonstrate that we will be
able to scale the manufacturing to produce a sufficient quantity of treatments, satisfying all applicable process performance qualification
(PPQ) requirements, to address the potential demand for the product. Our efforts to develop that manufacturing scale have
been impaired by the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We have experienced and expect to continue to experience shortages of raw materials
        and critical components necessary for our manufacturing processes.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We struggled to reserve manufacturing slots at our CMOs. During the latter half
        of 2020, and continuing into 2021, it was and continues to be more challenging and expensive to obtain these slots due to increased demand
        for production at our CMOs, many of which also manufacture vaccines and other therapeutics. </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Even after being reserved and paid for, the manufacturing slots for which we
        contracted were in some cases displaced as mandated from Rated Orders issued under the U.S Defense Production Act (DPA).
        This displacement risk has caused us to expend significant efforts to manage our supply chain and add additional CMOs. </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Some of our CMOs struggled or outright failed to produce lenzilumab meeting our
        specifications. The process of manufacturing biologics is extremely susceptible to product loss due to contamination, equipment failure
        or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes
        could result in reduced production yields, product defects and other supply disruptions. If microbial, viral, foreign substances or other
        contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities
        may need to be closed for an extended period of time to investigate and remedy the contamination. We lost batches of lenzilumab BDS to
        several of these disruptive errors, which has limited the number of potential treatments on hand. In addition, two of our CMOs have denied
        responsibility for the challenges they experienced and are demanding payment despite not delivering usable BDS; these payment demands,
        if resolved adversely to us, would further impair our liquidity.</span></td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.7in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Subsequent to FDAs declination to grant EUA following our initial request,
        we took action to cancel future manufacturing slots. While some in-process work is continuing, we do not yet have any capacity reserved
        for lenzilumab production beyond 2022, nor do we have agreements in place for the commercial production of lenzilumab. Accordingly, our
        ability to scale our manufacturing could be delayed if we were to attain a regulatory authorization or approval to commercialize lenzilumab
        in hospitalized COVID-19 patients later in 2022.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Interim, top-line, ad-hoc, retrospective, exploratory or preliminary
data from our clinical trials that we announce or publish from time-to-time may change as more patient data become available and are subject
to audit and verification procedures that could result in material changes in the final data.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">From time-to-time, we may publicly disclose preliminary,
top-line or other data from clinical trials, which is based on a preliminary analysis of then-available data, and the results
and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We may
also seek to publish additional ad-hoc, retrospective or exploratory data, including results from patients with baseline CRP levels &lt;150
mg/L. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received
or had the opportunity to fully and carefully evaluate all data. As a result, such results that we report may differ from future results
of the same trials, or different conclusions or considerations may qualify such results once additional data have been received and fully
evaluated. Such data also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data we previously published. As a result, interim, top-line, or preliminary data should be viewed with caution until
the final data are available. Such data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data become available. Adverse differences between such data and final data could
significantly harm our business prospects. Further, disclosure of interim, top-line or preliminary data by us or by our competitors could
result in volatility in the price of shares of our common stock and dramatic spikes in trading volume, as we experienced following our
announcement of top-line data from the LIVE-AIR study in March 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In addition, others, including regulatory agencies,
may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance
of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular
product candidate or product, and our business in general. FDAs action to decline our initial request for EUA represents a dramatic
manifestation of this risk. In addition, the information we choose to publicly disclose or to publish via a preprint publication regarding
a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we
determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose
may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular
drug, product candidate, or our business. If the top-line data that we report differ from actual results, or if others, including regulatory
authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our current or any our future
product candidate, our business, operating results, prospects or financial condition may be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Target enrollment in the ACTIV-5/BET-B study has
been reached in the primary analysis group (CRP&lt;150 mg/L &lt; 85 years old). Analysis of data can begin once the database lock has
occurred. The NIH controls the data analysis and we may be unable to influence the timeline for completion. The primary endpoint is based
on an assessment 29 days after treatment, and accordingly we believe top-line data from this study could be available in late first quarter
or early in the second quarter of 2022, but the NIH may choose to wait until day 60 to complete their analysis. In addition, the COVID-19
pandemic, and in particular the widespread transmission of the omicron variant even among vaccinated people, has had a significant negative
impact on worker productivity. It is possible that, due to COVID-19 or other reasons, the timeline to collect and analyze the data from
ACTIV-5/BET-B may be delayed, causing the anticipated timeline to slip. There can be no assurance that we will be able to report top-line
results within the timeline established by our guidance or that the top-line results will be consistent with the final results as reported
after Day 60.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We cannot predict public reaction or the impact
on the market price of our common stock once further announcements regarding lenzilumab or developments from ACTIV-5/BET-B are announced.
Given the attention being paid to the&nbsp;COVID-19&nbsp;pandemic and the public scrutiny of&nbsp;COVID-19&nbsp;development announcements
and data releases to date, any public announcements we make in the coming months regarding the ongoing development and regulatory process
for lenzilumab&nbsp;may attract significant attention and scrutiny and as a result, the price of our common stock may be volatile during
this time.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If an authorization or approval were granted for lenzilumab,
we may be unable to accurately predict demand for lenzilumab or to produce sufficient quantities on a timely basis to meet demand.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If lenzilumab were authorized or approved for
commercial use, we may be unsuccessful in estimating user demand and may not be effective in matching inventory levels and locations to
actual end user demand, in particular if the COVID-19 pandemic, including emerging variants, is effectively contained or the risk of patients
being hospitalized as a result of coronavirus infection is significantly diminished. In addition, adverse changes in economic conditions,
increased competition, including through approved/authorized vaccines or other therapeutics (including neutralizing antibodies and oral
antivirals), or other factors may cause hospitals or other users or distributors of lenzilumab to reduce inventories of our products,
which would reduce their orders for lenzilumab, even if end user demand has not changed. As a result, our revenues could be difficult
to predict and vulnerable to extreme fluctuations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>There can be no assurance that lenzilumab,
even if approved, would ever become profitable, due to government or healthcare provider or payer interest and public perception regarding
vaccines and treatments for COVID-19 related complications.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; background-color: white">As a result of the emergency
situations in many countries, there is a heightened risk that a&nbsp;COVID-19&nbsp;therapy or other treatments for COVID-19 symptoms may
be subject to adverse governmental actions in certain countries, including intellectual property expropriation, compulsory licenses, strict
price controls or other actions. Additionally, we may need, or we may be required by governmental or&nbsp;non-governmental&nbsp;authorities,
to set aside specific quantities of doses of lenzilumab for designated purposes or geographic areas. We may face challenges related to
the allocation of supply of lenzilumab, particularly with respect to geographic distribution. Thus, even if lenzilumab is approved, such
governmental actions may limit our ability to recoup our current and future expenses incurred to develop and commercialize lenzilumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; background-color: white">Furthermore, public sentiment
regarding commercialization of a COVID-19 therapy or other treatment may limit or negate our ability to generate revenues from sales of
lenzilumab. If authorized or approved, we may face significant public attention and scrutiny over any future business models and pricing
decisions with respect to lenzilumab. If we are unable to successfully manage these risks, we could face significant reputational harm,
which could negatively affect the price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently have no internal sales and
marketing capabilities and will rely on third parties to market and sell lenzilumab if we attain an EUA or other regulatory approval for
its commercialization, and any product candidates we may successfully develop. We or they may not be able to effectively market and sell
any such product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We currently do not have internal sales and marketing
infrastructure in place that would be necessary to sell and market products and we may choose to not build this capability in-house. As
is the case with many, if not most, small companies seeking to commercialize their products and who have not yet partnered with a larger
biotech or pharmaceutical company, we have entered into an arrangement to outsource logistics and distribution services as described under
Item 1. BusinessSales and Marketing. There can be no assurance that our partner will be effective in distributing
lenzilumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If we or any of our potential partners fail to
hire, train, retain and manage qualified sales personnel, market our product successfully or on a cost-effective basis, our ability to
generate revenue will be limited and we will need to identify and retain an alternative third-party, or develop our own sales and marketing
capability. The establishment of an in-house sales and marketing operation can be expensive and time consuming and could delay any product
candidate launch.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt"><b><i>Other Risks Related
to Our Business and Industry</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a history of operating losses, we
expect to continue to incur losses, and we may never become profitable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have incurred net losses in nearly every year
since our inception. For the year ended December 31, 2021, we incurred a net loss of $236.6 million, and we have an accumulated deficit
of $611.1 million as of December 31, 2021. Since inception, we have recognized a nominal amount of revenue from payments for license or
collaboration fees, $3.6 million of which was recognized in the year ended December 31, 2021. We expect to make substantial expenditures
and incur additional operating losses in the future to further develop and commercialize our product candidates. Our accumulated deficit
is expected to increase significantly as we continue our development and clinical trial efforts. Our ability to achieve and sustain profitability
depends on obtaining regulatory approvals for and successfully commercializing our product candidates, either alone or with third parties.
We do not currently have the required approvals to market any of our product candidates and we may never receive them. We may not be profitable
even if we or any future development partners succeed in commercializing any of our product candidates. Because of the numerous risks
and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future
losses or when we will become profitable, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our business depends on the success of our current product candidates.
We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">We have a limited pipeline
of product candidates and we do not plan to conduct active research at this time for discovery of new molecules or antibodies. We depend
on the successful development and attainment of regulatory authorization or approval of our current product candidates for our future
business success. The future clinical, regulatory and commercial success of our product candidates is subject to a number of risks, including
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we may not be able to enroll adequate numbers of
        eligible patients in the clinical trials we propose to conduct, whether alone or through collaborations;</span></td></tr>
  </tbody></table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we may not have sufficient financial and other resources
        to fund our clinical trials or collaborations;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we may not be able to provide acceptable evidence
        of safety and efficacy for our product candidates;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the results of our clinical trials or collaborations
        may not meet the level of statistical or clinical significance, or product safety, required to move to the next stage of development or,
        ultimately, obtain marketing approval from FDA;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we may not be able to obtain, maintain and enforce
        our patents and other intellectual property rights; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we may not be able to obtain and maintain commercial
        manufacturing arrangements with third-party manufacturers or establish commercial-scale manufacturing capabilities.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the fluid and
unpredictable nature of the COVID-19 pandemic may affect our ability to conduct our ongoing clinical trials, delay the initiation of planned
and future clinical trials, cause interruptions in the supply of raw materials or products, delay the collection of clinical trial data,
and disrupt regulatory activities. Accordingly, we cannot assure you that our product candidates will be successfully developed or commercialized.
If we or any future development partners are unable to develop, or obtain regulatory approval for or, if approved, successfully commercialize
one or more of our product candidates, we may not be able to generate sufficient revenue to continue our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, even if we do
receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated
uses for which we may market the product. If any of our product candidates are unsuccessful, that could have a substantial negative impact
on our business.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The adoption of CAR-T therapies as the potential standard of
care for treatment of certain cancers is uncertain, and dependent on the efforts of a limited number of market entrants, and if not adopted
as anticipated, the market for lenzilumab or next-generation gene-edited CAR-T therapies may be limited or not develop.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are seeking to advance the development of lenzilumab
to address, among other things, the serious and potentially fatal side effects, specifically ICANS and CRS associated with CAR-T therapies
and to improve the efficacy of these treatments. We, through our collaboration with Mayo Clinic, are also working to create next-generation
gene-edited CAR-T therapies using GM-CSF gene knockout technologies. Although five CAR-T therapies have been approved by FDA to date,
the use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients,
hospitals, cancer treatment centers, payers and others in the medical community.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If the medical and payer community is not sufficiently
persuaded of the safety, efficacy and cost-effectiveness of CAR-T therapy and the potential advantages of using lenzilumab compared to
existing and future therapeutics, and there is not significant market acceptance of CAR-T therapy as the standard of care for treatment
of certain cancers, the market for lenzilumab or next-generation gene-edited CAR-T therapies may be limited or not develop, and our stock
price could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>CAR-T therapies currently in early development purport to incorporate
technology that may minimize or eliminate the adverse side-effects, namely ICANS and CRS, and improve on efficacy, that we believe have
impaired the uptake of the approved CAR-T therapies. If these developing therapies are proven safer and equally or more efficacious in
their proposed indications and approved for use by FDA and other regulatory agencies, the market growth for the currently approved CAR-T
therapies may be limited, impairing demand for lenzilumab.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In recent years, several biotechnology companies
describing business plans focusing on development of CAR-T therapies have completed or announced they are pursuing initial public offerings
(IPOs). Several of these companies have described their belief that their therapies will not result in the same level of
ICANS or CRS as has been experienced in use of previously FDA-approved CAR-T therapies. While these products are in early-stage development,
the data is limited and these products have not yet been approved for use by FDA, if new CAR-T therapies with lower occurrences of CRS
and ICANS are approved, the market for lenzilumab in conjunction with CAR-T therapy may be diminished. Any such failure of a market for
lenzilumab to develop could adversely affect our stock price. In addition, if new CAR-T therapies that offer improved efficacy, either
with or without improved safety, are approved, the market for lenzilumab which is used in conjunction with CAR-T therapy may be diminished
if such CAR-T therapy is used in preference to existing CAR-T therapy. For more information regarding FDA-approved CAR-T therapies, see
Item 1. BusinessLenzilumab in CAR-T.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our business could target benefits from various regulatory incentives,
such as orphan drug exclusivity, breakthrough therapy designation, fast track designation, and priority review, but we may not ultimately
qualify for or benefit from these incentives.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We may seek various regulatory incentives, such
as orphan drug exclusivity, breakthrough therapy designation, fast track designation, accelerated approval, priority review and Priority
Review Vouchers (PRVs), where available, that provide for certain periods of exclusivity, expedited review and/or other
benefits, and we may also seek similar designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining
whether or not products qualify for such regulatory incentives and benefits. We cannot guarantee that we will be able to receive orphan
drug status from FDA or equivalent regulatory designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy
or fast track designation, which may provide certain potential benefits such as more frequent meetings with FDA to discuss the development
plan, intensive guidance on an efficient drug development program, and potential eligibility for rolling review or priority review. Legislative
developments in the U.S., including proposed legislation that would restrict eligibility for PRVs, may affect our ability to qualify for
these programs in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Even if we are successful in obtaining beneficial
regulatory designations by FDA or other regulatory agency for our product candidates, such designations may not lead to faster development
or regulatory review or approval and does not increase the likelihood that our product candidates will receive marketing approval. We
may not be able to obtain or maintain such designations for our product candidates, and our competitors may obtain these designations
for their product candidates, which could impact our ability to develop and commercialize our product candidates or compete with such
competitors, which would adversely impact our business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>There is a limited amount of information about us upon which
investors can evaluate our product candidates and business prospects, including because we have a limited operating history developing
product candidates, and we have not yet successfully commercialized any products, and have a relatively small management team.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our primary focus is developing our proprietary
monoclonal antibody portfolio, primarily lenzilumab and iFab. Our limited operating history developing clinical-stage product candidates
may make it more difficult for us to succeed or for investors to be able to evaluate our business and prospects. In addition, as an early-stage
clinical development company, we have limited experience in development activities, including conducting clinical trials, or seeking and
obtaining regulatory approvals, even though our executives have had relevant experience at other companies. We currently have ten full-time
employees and therefore are heavily dependent on external consultants and expert vendors for clinical, scientific, contract manufacturing
and regulatory expertise. To execute our business plan, we will need to successfully:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">execute our product candidate development activities,
        including successfully completing our clinical trial programs, including those conducted under our collaborations and partnerships;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">obtain required regulatory approvals or authorizations
        for the development and commercialization of our product candidates;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">manage our costs and expenses related to clinical
        trials, regulatory approvals, manufacturing and commercialization;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">secure substantial additional funding;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">develop and maintain successful strategic relationships;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">build and maintain a strong intellectual property
        portfolio;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">build and maintain appropriate clinical, sales, manufacturing,
        distribution, and marketing capabilities on our own or through third parties; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">gain market acceptance and favorable reimbursement
        status for our product candidates.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If we are unsuccessful in accomplishing these
objectives, we may not be able to develop product candidates, raise capital, expand our business, or continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>In addition to our collaborations with the NIH, Mayo Clinic,
IMPACT Partnership, SAHMRI and the University of Adelaide, and the Olivia Newton-John Cancer Research Centre, we may, in the future, seek
to enter into collaborations with other third parties for the discovery, development and commercialization of our product candidates.
If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these
collaborations may fail to lead to commercial products, and we may never receive milestone payments or future royalties under these agreements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We may in the future seek to enter into agreements
with other third-party collaborators for research, development and commercialization of other therapeutic technologies or product candidates.
Biopharmaceutical companies are our likely future collaborators for any marketing, distribution, development, licensing, or broader collaboration
arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or at all, or such collaborations are not
successful, we may not be able to execute our strategy to develop our product candidates or therapies that we believe could benefit from
the resources of either larger biopharmaceutical companies or those specialized in a particular area of relevance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">With respect to our existing collaboration agreements,
we have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization
of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators
abilities to successfully perform the functions assigned to them in these arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Collaborations involving our product candidates
pose the following risks to us, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborators have significant discretion in determining the efforts and resources
        that they will apply to these collaborations;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborators may not pursue development and commercialization of our product
        candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial
        results, changes in the collaborators strategic focus or available funding, or external factors such as an acquisition that diverts
        resources or creates competing priorities;</span></td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborators may delay clinical trials, provide insufficient funding for a clinical
        trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation
        of a product candidate for clinical testing;&nbsp;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborators could independently develop, or develop with third parties, products
        that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely
        to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborators with marketing and distribution rights to one or more products
        may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborators may not properly maintain or defend our intellectual property rights
        or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property
        or proprietary information or expose us to litigation or potential liability;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborators may infringe the intellectual property rights of third parties,
        which may expose us to litigation and potential liability;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">disputes may arise between the collaborators and us that result in the delay
        or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration
        that diverts management attention and resources; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">collaborations may be terminated and, if terminated, may result in a need for
        additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">As a result of the foregoing, our current and
any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner
or at all. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration
agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Moreover, to the extent that any of our existing
or future collaborators were to terminate a&nbsp;collaboration agreement, we may be forced to independently develop these product candidates,
including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property
rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and
have a material adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;<b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have relied and may in the future rely on third parties to
conduct Investigator Sponsored Trials (ISTs) of our products, which is cost-effective for us but affords the investigators
the ability to retain significant control over the design and conduct of the trials, as well as the use of the data generated from their
efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have relied and may in the future rely on third
parties to conduct and sponsor clinical trials relating to lenzilumab, our GM-CSF gene knockout platform and our other immunotherapy product
candidates, iFab and HGEN005. Such ISTs may provide us with valuable clinical&nbsp;data&nbsp;that can inform our future development strategy
in a&nbsp;cost-efficient manner, but we do not control the design or conduct of the ISTs, and it is possible that FDA or non-U.S. regulatory
authorities will not view these ISTs as providing adequate support for future clinical trials, whether controlled by us or third parties,
for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">These arrangements provide us limited information
rights with respect to the&nbsp;ISTs, including access to and the ability to use and reference the&nbsp;data, including for our own regulatory
filings, resulting from the&nbsp;ISTs. However, we would not have&nbsp;control&nbsp;over the timing and reporting of the&nbsp;data&nbsp;from&nbsp;ISTs,
nor would we own the data from the ISTs. If we are unable to confirm or replicate the results from the ISTs or if negative results are
obtained, we would likely be further delayed or prevented from advancing further clinical development. Further, if investigators or institutions
breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared
to the first-hand knowledge, we might have gained had the ISTs been sponsored and conducted by us, then our ability to design and conduct
any future clinical trials ourselves may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If the third parties conducting our clinical trials do not conduct
the trials in accordance with our agreements with them, our ability to pursue our clinical development programs could be delayed or unsuccessful
and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We do not have the ability to conduct all aspects
of our preclinical testing or clinical trials ourselves. Therefore, the timing of the initiation and completion of these trials is uncertain
and may occur on substantially different timing from our estimates. We also use CROs to conduct our clinical trials and rely on medical
institutions, clinical investigators, CROs, and consultants to conduct our trials in accordance with our clinical protocols and regulatory
requirements. Our CROs, investigators, and other third parties play a significant role in the conduct of these trials and subsequent collection
and analysis of data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">There is no guarantee that NIH, any CROs, investigators,
or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources
to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to
our clinical protocols, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. If
any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in
our ongoing clinical trials unless we are able to transfer those subjects to another qualified clinical trial site. In addition, principal
investigators for our clinical trials may serve as scientific advisors or consultants to us from time-to-time and may receive cash or
equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual
conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be jeopardized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may experience delays in commencing or conducting our clinical
trials, in receiving data from third parties or in the continuation or completion of clinical testing, which could result in increased
costs to us, delay our ability to generate product candidate revenue or, ultimately, render us unable to complete the development and
commercialization of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have product candidates in clinical development
and preclinical development. To obtain marketing approval from regulatory authorities for the sale of any product candidate, we must complete
preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in
humans. Before we can initiate clinical trials in the U.S. for any new product candidates, we are required to submit the results of preclinical
testing to FDA as part of an IND application, along with other information including information about product candidate chemistry, manufacturing,
and controls and our proposed clinical trial protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In order to continue with our testing programs
already underway, we are required to report or provide information to appropriate regulatory authorities, and any failure to timely submit
such reports or information will delay our plans for our clinical trials. If third parties conducting our trials do not make the required
data available to us, we will likely have to identify and contract with another third party or develop necessary preclinical and clinical
data on our own, which will lead to significant delays. In addition, FDA may require us to conduct additional preclinical testing for
any product candidate before it allows us to initiate clinical testing under any IND application, which may lead to additional delays.
Moreover, despite the presence of an active IND application for a product candidate, clinical trials can be delayed for a variety of reasons,
including delays in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">identifying, recruiting, enrolling and retaining or replacing qualified subjects
        to participate in a clinical trial, which may be slower than anticipated due to the number of companies and institutions competing for
        subjects in clinical studies with similar patient populations;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">identifying, recruiting, and training suitable clinical investigators;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">reaching agreements on acceptable terms with prospective CROs and trial sites,
        the terms of which can be subject to extensive negotiation, may be subject to modification from time-to-time, and may vary significantly
        among different CROs and trial sites;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">obtaining and maintaining sufficient quantities of a product candidate for use
        in clinical trials;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">obtaining and maintaining Institutional Review Board (IRB) or ethics
        committee approval to conduct a clinical trial at an existing or prospective site;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">developing any companion diagnostic necessary to ensure the study enrolls the
        target population;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">being required by FDA to add more patients or sites or to conduct additional
        trials; or</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">FDA placing a clinical trial on hold.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Clinical trials may also be delayed as a result
of ambiguous or negative interim results. Further, a clinical trial may be suspended or terminated by us, an IRB, an ethics committee,
or a data safety monitoring committee overseeing the clinical trial, any of our clinical trial sites with respect to that site, or FDA
or other regulatory authorities, due to several factors, including unforeseen safety issues, known safety issues that occur at a greater
frequency or severity than we anticipate, any determination that the clinical trial presents unacceptable health risks, or lack of adequate
funding.	</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Any delays in our clinical trials may delay or
preclude our ability to further develop or pursue regulatory approval for our product candidates. Changes in U.S. and foreign regulatory
requirements and guidance also may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require
us to resubmit our clinical trial protocols to IRBs for re-examination, which may affect the costs, timing, and likelihood of a successful
completion of a clinical trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If we are required to conduct additional clinical
trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete
clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or do not meet the
standard for acceptability by regulatory authorities or if there are safety concerns, we may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">be delayed in obtaining marketing approval for our product candidates;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">not obtain marketing approval or EUA at all;</span></td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">obtain approval for indications or patient populations that are not as broad
        as intended or desired;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">obtain approval with labeling that includes significant use or distribution restrictions
        or safety warnings;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">be subject to additional post-marketing testing requirements; or</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">have the product removed from the market after obtaining marketing approval.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our product development costs will also increase
if we experience delays in testing or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical
trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change
the design or protocol of one or more of our clinical trials, including to add additional arms or patient populations, which could result
in increased costs and expenses and/or delays. If we or any future development partners experience delays in the completion of, or if
we or any future development partners must terminate, any clinical trial of any product candidate, our ability to obtain regulatory approval
for that product candidate will be delayed and the commercial prospects, if any, for the product candidate may suffer as a result. Significant
preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize
our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
our product candidates and may harm our business and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our product candidates are subject to extensive regulation, compliance
with which is costly and time consuming, may cause unanticipated delays, may prevent the receipt of the required approvals to commercialize
our product candidates, or may result in substantial harm to our business if we fail to comply with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The clinical development, approval, manufacturing,
labeling, storage, record-keeping, advertising, promotion, import, export, marketing, and distribution of our product candidates are subject
to extensive regulation by FDA in the U.S. and by comparable authorities in foreign markets. In the U.S., we are not permitted to market
our product candidates until we receive regulatory approval or other authorization, such as EUA, from FDA. The process of obtaining regulatory
approval is expensive, often takes many years, and can vary substantially based upon the type, complexity, and novelty of the products
involved, as well as the target indications. Approval policies or regulations may change, and FDA has substantial discretion in the drug
approval process, including the ability to delay, limit, or deny approval of a product candidate for many reasons. Despite the time and
expense invested in clinical development of product candidates, regulatory approval is never guaranteed. FDA or other comparable foreign
regulatory authorities can delay, limit, or deny approval of a product candidate for many reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">such authorities may disagree with the design or implementation of our or any
        future development partners clinical trials;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">such authorities may not accept clinical data from trials that are conducted
        at clinical facilities or in countries where the standard of care is potentially different from the U.S.;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the results of clinical trials may not demonstrate the safety or efficacy required
        by such authorities for approval;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">we or any future development partners may be unable to demonstrate that a product
        candidates clinical and other benefits outweigh its safety risks;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">such authorities may disagree with our interpretation of data from preclinical
        studies or clinical trials;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">such authorities may find deficiencies in the manufacturing processes or facilities
        of third-party manufacturers with which we or any future development partners contract for clinical and commercial supplies; or</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the approval policies or regulations of such authorities may significantly change
        in a manner rendering our or any future development partners clinical data insufficient for approval.&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">With respect to foreign markets, approval procedures
vary widely among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review
periods, and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals
may result in increased caution by FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy
or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or
inability to obtain, applicable regulatory approvals may delay or prevent us or any future development partners from commercializing our
product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If we receive regulatory approval for our product
candidates, we will be subject to ongoing FDA obligations and continued regulatory oversight and review, such as continued safety reporting
requirements, and we may also be subject to additional FDA post-marketing obligations. If we are not able to maintain regulatory compliance,
we may not be permitted to market our product candidates, may be subject to product recalls, import and export restrictions or seizures,
and/or may be subject to civil and/or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The results of preclinical studies and early clinical trials
are not always predictive of future results. Any product candidate we or any future development partners advance into clinical trials
may not have favorable results in later clinical trials, if any, or receive regulatory approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Drug development has substantial inherent risk.
We or any future development partners will be required to demonstrate through adequate and well-controlled clinical trials that our product
candidates are effective, with a favorable benefit-risk profile, for use in their target populations for their intended indications before
we can seek regulatory approvals for their commercial sale. Drug development is a long, expensive and uncertain process, and delay or
failure can occur at any stage of development, including after commencement of any of our clinical trials. Success in early clinical trials
does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate
sufficient safety or efficacy despite having progressed through initial clinical testing. Furthermore, our future trials will need to
demonstrate sufficient safety and efficacy for approval by regulatory authorities in larger patient populations. Companies frequently
suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition,
only a small percentage of drugs under development result in the submission of an NDA or BLA to FDA, and even fewer are approved for commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We face risks associated with clinical operations abroad, which
may adversely affect our financial condition and results of operations, and we may not be able to receive conditional marketing or other
approvals for lenzilumab in COVID-19 patients in markets outside the U.S.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Partners are conducting or planning to conduct
clinical trials involving lenzilumab in the UK, Korea and Australia, as well as potentially in other countries in patients with COVID-19
and other indications. In addition, we are working to seek CMA for lenzilumab in hospitalized COVID-19 patients in the European Union
and the United Kingdom. We have not received any authorization or approval to sell lenzilumab in any country but would expect to commence
commercial operations, through a partner or on our own, only after such authorization or approval were received. As with our development
programs in the U.S., our product candidates must be approved for marketing and sale by regulatory authorities in each jurisdiction to
which we may apply for approval and, once approved, are subject to extensive regulation by regulatory agencies in other countries. We
anticipate that we may file for marketing approval in additional countries and for additional indications and products over the next several
years. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at
all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with
certainty when or whether any of our product candidates under development will be approved by any foreign regulators or launched; whether
we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will
be commercially successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">International operations involve risks that are
different from those faced in the U.S. and would subject us to complex and frequently changing laws and regulations, including differing
labor laws, such as the United Kingdom (UK) Modern Slavery Act. In addition, operations abroad are accompanied by certain
financial, political, economic and other risks, including those listed below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Foreign Currency Exchange: Operations internationally may subject us to risks
        related to foreign currency exchange risks as we make payments, or incur obligations, denominated in foreign currencies. We cannot predict
        future fluctuations in the foreign currency exchange rates of the U.S. dollar. If the U.S. dollar appreciates significantly against certain
        currencies and our practices do not sufficiently offset the effects of such appreciation, our results of operations would be adversely
        affected, and our stock price may decline.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar
        worldwide anti-bribery laws that will govern our international operations with respect to payments to government officials. Our international
        operations would be heavily regulated and require significant interaction with foreign officials. In certain circumstances, strict compliance
        with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of
        which may be state controlled, in a manner that is different than local custom. In addition, despite our efforts, our policies and procedures
        may not protect us from reckless or criminal acts committed by persons who act on our behalf. Enforcement activities under anti-bribery
        laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including
        monetary penalties and exclusion from health care programs.</span></td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other risks inherent in conducting foreign operations
include:</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">International operations, including any use of third-party manufacturers, distributors,
        CROs and collaboration arrangements outside the U.S., expose us to increased risk of theft of our intellectual property and other proprietary
        technology, particularly in jurisdictions with less robust intellectual property protections than the U.S., as well as restrictive government
        actions against our intellectual property and other foreign assets such as nationalization, expropriation or the imposition of compulsory
        licenses.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">We may be subject to protective economic policies taken by foreign governments,
        such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions
        or similar restrictions by the U.S. or other governments.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Our foreign operations, third-party manufacturers, CROs or strategic partners
        could be subject to business interruptions for which we or they may be uninsured or inadequately insured.</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Our operations may also be adversely affected if there is political instability
        or disruption in any other geographic region where we may have operations, which could impact our ability to do business in those areas.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we were to encounter any of these risks, our
foreign operations may be adversely affected, which could have an adverse effect on our overall business and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we fail to attract and retain key management and clinical
development personnel, or if the attention of such personnel is diverted, we may be unable to successfully manage our business and develop
or commercialize our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We will need to effectively manage our managerial,
operational, financial, and other resources in order to successfully pursue our clinical development and commercialization efforts. As
a company with a limited number of personnel, we are heavily affected by turnover and highly dependent on the expertise of the members
of our senior management. If we are unable to provide competitive compensation to these employees, it may be difficult to retain them.
For 2021, the Board of Directors froze the salary levels of all but one employee who was promoted and did not award any cash bonuses for
2021 performance, opting instead to grant options to employees to purchase shares of common stock in satisfaction of amounts earned under
the Company's 2021 annual incentive plan. There can be no assurance that these decisions will not have a negative impact on the retention
of our employees. Furthermore, we rely on third party consultants for a variety of services. We cannot predict the impact of the loss
of such individuals or the loss of services of any of our other senior management, should they occur, or the difficulty in replacing such
individuals. Such losses could delay or prevent the further development and potential commercialization of our product candidates and,
if we are not successful in finding suitable replacements, could harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If our competitors develop similar or comparable treatments for
the target indications of our product candidates that are approved more quickly, marketed more successfully or are demonstrated to be
safer or more effective than our product candidates, or if FDA approves generic or biosimilar competitors to our products post-approval,
our commercial opportunity will be reduced or eliminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We compete in an industry characterized by rapidly
advancing technologies, intense competition, a changing regulatory and legislative landscape and a strong emphasis on the benefits of
intellectual property protection and regulatory exclusivities. Our competitors include pharmaceutical companies, other biotechnology companies,
academic institutions, government agencies and other private and public research organizations. We compete with these parties in immunotherapy
and oncology treatments and in recruiting highly qualified personnel. Our product candidates, if successfully developed and approved,
may compete with established therapies, with new treatments that may be introduced by our competitors, including competitors relying on
our biologics approvals under section 351(k) of the Public Health Service Act, or with generic copies of our products approved by FDA
under an abbreviated new drug application (ANDA), referencing our drug products. We believe that competitors are actively
developing competing products to our product candidates. See Item 1. BusinessCompetition for a discussion of competition
with respect to our current product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Many of our competitors and potential competitors
have substantially greater scientific, research, and product development capabilities, as well as greater financial, marketing, sales
and human resources capabilities than we do. In addition, many specialized biotechnology firms have formed collaborations with large,
established companies to support the research, development and commercialization of products that may be competitive with ours. Accordingly,
our competitors may be more successful with respect to their products than we may be in developing, commercializing, and achieving widespread
market acceptance for our products. If a competitor obtains approval for an orphan drug that is the same drug or the same biologic as
one of our candidates before we do, we will be blocked from obtaining FDA approval for seven years from the date of the competitors
product, unless we can establish that our product is clinically superior to the previously-approved competitors product or we can
meet another exception, such as by showing that the competitor has failed to provide an adequate supply of its product to patients after
approval. In addition, our competitors products may be more effective or more effectively marketed and sold than any treatment
we or our development partners may commercialize and may render our product candidates obsolete or non-competitive before we can recover
the expenses related to developing and supporting the commercialization of any of our product candidates. Developments by competitors
may render our product candidates obsolete or noncompetitive. After one of our product candidates is approved, FDA may also approve a
generic version with the same dosage form, safety, strength, route of administration, quality, performance characteristics and intended
use as our product. These generic equivalents would be less costly to bring to market and could generally be offered at lower prices,
thereby limiting our ability to gain or retain market share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The acquisition or licensing of pharmaceutical
products is also very competitive, and a number of more established companies, which have acknowledged strategies to in-license or acquire
products, may have competitive advantages as may other emerging companies taking similar or different approaches to product acquisitions.
The more established companies may have a competitive advantage over us due to their size, cash flows, institutional experience and historical
corporate reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are subject to a multitude of manufacturing risks, any of
which could substantially increase our costs and limit supply of our products and rely completely on third parties to manufacture drug
product, which could adversely impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The process of manufacturing our products is complex,
costly, highly regulated, and subject to several risks. As such, we have no present plan or intention of developing in-house manufacturing
capabilities for nonclinical, clinical or commercial scale production, and are wholly dependent on third party contract manufacturers
for the timely supply of adequate quantities of our products which meet or exceed requisite quality and production standards for use in
clinical and nonclinical studies. Our dependence on CMOs increases our manufacturing risks, including the possible breach of the manufacturing
agreement by the CMO, the possible cancellation, delay or modification of contracted manufacturing slots by the CMO, or the termination
or nonrenewal of the agreement by the CMO at a time that is costly or inconvenient for us, and could adversely affect our ability to develop
and commercialize our product candidates on a timely basis. In addition, in order to balance risk and conserve financial and human resources,
we have and may continue from time-to-time to defer commitment to production of product, which could result in delays to the continued
progress of our clinical and nonclinical testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We, and our CMOs, must comply with extensive Good
Manufacturing Practices (cGMP) regulations and are subject to inspections by FDA and comparable agencies in other jurisdictions
to confirm compliance with applicable regulatory requirements. If, as a result of these inspections, a regulatory authority determines
that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval,
the regulatory authority may suspend the manufacturing operations. Suppliers of key components and materials must also be named in the
EUA, BLA or other marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking
marketing approval, and significant delays can occur if the qualification of a new supplier is required. Foreign agencies have not inspected
the Catalent site in Madison, WI. This site is the primary source of BDS for lenzilumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We, and our CMOs, may encounter difficulties in
achieving quality control and quality assurance and may experience shortages in qualified personnel. Any failure to follow cGMP or other
regulatory requirements or any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of
our products as a result of a failure of our or our CMOs facilities, could significantly impair our ability to develop and commercialize
our products, including leading to significant delays in the availability of products for our clinical studies or the termination or hold
of a clinical study, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Further,
we may have to pay the costs of manufacturing any batch produced by a CMO that fails to pass quality inspection or meet regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Significant noncompliance with manufacturing regulations
could also result in the imposition of sanctions, including injunctions, civil penalties, failure of regulatory authorities to grant marketing
approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products,
operating restrictions, adverse publicity, and criminal prosecutions, any of which could damage our reputation. If we are not able to
maintain regulatory compliance, we may not be permitted to market our products and/or may be subject to product recalls, seizures, injunctions,
or criminal prosecution. Any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory
shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. Once our product candidates
are approved, we may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications,
undertake costly remediation efforts or seek more costly manufacturing alternatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As is the case with MHRA, we are required to provide
information from the PPQ runs at certain CMOs. It is our belief that lenzilumab manufactured at CMOs that have not completed PPQ will
not be available for commercial sale in the UK. Historically, FDA provided guidance that we would not have to complete PPQ at all of our
CMOs and that we could rely on compatibility reports to sell product under EUA. We believe EMA may require PPQ information similar to
the requirements from MHRA. We do not know if FDAs position on the PPQ requirement has changed. If FDA requires similar PPQ information,
our ability to commercialize a significant amount of the lenzilumab produced to date will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the manufacturing facilities in which
our products are made could be adversely affected by equipment failures, plant closures, capacity constraints, competing customer priorities
or changes in corporate strategy or priorities, process changes or failures, changes in business models or operations, materials or labor
shortages, natural disasters, power failures and numerous other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our third-party manufacturers are independent
entities subject to their own unique operational and financial risks that are out of our control. Additionally, our third-party manufacturers
may only be able to produce some of our products at one or a limited number of facilities and, therefore, we have limited manufacturing
capacity for certain products, and we may not be able to locate additional or replacement facilities on a reasonable basis or at all.
Our sales of such products could also be adversely impacted by our reliance on such limited number of facilities. To the extent these
risks materialize and affect their performance obligations to us, our financial results may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In addition, we, our third-party suppliers and
our CMOs have experienced disruptions in supply of product candidates and/or procuring items that are essential for our research, development
and manufacturing activities, including raw materials and components used in the manufacturing of our product candidates for which there
have been shortages because of ongoing efforts to address the COVID-19 pandemic. These delays have impacted our overall manufacturing
supply chain operations to date, and while we continue to explore back up or alternative sources of supply, any future disruption in the
supply chain from the COVID-19 outbreak, or any continued outbreak, could have a material adverse impact on our clinical trial plans,
manufacturing activities and business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If any product candidate that we successfully develop does not
achieve broad market acceptance among physicians, patients, healthcare payers and the medical community, the revenue that it generates
may be limited.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Even if our product candidates receive regulatory
approval, they may not gain market acceptance among physicians, patients, healthcare payers, and the medical community. Coverage and reimbursement
of our product candidates by third-party payers, including government payers, generally is also necessary for commercial success. The
degree of market acceptance of any approved product candidates will depend on several factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the efficacy and safety as demonstrated in clinical trials;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the clinical indications for which the product candidate is approved;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">acceptance by physicians, major operators of hospitals and clinics, and patients
        of the product candidate as a safe and effective treatment;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the potential and perceived advantages of product candidates over alternative
        treatments;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the safety of product candidates seen in a broader patient group, including its
        use outside the approved indications;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the cost of treatment in relation to alternative treatments;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the availability of adequate reimbursement and pricing by payers;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">relative convenience and ease of administration;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the prevalence and severity of adverse events;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the effectiveness of our sales and marketing efforts; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the ability to manage any unfavorable publicity relating to the product candidate.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If any product candidate is approved but does
not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers, and patients, we may not generate sufficient
revenue from that product candidate and may not become or remain commercially attractive as a standalone indication for that product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Reimbursement may be limited or unavailable in certain market
segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Market acceptance and sales of our product candidates
will depend significantly on the availability of adequate insurance coverage and reimbursement from third-party payers for any of our
product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers,
such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement
levels. Reimbursement by a third-party payer may depend upon a number of factors including the third-party payers determination
that use of a product candidate is:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">a covered benefit under its health plan;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">safe, effective, and medically necessary;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">appropriate for the specific patient;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">cost-effective; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">neither experimental nor investigational.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Obtaining coverage and reimbursement approval
for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide
supporting scientific, clinical, and cost effectiveness data for the use of our product candidates to the payer. We may not be able to
provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement
will be available for any of our product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for,
or the price of, our product candidates. If reimbursement is not available or is available only to limited levels or with restrictions,
we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In the U.S. and in certain foreign jurisdictions,
there have been a number of legislative and regulatory changes to the health care system that could affect our ability to sell our product
candidates profitably. In particular, the Medicare Modernization Act of 2003 revised the payment methods for many product candidates under
Medicare. This has resulted in lower rates of reimbursement. There have been numerous other federal and state initiatives designed to
reduce payment for pharmaceuticals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">As a result of legislative proposals and the trend
toward managed health care in the U.S., third-party payers are increasingly attempting to contain health care costs by limiting both coverage
and the level of reimbursement of new drugs. They may also refuse to provide coverage of approved product candidates for medical indications
other than those for which FDA has granted market approvals. As a result, significant uncertainty exists as to whether and how much third-party
payers will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs. We could
be subject to pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the
increasing influence of health maintenance organizations, and additional legislative proposals as well as country, regional, or local
healthcare budget limitations. Similar concerns about the costs of treatment have been raised in Europe and the United Kingdom.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We face potential product liability exposure and, if successful
claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The use of our product candidates in clinical
trials and the sale of any product candidates for which we may obtain marketing approval expose us to the risk of product liability claims.
Product liability claims may be brought against us or any future development partners by participants enrolled in our clinical trials,
patients, health care providers, or others using, administering, or selling our product candidates. If we cannot successfully defend ourselves
against any such claims, or have insufficient insurance protection, we would incur substantial liabilities. Regardless of merit or eventual
outcome, product liability claims may result in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">withdrawal of clinical trial participants;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">termination of clinical trial sites or entire trial programs;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">costs of related litigation;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">substantial monetary awards to trial participants or other claimants;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">decreased demand for our product candidates and loss of revenue;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">impairment of our business reputation;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">diversion of management and scientific resources from our business operations;
        and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the inability to commercialize our product candidates.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have obtained limited product liability insurance
coverage for our clinical trials domestically and in selected foreign countries where we are conducting clinical trials. As such, our
insurance coverage may not reimburse us or may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance
coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost
or in sufficient amounts to protect us against losses due to product liability. We intend to expand our insurance coverage for product
candidates to include the sale of commercial products if we obtain marketing approval for our product candidates in development; however,
we may be unable to obtain commercially reasonable product liability insurance for any product candidates approved for marketing. Large
judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability
claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our working capital
and adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our employees and consultants may engage in misconduct or other
improper activities, including noncompliance with regulatory standards, which could have a material adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are exposed to the risk of employee fraud or
other misconduct.&nbsp;Misconduct by employees or consultants could include intentional failures to comply with FDA regulations or similar
regulations of comparable foreign regulatory authorities, failure to provide accurate information to FDA or comparable foreign regulatory
authorities, failure to comply with manufacturing standards, failure to comply with federal and state healthcare fraud and abuse laws
and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, failure to report
financial information or data accurately, violations of anti-bribery laws, or failure to disclose unauthorized activities to us.&nbsp;In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended
to prevent fraud, kickbacks, self-dealing and other abusive practices.&nbsp;These laws and regulations may restrict or prohibit a wide
range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.&nbsp;Employee
or consultant misconduct could also involve the improper use of confidential information obtained in the course of our business, which
could result in civil or criminal legal actions, regulatory sanctions, or serious harm to our reputation.&nbsp;We have adopted a Code
of Business Conduct and Ethics and other corporate policies, but it is not always possible to identify and deter employee misconduct,
and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such
laws or regulations.&nbsp;If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant
fines or other sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may encounter difficulties in managing our growth and expanding
our operations successfully</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">As we seek to advance our product candidates through
clinical trials, we will need to expand our development, regulatory, manufacturing, marketing, and sales capabilities, and contract with
third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships
with various development partners, suppliers, and other third parties. Future growth will impose significant added responsibilities on
members of management. Our future financial performance and our ability to commercialize our product candidates and to compete effectively
will depend in part on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts
and clinical trials effectively. We may not be able to accomplish these tasks and our failure to accomplish any of them could prevent
us from successfully growing our company.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We and any current or future development partners, third-party
manufacturers and suppliers may use hazardous materials, and any claims relating to improper handling, storage, or disposal of these materials
could be time consuming or costly.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We and any current or future development partners,
third-party manufacturers and suppliers may use hazardous materials, including chemicals and biological agents and compounds that could
be dangerous to human health and safety or the environment. Our operations and the operations of our development partners, third-party
manufacturers and suppliers also produce hazardous waste products. Federal, state, and local laws and regulations govern the use, generation,
manufacture, storage, handling, and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations
may be expensive and current or future environmental laws and regulations may impair our product development efforts. In addition, we
cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or
hazardous waste insurance coverage and our property, casualty, and general liability insurance policies specifically exclude coverage
for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination
or injury we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials
or regulatory approvals could be suspended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Legislative or regulatory healthcare reforms in the U.S. may
make it more difficult and costly for us to obtain regulatory approval of our product candidates and to produce, market, and distribute
our products after approval is obtained. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">From time-to-time, legislation is drafted and
introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture, and marketing
of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by FDA
in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing
regulations may impose additional costs or lengthen review times of our current product candidates or any future product candidates. There
have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening
the availability of health care and containing or lowering the overall cost of health care. We cannot predict the initiatives that may
be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payers
of healthcare services to contain or reduce costs of health care may adversely affect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the demand for any drug products for which we may obtain regulatory approval;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">our ability to set a price that we believe is fair for our product candidates;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">our ability to gain reimbursement at commercially acceptable levels;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">our ability to generate revenue and achieve or maintain profitability;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the level of taxes that we are required to pay; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the availability of capital.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, such changes could, among other things,
require:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">changes to manufacturing methods; </span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">additional studies, including clinical studies;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">recall, replacement, or discontinuance of one or more of our products; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">additional record-keeping.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Each of these would likely entail substantial
time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive
regulatory approvals for any future products would harm our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We and any of our future development partners will be required
to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to
do so would result in sanctions that would materially harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If we and any future development partners are
successful in commercializing our products, FDA and foreign regulatory authorities would require that we and any future development partners
report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The
timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event.
We and any future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any
future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not
reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If
we and any future development partners fail to comply with our reporting obligations, FDA or a foreign regulatory authority could take
action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance
of future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our product candidates for which we intend to seek approval as
biologic products may face competition sooner than anticipated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">With the enactment of the Biologics Price Competition
and Innovation Act of 2009, or the BPCIA, as part of the Affordable Care Act, an abbreviated pathway for the approval of biosimilar and
interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for FDA to review and
approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based
on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by FDA until
12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented
by FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes
intended to implement BPCIA may be fully adopted by FDA, any such processes could have a material adverse effect on the future commercial
prospects for our biological products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We believe that any of our product candidates,
such as lenzilumab, iFab and/or HGEN005, if approved as biological products under a BLA, should qualify for the 12-year period of exclusivity.
However, there is a risk that FDA will not consider our product candidates to be reference products for competing products, potentially
creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved,
will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Finally, there
is a risk that the 12-year exclusivity period could be reduced which could negatively affect our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In addition, foreign regulatory authorities may
also provide for exclusivity periods for approved biological products. For example, biological products in Europe may be eligible for
a 10-year period of exclusivity. However, biosimilar products have been approved under a sub-pathway of the centralized procedure since
2006. The pathway allows sponsors of a biosimilar product to seek and obtain regulatory approval based in part on the clinical trial data
of an originator product to which the biosimilar product has been demonstrated to be similar. In many cases,
this allows biosimilar products to be brought to market without conducting the full suite of clinical trials typically required of originators.
It is unclear whether we and any future development partners would face competition to our products in European markets sooner than anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may in the future be subject to various U.S. federal and state
laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations
by us of such laws could result in fines or other penalties</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If one or more of our product candidates is approved,
we will likely be subject to the various U.S. federal and state laws intended to prevent health care fraud and abuse. The federal anti-kickback
statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products
or services that would be paid for in whole or part by Medicare, Medicaid, or other federal health care programs. Remuneration has been
broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. Many states
have similar laws that apply to their state health care programs as well as private payers. Violations of the anti-kickback laws can result
in exclusion from federal health care programs and substantial civil and criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The False Claims Act imposes liability on persons
who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The
False Claims Act has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services
not provided as claimed, or for services that are not medically necessary. The False Claims Act includes a whistleblower provision that
allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. If our
marketing or other arrangements were determined to violate the False Claims Act or anti-kickback or related laws, then our revenue could
be adversely affected, which would likely harm our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">State and federal authorities have aggressively
targeted medical technology companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts
with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional
practices. Companies targeted in such prosecutions have paid substantial fines in the hundreds of millions of dollars or more, have been
forced to implement extensive corrective action plans or corporate integrity agreements, and have often become subject to consent decrees
severely restricting the manner in which they conduct their business. If we become the target of such an investigation or prosecution
based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar
sanctions, which would materially harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Even if regulatory authorization or
approval were received for lenzilumab or any other product candidate, the later discovery of previously unknown problems associated with
the use of lenzilumab or other product may result in restrictions, including withdrawal of the product from the market, and lead to significant
liabilities and reputational damage.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Serious adverse or undesirable side effects may
emerge or be identified during later stages of development of our products that were not observed in earlier stages. If our product candidates,
either alone or in combination with other therapeutics, are associated with serious adverse events or undesirable side effects or unacceptable
drug interactions in clinical trials or have characteristics that are unexpected in clinical trials or preclinical testing, we may need
to abandon their development or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable
side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical
development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that
prevent further development of the compound. In addition, if third parties manufacture or use our product candidates without our permission,
and generate adverse events or unacceptable side effects, this could also have an adverse impact on our development efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; background-color: white">Unacceptable adverse
events caused by any of our product candidates that we advance into clinical trials could cause us or regulatory authorities to interrupt,
delay, or halt clinical trials and could result in the denial of regulatory approval by the applicable regulatory authorities for any
or all targeted indications and markets. This in turn could prevent us from completing development or commercializing the affected product
candidate and generating revenue from its sale. We have not yet successfully completed testing of any of our product candidates for the
treatment of the indications for which we intend to seek approval in humans, and we currently do not know the extent of adverse events,
if any, that will be observed in individuals who receive any of our product candidates. Even if lenzilumab or any other products are approved,
if previously unknown problems with the product or its manufacture are subsequently discovered, we may be restricted or prohibited from
marketing or manufacturing such product and/or may be subject to substantial liabilities, which may adversely affect our ability to generate
revenue and our financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our ability to utilize our net operating loss carryforwards and
certain other tax attributes may be subject to certain limitations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have incurred substantial losses during our
history and do not expect to become profitable in the foreseeable future and may never achieve profitability. To the extent that we continue
to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire.
We may be unable to use these losses to offset income before such unused losses expire. The Tax Cuts and Jobs Act, enacted in 2017, limited
the use of net operating loss carryforwards for periods beginning after 2017 to eighty percent of taxable income in the period to which
the losses were carried. However, this limitation on the use of the carryforwards was eliminated by the Coronavirus Aid, Relief and Economic
Security Act (the CARES Act) for tax years beginning before January 1, 2021. In addition, Section 382 of the Internal Revenue
Code of 1986, as amended, may limit the utilization of net operating loss carryforwards. Under Section 382, if a corporation undergoes
an ownership change (generally defined as a greater than 50% change (by value) in its equity ownership over
a three-year period), the corporations ability to use its pre-change net operating loss carryforwards and other pre-change tax
attributes to offset its post-change income may be limited. We have recently and in the past experienced ownership changes that have resulted
in limitations on the use of a portion of our net operating loss carryforwards. If we experience further ownership changes our ability
to utilize our net operating loss carryforwards could be further limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We rely completely on third parties to supply drug substance
and manufacture drug product for our clinical trials and preclinical studies and intend to rely on other third parties to produce commercial
supplies of product candidates, and our dependence on third parties could adversely impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are dependent on third-party suppliers. If
our third-party suppliers do not supply sufficient quantities for product candidates to us on a timely basis and in accordance with applicable
specifications and other regulatory requirements including PPQ, we may be unable to supply our product candidates in development for clinical
trials or ship them to customers, if authorized or approved for commercial use. In addition, as further discussed above, our third-party
suppliers have experienced disruptions in supply of product and/or procuring essential items as a result of supply chain issues caused
by the COVID-19 pandemic. We regularly evaluate potential alternate sources of supply of raw materials, various components used in production,
drug substance and drug product, but there can be no assurance that any such suppliers would be available, acceptable, or successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We will also rely on our CMOs to purchase from
third-party suppliers the materials necessary to produce our product candidates for our anticipated clinical trials. There are a small
number of suppliers for certain capital equipment and raw materials used to manufacture our product candidates. We do not have any control
over the process or timing of the acquisition of these raw materials by our contract manufacturers. Moreover, we currently do not have
agreements in place for the commercial production of these raw materials. Any significant delay in the supply of a product candidate or
the raw material components thereof for an ongoing clinical trial could considerably delay completion of that clinical trial, product
candidate testing, and potential regulatory approval of that product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In addition, a significant portion of the raw
materials and intermediates used to manufacture our product candidates are supplied by third-party manufacturers and corporate partners
outside of the U.S. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations
of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the U.S. from supplying
these materials could adversely affect our ability to conduct our pending or contemplated clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may not be successful in establishing and maintaining development
partnerships and licensing agreements, which could adversely affect our ability to develop and commercialize product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Part of our strategy is to enter into development
partnerships and licensing agreements. We face significant competition in seeking appropriate partners and the negotiation process is
time consuming and complex. Even if we are successful in securing a development partnership, we may not be able to continue it. Moreover,
we may not be successful in our efforts to establish a development partnership or other alternative arrangements for any of our other
existing or future product candidates and programs because, among other reasons, our research and development pipeline may be insufficient,
our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and/or third parties
may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. Even if we are
successful in our efforts to establish new development partnerships, the terms that we agree upon may not be favorable to us and we may
not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales
of an approved product candidate are disappointing. In addition, our ability to enforce our partners obligations under any future
collaboration efforts may be limited due to time and resource constraints, competing corporate priorities of our future partners, and
other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If we fail to establish and maintain additional
development partnerships related to our product candidates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the development and commercialization of our current or future product candidates
        may be terminated or delayed;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">our cash expenditures related to development of certain of our current or future
        product candidates would increase significantly and we may need to seek additional financing;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">we may be required to hire additional employees or otherwise develop expertise,
        such as sales and marketing expertise, for which we have not budgeted; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">we will bear all of the risk related to the development of any such product candidates.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our or any new partners failure to develop,
manufacture or effectively commercialize our product would result in a material adverse effect on our business and results of operations
and would likely cause our stock price to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Currently pending, threatened or future litigation, arbitration,
governmental proceedings or inquiries could result in material adverse consequences, including judgments or settlements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are, or may from time-to-time become, involved
in lawsuits and other legal or governmental proceedings. See Item 3. to this Annual Report on Form 10-K and Note 11 to the Consolidated
Financial Statements included in this Annual Report on Form 10-K for information regarding currently pending litigation that could have
a material impact on us. Many of these matters raise complicated factual and legal issues and are subject to uncertainties and complexities,
all of which make the matters costly to address. The timing of the final resolutions to any such lawsuits, inquiries, and other legal
proceedings is uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Additionally, the possible outcomes or resolutions
to these matters could include adverse judgments or settlements, either of which could require substantial payments, adversely affecting
our consolidated financial condition, results of operations and cash flows. Any judgment against us, the entry into any settlement agreement,
or the imposition of any fine could have a material adverse effect on our consolidated financial condition, results of operations and
cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The terms of our loan agreement with Hercules may restrict our
current and future operations, particularly our ability to respond to changes in business or to take certain actions, including to pay
dividends to our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 10, 2021, we entered into the Loan and
Security Agreement with Hercules Capital, Inc. (the Term Loan) with a scheduled maturity date of March 1, 2025. As described
in more detail in Note 5 to the Consolidated Financial Statements, the Term Loan contains, and any future indebtedness we incur will likely
contain, a number of restrictive covenants that impose operating restrictions, including restrictions on our ability to engage in acts
that may be in our best long-term interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A breach of any of these covenants could result
in an event of default under the Loan Agreement. Upon the occurrence of such an event of default, Hercules may, at its discretion, accelerate
and demand payment of all or any part of the outstanding advances, together with a prepayment charge, end of term charge, and all interest
due and payable under the Term Loan. Hercules also may seek to realize on the collateral we have pledged as security for the Term Loan.
If our indebtedness is accelerated, we cannot assure you that we will have sufficient assets to repay the indebtedness. The restrictions
and covenants in the Term Loan and any future financing agreements may adversely affect our ability to finance future operations or capital
needs or to engage in other business activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We review and explore strategic alternatives on an on-going basis,
but there can be no assurance that we will be successful in identifying or completing any strategic alternative, and any such strategic
alternative, including future acquisitions of and investments in new businesses, could impact our business and financial condition. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We regularly review strategic alternatives to
ensure our current structure optimizes our ability to execute our strategic plan and to maximize stockholder value. The review of strategic
alternatives could result in, among other things, a sale, merger, consolidation or business combination, asset divestiture, partnering,
licensing or other collaboration agreements, or potential acquisitions of or investments in new businesses or recapitalizations, in one
or more transactions, or continuing to operate with our current business plan and strategy. There can be no assurance that the exploration
of strategic alternatives will result in the identification or consummation of any transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The process of exploring strategic alternatives
may be time consuming, disruptive to our business operations and divert the attention of management, and if we are unable to effectively
manage the process or successfully integrate any acquired personnel or operations, our business, financial condition and results of operations
could be adversely affected. We also cannot assure that any potential transaction or other strategic alternative, if identified, evaluated
and consummated, will perform as expected, will realize the expected benefits, synergies, or developments or that it will provide greater
value to our stockholders than that reflected in our current stock price. Any potential transaction would be dependent upon a number of
factors that may be beyond our control, including, among other factors, market conditions, industry trends, the interest of third parties
in our business or product candidates and the availability of financing to potential buyers on reasonable terms.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may incur
substantial expenses associated with identifying and evaluating potential strategic alternatives. To the extent we finance any acquisition
or other strategic alternative in cash, it would reduce our cash reserves, and to the extent the purchase price is paid with shares of
our common or preferred stock, it could be dilutive to our current stockholders. To the extent we finance any acquisition or investment
with the proceeds from the incurrence of debt, this would increase our level of indebtedness and could negatively affect our liquidity,
credit rating and restrict our operations. Moreover, we may face contingent liabilities in connection with any acquisitions or investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we fail to obtain, maintain and adequately protect or enforce
our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish,
and our business and competitive position would suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.2pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our success, competitive position and future revenues
will depend in part on our ability and the abilities of our licensors and licensees to obtain and maintain patent protection for our products,
methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary
rights and to operate without infringing the proprietary rights of third parties. We have an active patent protection program that includes
filing patent applications on new compounds, formulations, delivery systems and methods of making and using products and prosecuting these
patent applications in the U.S. and abroad. As patents issue, we also file continuation applications as appropriate. Although we have
taken steps to build what we believe to be a strong patent portfolio, we cannot predict:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">the degree and range of protection any patents will afford us against competitors,
        including whether third parties find ways to invalidate or otherwise circumvent our licensed patents;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">if and when patents will issue in the U.S. or any other country;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">whether or not others will obtain patents claiming aspects similar to those covered
        by our licensed patents and patent applications;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">whether we will need to initiate litigation or administrative proceedings to
        protect our intellectual property rights, which may be costly whether we win or lose;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">whether any of our patents will be challenged by our competitors alleging invalidity
        or unenforceability and, if opposed or litigated, the outcome of any administrative or court action as to patent validity, enforceability
        or scope;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">whether a competitor will develop a similar compound that is outside the scope
        of protection afforded by a patent or whether the patent scope is inherent in the claims modified due to interpretation of claim scope
        by a court;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">whether there were activities previously undertaken by a licensor that could
        limit the scope, validity or enforceability of licensed patents and intellectual property; or</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">whether a competitor will assert infringement of its patents or intellectual
        property, whether or not meritorious, and what the outcome of any related litigation or challenge may be.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our success also depends upon the skills, knowledge
and experience of our scientific and technical personnel, our consultants and advisors as well as our licensors, sublicensees and contractors.
To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade
secret protection and confidentiality agreements. To this end, we require all employees, consultants and board members to enter into agreements
that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas,
developments, discoveries and inventions important to our business. These agreements may not provide adequate protection for our trade
secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others
of such information. If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets,
know-how and other proprietary rights would be significantly impaired, and our business and competitive position would suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Due to legal and factual uncertainties regarding the scope and
protection afforded by patents and other proprietary rights, we may not have meaningful protection from competition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our long-term success will substantially depend
upon our ability to protect our proprietary technologies from infringement, misappropriation, discovery and duplication and avoid infringing
the proprietary rights of others. Our patent rights, and the patent rights of biopharmaceutical companies in general, are highly uncertain
and include complex legal and factual issues. These uncertainties also mean that any patents that we own or may obtain in the future could
be subject to challenge, and even if not challenged, may not provide us with meaningful protection from competition. Patents already issued
to us, or our pending applications may become subject to dispute, and any dispute could be resolved against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If some or all of our or any licensors patents expire
or are invalidated or are found to be unenforceable, or if some or all of our patent applications do not result in issued patents or result
in patents with narrow, overbroad, or unenforceable claims, or claims that are not supported in regard to written description or enablement
by the specification, or if we are prevented from asserting that the claims of an issued patent cover a product of a third party, we may
be subject to competition from third parties with products in the same class of products as our product candidates or products with the
same active pharmaceutical ingredients as our product candidates, including in those jurisdictions in which we have no patent protection.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our commercial success will depend in part on
obtaining and maintaining patent and trade secret protection for our product candidates, as well as the methods for treating patients
in the product indications using these product candidates. We will be able to protect our product candidates and the methods for treating
patients in the applicable product indications using these product candidates from unauthorized use by third parties only to the extent
that we or any licensor owns or controls such valid and enforceable patents or trade secrets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Even if our product candidates and the methods
for treating patients for prescribed indications using these product candidates are covered by valid and enforceable patents and have
claims with sufficient scope, disclosure and support in the specification, the patents will provide protection only for a limited amount
of time. Our and any licensors ability to obtain patents can be highly uncertain and involve complex and in some cases unsettled
legal issues and factual questions. Furthermore, different countries have different procedures for obtaining patents, and patents issued
in different countries provide different degrees of protection against the use of a patented invention by others. Therefore, if the issuance
to us or any licensor, in a given country, of a patent covering an invention is not followed by the issuance, in other countries, of patents
covering the same invention, or if any judicial interpretation of the validity, enforceability, or scope of the claims in, or the utility,
written description or enablement in, a patent issued in one country is not similar to the interpretation given to the corresponding patent
issued in another country, our ability to protect our intellectual property in those countries may be limited. Changes in either patent
laws or in interpretations of patent laws in the U.S. and other countries may materially diminish the value of our intellectual property
or narrow the scope of our patent protection.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We may be subject to competition from third parties
with products in the same class of products as our product candidates, or products with the same active pharmaceutical ingredients as
our product candidates in those jurisdictions in which we have no patent protection. Even if patents are issued to us or any licensor
regarding our product or methods of using them, those patents can be challenged by our competitors who can argue such patents are invalid
or unenforceable on a variety of grounds, including lack of utility, lack sufficient written description or enablement, utility, or that
the claims of the issued patents should be limited or narrowly construed. Patents also will not protect our product candidates if competitors
devise ways of making or using these products without legally infringing our patents. The current U.S. regulatory environment may have
the effect of encouraging companies to challenge branded drug patents or to create non-infringing versions of a patented product in order
to facilitate the approval of ANDAs for generic substitutes. These same types of incentives encourage competitors to submit NDAs that
rely on literature and clinical data not prepared for or by the drug sponsor, providing another less burdensome pathway to approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we infringe the rights of third parties, we could be prevented
from selling products and be forced to defend against litigation and pay damages.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">There is a risk that we may be inadvertently infringing
the proprietary rights of third parties because numerous U.S. and foreign issued patents and pending patent applications, which are owned
by third parties, exist in the fields that are the focus of our development and manufacturing efforts. Others might have been the first
to make the inventions covered by each of our or any licensors pending patent applications and issued patents and/or might have
been the first to file patent applications for these inventions. In addition, because patent applications take many months to publish
and patent applications can take many years to issue, there may be currently pending applications, unknown to us or any licensor, which
may later result in issued patents that cover the production, manufacture, synthesis, commercialization, formulation or use of our product
candidates. In addition, the production, manufacture, synthesis, commercialization, formulation or use of our product candidates may infringe
existing patents of which we are not aware. Defending ourselves against third-party claims, including litigation in particular, would
be costly and time consuming and would divert managements attention from our business, which could lead to delays in our development
or commercialization efforts. If third parties are successful in their claims, we might have to pay substantial damages or take other
actions that are adverse to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If our products, methods, processes and other
technologies infringe the proprietary rights of other parties, we could incur substantial costs and may have to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">obtain licenses, which may not be available on commercially reasonable terms,
        if at all;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">redesign our products or processes to avoid infringement, which may not be possible
        or could require substantial funds and time;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">stop using the subject matter claimed in patents held by others, which could
        cause us to lose the use of one or more of our drug candidates;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">pay damages royalties, or other amounts; or</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">grant a cross license to our patents to another patent holder.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We expect that, as our drug candidates move further
into clinical trials and commercialization and our public profile is raised, we will be more likely to be subject to such claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may fail to comply with any of our obligations under existing
agreements pursuant to which we license or have otherwise acquired rights or technology, which could result in the loss of rights or technology
that are material to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are a party to technology licenses and have
acquired certain assets and rights that are important to our business and we may enter into additional licenses or acquire additional
assets and rights in the future. We currently hold licenses from Ludwig Institute for Cancer Research (LICR), BioWa, Inc.
(BioWa), Lonza Sales AG (Lonza), Mayo Foundation (Mayo) and the University of Zurich (UZH).
These licenses impose various commercial, contingent payments, royalty, insurance, indemnification, and other obligations on us. If we
fail to comply with these obligations, the licensor may have the right to terminate the license or take back rights or assets, in which
event we would lose valuable rights under our collaboration agreements, potential claims and our ability to develop product candidates.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be subject to claims that our consultants or independent
contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">As is common in the biotechnology and pharmaceutical
industry, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants were
previously employed at or may have previously or may be currently providing consulting services to, other biotechnology or pharmaceutical
companies, including our competitors or potential competitors. We may become subject to claims that our company or a consultant inadvertently
or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients.
Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could
result in substantial costs and be a distraction to our management team.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may not be able to protect our intellectual property rights
throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Filing, prosecuting and defending patents on product
candidates in all countries throughout the world would be prohibitively expensive, and we intend to seek patent protection only in selected
countries. Our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling
or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories
where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating
to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products
in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted
narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail
in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our
efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from
the intellectual property that we develop or license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>A significant portion of our total outstanding shares are eligible
to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our
business is doing well.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Sales of a substantial number of shares of our
common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell shares,
could depress the market price of our common stock and could impair our future ability to obtain capital, especially through an offering
of equity securities. In addition, holders of a substantial number of shares of our common stock have rights, subject to certain conditions,
to require us to file registration statements covering their shares or to include their shares in registration statements that we may
file for ourselves or other stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have also entered into a Controlled Equity
Offering<sup>SM</sup> Sales Agreement (the Sales Agreement) with Cantor Fitzgerald &amp; Co. (Cantor), under
which we may issue and sell from time-to-time shares of common stock through Cantor, as sales agent. Sales of a substantial number of
shares under the Sales Agreement, or the perception that those sales may occur, could cause the market price of our common stock to decline.
See Notes 8 and 13 to the Consolidated Financial Statements for additional information regarding the Sales Agreement and our sales of
common stock pursuant to the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Further, certain shares of our common stock that
are currently outstanding but have not been registered for resale may currently be sold under Rule 144 under the Securities Act or the
Securities Act. Sales of a substantial number of these shares in the public market, or the perception that those sales may occur, could
cause the market price of our common stock to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Despite our listing on the Nasdaq Capital Market, there can be
no assurance that an active trading market for our common stock will develop or be sustained, and the Nasdaq Capital Market may subsequently
delist our common stock if we fail to comply with ongoing listing standards. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The Nasdaq Capital Markets rules for listed
companies require us to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue
the listing of our common stock. In addition to specific listing and maintenance standards, the Nasdaq Capital Market has broad discretionary
authority over the continued listing of securities, which it could exercise with respect to the listing of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">As a listed company, we are required to meet the
continued listing requirements applicable to all Nasdaq Capital Market companies. If we fail to meet those standards, as applied by the
Nasdaq Capital Market in its discretion, our common stock may be subject to delisting. We intend to take all commercially reasonable actions
to maintain our Nasdaq listing. If our common stock is delisted in the future, it is not likely that we will be able to list our common
stock on another national securities exchange and, as a result, we expect our securities would be quoted on an over-the-counter market;
however, if this were to occur, our stockholders could face significant material adverse consequences, including limited availability
of market quotations for our common stock and reduced liquidity for the trading of our securities. In addition, in the event of such delisting,
we could experience a decreased ability to issue additional securities and obtain additional financing in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The National Securities Markets Improvement Act
of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred
to as covered securities. Because our common stock is listed on the Nasdaq Capital Market, shares of our common stock qualify
as covered securities under the statute. Although the states are preempted from regulating the sale of our securities, the federal statute
does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then
the states can regulate or bar the sale of covered securities in a particular case. Further, if we were no longer listed on the Nasdaq
Capital Market, our securities would not qualify as covered securities under the statute, and we would be subject to regulation in each
state in which we offer our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Further, there can be no assurance that an active
trading market for our common stock will be sustained despite our listing on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Raising additional funds by issuing securities or through licensing
or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary
rights.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">To the extent that we raise additional capital
by issuing equity securities, the share ownership of existing stockholders will be diluted. To the extent that additional capital is raised
through the sale of equity or convertible debt securities, the issuance could result in further dilution to our stockholders by causing
a reduction in their proportionate ownership and voting power.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Any future debt financing may involve covenants
that restrict our operations, including, among other restrictions, limitations on our ability to incur liens or additional debt, pay dividends,
redeem our stock, make certain investments, and engage in certain merger, consolidation, or asset sale transactions. In addition, if we
raise additional funds through licensing arrangements, it may be necessary to grant potentially valuable rights to our product candidates
or grant licenses on terms that are not favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Any material weaknesses in our internal control over financial
reporting that we may identify in the future could adversely affect investor confidence, impair the value of our common stock and increase
our cost of raising capital.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">If we were to identify any material weaknesses
or significant deficiencies in our internal controls over financial reporting in the future, our operating results might be harmed, we
may fail to meet our reporting obligations or fail to prevent or detect material misstatements in our financial statements. Any such failure
could, in turn, affect the future ability of our management to certify that internal control over our financial reporting is effective.
Inferior internal control over financial reporting could also subject us to the scrutiny of the SEC and other regulatory bodies which
could cause investors to lose confidence in our reported financial information and could subject us to civil or criminal penalties or
stockholder litigation, which could have an adverse effect on our results of operations and the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In addition, if we or our independent registered
public accounting firm identify deficiencies in our internal control over financial reporting, the disclosure of that fact, even if quickly
remedied, could reduce the markets confidence in our financial statements and harm our share price. Furthermore, deficiencies could
result in future non-compliance with Section 404 of the Sarbanes-Oxley Act of 2002. Such non-compliance could subject us to a variety
of administrative sanctions, including review by the SEC or other regulatory authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have never paid and do not intend to pay cash dividends and,
consequently, the ability to achieve a return on any investment in our common stock will depend on appreciation in the price of our common
stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have never paid cash dividends on any of our
capital stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our business. Therefore,
a holder of our stock is not likely to receive any dividends on our common stock for the foreseeable future. Since we do not intend to
pay dividends, the ability to receive a return on an investment in our common stock will depend on any future appreciation in the market
value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which it was purchased.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Anti-takeover provisions in our charter documents and Delaware
law, could discourage, delay, or prevent a change in control of our company and may affect the trading price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are a Delaware corporation, and the anti-takeover
provisions of the Delaware General Corporation Law may discourage, delay, or prevent a change in control by prohibiting us from engaging
in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder,
even if a change in control would be beneficial to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our Amended and Restated Certificate of Incorporation,
as amended (the Charter), and our Second Amended and Restated Bylaws (the Bylaws) may discourage, delay, or
prevent a change in our management or control over us that stockholders may consider favorable. Our Charter and Bylaws:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">provide that vacancies on our board of directors, including newly created directorships,
        may be filled only by a majority vote of directors then in office;</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">do not provide stockholders with the ability to cumulate their votes; and</span></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol"></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">require advance notification of stockholder nominations and proposals.</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In addition, our Charter permits the Board to
issue up to 25 million shares of preferred stock with such powers, rights, terms and conditions as may be designated by the Board upon
the issuance of shares of preferred stock at one or more times in the future. Specifically, the Charter permits the Board to approve the
future issuance of all or any shares of the preferred stock in one or more series, to determine the number of shares constituting any
series and to determine any voting powers, conversion rights, dividend rights, and other designations, preferences, limitations, restrictions
and rights relating to such shares without any further authorization by our stockholders. The Boards power to issue preferred stock
could have the effect of delaying, deterring or preventing a transaction or a change in control of our company that might otherwise be
in the best interest of our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our internal computer systems, or those of our third-party vendors,
collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of
our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information,
potentially exposing us to liability or otherwise adversely affecting our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Our internal computer systems and those of our
current and any future third-party vendors, collaborators and other contractors or consultants are vulnerable to damage or interruption
from computer viruses, computer hackers, malicious code, employee theft or misuse, denial-of-service attacks, sophisticated nation-state
and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
While we seek to protect our information technology systems from system failure, accident and security breach, if such an event were to
occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations,
whether due to a loss of our trade secrets or other proprietary information or other disruptions. For example, the loss of clinical trial
data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated
with the investigation, remediation and potential notification of the breach to counterparties and data subjects could be material. In
addition, our remediation efforts may not be successful. If we do not allocate and effectively manage the resources necessary to build
and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction
errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property
or other proprietary information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">To the extent that any disruption or security
breach were to result in a loss of, or damage to, our or our third-party vendors, collaborators or other contractors
or consultants data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability
including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive
position could be harmed and the further development and commercialization of our product candidates could be delayed. Any of the above
could have a material adverse effect on our business, financial condition, results of operations or prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our insurance policies are expensive and
protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We do not carry insurance for all categories of
risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability,
property, inventory and cargo, auto, workers compensation, products liability, and directors and officers insurance.
We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant, uninsured
liability may require us to pay substantial amounts, which would adversely affect our working capital and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in laws or regulations relating
to data privacy and security, or any actual or perceived failure by us to comply with such laws and regulations, or contractual or other
obligations relating to data privacy and security, could have a material adverse effect on our reputation, results of operations, financial
condition and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are, and may increasingly become, subject to
various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which
we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing
requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws
and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they
will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations
or prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">In the U.S., various federal and state regulators,
including governmental agencies like the Consumer Financial Protection Bureau and the Federal Trade Commission, have adopted, or are considering
adopting, laws and regulations concerning personal information and data security. In particular, regulations promulgated pursuant to the
Health Insurance Portability and Accountability Act of 1996 (HIPAA) establish privacy and security standards that limit
the use and disclosure of protected health information and require the implementation of safeguards to protect the privacy, integrity
and availability of protected health information. Determining whether protected health information has been handled in compliance with
applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. If we fail
to comply with applicable HIPAA privacy and security standards, we could face civil and criminal penalties. In addition, state attorneys
general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy
of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Certain state laws may be more stringent or broader
in scope, or offer greater individual rights, with respect to personal information than federal, international, or other state laws, and
such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act
(CCPA), which increases privacy rights for California residents and imposes obligations on companies that process their
personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures
to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain
sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain
data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks
associated with, data breach litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">On August 10, 2021, we were notified that the
production website used by one of our service providers to prepare for FDAs decision regarding our EUA request for lenzilumab had
been compromised and source code from the website was posted on various internet message boards. Our service provider has taken additional
security measures to ensure that drafts and other unapproved materials are no longer visible to the public. Despite additional security
measures taken by our service provider, there can be no assurance that their information systems, or any materials prepared in advance
by us, or any of our service providers related to potential regulatory decisions would not be compromised, stolen, copied or manipulated.
We remind investors that information posted online may be false, misleading or inaccurate. We undertake no obligation to review and/or
correct false, misleading, or inaccurate information posted, published or disclosed other than that information made available by us in
formal submissions to the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Internationally, laws, regulations and standards
in many jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal
information. For example, the E.U. General Data Protection Regulation (GDPR), which became effective in May 2018, greatly
increased the European Commissions jurisdictional reach of its laws and adds a broad array of requirements for handling personal
data. EU member states are tasked under the GDPR to enact, and have enacted, certain implementing legislation that adds to and/or further
interprets the GDPR requirements and potentially extends our obligations and potential liability for failing to meet such obligations.
The GDPR, together with national legislation, regulations and guidelines of the EU member states governing the processing of personal
data, impose strict obligations and restrictions on the ability to collect, use, retain, protect, disclose, transfer and otherwise process
personal data. In particular, the GDPR includes obligations and restrictions concerning the consent and rights of individuals to whom
the personal data relates, the transfer of personal data out of the European Economic Area, security breach notifications and the security
and confidentiality of personal data. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or 20
million, whichever is greater.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">All of these evolving compliance and operational
requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies,
training associates and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to
modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of
which could have a material adverse effect on our results of operations, financial condition and cash flows. Any failure or perceived
failure by us to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security
could result in damage to our reputation and our relationship with our customers, as well as proceedings or litigation by governmental
agencies or customers, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines,
sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results
of operations or prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><span id="p1i1b"></span><b>ITEM 1B.&nbsp;&nbsp;UNRESOLVED
STAFF COMMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p1i2"></span>ITEM 2.&nbsp;&nbsp;PROPERTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located at
830 Morris Turnpike, 4th Floor, Short Hills, New Jersey 07078. We lease the office in Short Hills, New Jersey and another office in Burlingame,
California, which leases will expire on August 31, 2023 and September 30, 2022, respectively. We believe these leased offices are in satisfactory
condition and are suitable for the conduct of our business.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p1i3"></span>ITEM 3.&nbsp;&nbsp;LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see Note 11 to the
Consolidated Financial Statements for a summary of material pending legal proceedings. As further described in Note 11, one of our CMOs
filed a demand for arbitration, claiming more than $20.5 million in damages. The demand is for breach of contract and trade defamation
relating to their inability to perform. The CMO claims that we cancelled the contract after the CMO was unable to successfully produce
any full batches of lenzilumab BDS, but that we still owe the full amount due under the contract for all batches never produced. The CMO
blamed its failed attempts on a subcontractor. To date, we have paid this CMO $10.6 million, despite it not being able to produce any
full BDS batches. We intend to vigorously defend against these claims and to assert our own claims against this CMO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p1i4"></span>ITEM 4.&nbsp;&nbsp;MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="p2i5"></span>ITEM 5.&nbsp;&nbsp;MARKET FOR REGISTRANTS
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is currently
listed on the Nasdaq Capital Market under the symbol HGEN. As of February 16, 2022, we had 65,329,177 shares of common stock
outstanding held by approximately 33 stockholders of record. The actual number of stockholders is greater than this number of record holders,
and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective as of 4:30 p.m. Eastern Time on September
11, 2020, we amended our charter to effect a reverse stock split at a ratio of 1-for-5. Unless stated otherwise, all share data in this
Annual Report on Form 10-K have been adjusted, as appropriate, to reflect the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p2i6"></span>ITEM 6.&nbsp;&nbsp;RESERVED</b>&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="p2i7"></span>ITEM 7. MANAGEMENTS DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>You should read the following discussion and analysis of our financial
condition and results of operations together with our consolidated financial statements and related notes and other financial information
appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth
elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes
forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part
I, Item 1A - Risk Factors section of this Annual Report on Form 10-K, our actual results could differ materially from the results
described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are a clinical stage biopharmaceutical company,
developing our portfolio of proprietary Humaneered<sup></sup> anti-inflammatory immunology and immuno-oncology monoclonal antibodies.
Our proprietary, patented Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered,
high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. We have developed or in-licensed
targets or research antibodies, typically from academic institutions, and then applied our Humaneered technology to optimize them. Our
lead product candidate, lenzilumab (known as LENZ in the U.S.), and our other two product candidates, ifabotuzumab (iFab)
and HGEN005, are Humaneered monoclonal antibodies. Our Humaneered antibodies are closer to human antibodies than chimeric or conventionally
humanized antibodies and have a high affinity for their target. In addition, we believe our Humaneered antibodies offer further important
advantages, such as high potency, a slow off-rate and a lower likelihood to induce an inappropriate immune response or infusion related
reaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We are focusing our efforts on the development
of our lead product candidate, lenzilumab. Lenzilumab is a monoclonal antibody that has been demonstrated to neutralize human granulocyte-macrophage
colony-stimulating factor (GM-CSF), a cytokine that we believe is of critical importance in the hyperinflammatory cascade,
sometimes referred to as cytokine release syndrome (CRS) or cytokine storm, associated with COVID-19, chimeric antigen receptor
T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD) associated with bone marrow transplants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We have completed a Phase 3 registrational trial
with lenzilumab in newly hospitalized COVID-19 patients and announced positive topline data from the study known as LIVE-AIR
in March 2021. Following completion of the LIVE-AIR study, we commenced a series of efforts to attain authorization to commercialize lenzilumab
for use in hospitalized COVID-19 patients in the United States and other territories. We filed an application for Emergency Use Authorization
(EUA) with U.S. Food and Drug Administration (FDA) at the end of May 2021. We also submitted an application
for marketing authorization of lenzilumab in hospitalized COVID-19 patients to Medicines and Healthcare products Regulatory Agency (MHRA)
of the United Kingdom and conducted a series of exploratory discussions with representatives of European Medicines Agency (EMA)
regarding our potential submission of lenzilumab for marketing authorization in the European Union. In addition, we commenced significant
manufacturing efforts in support of potential commercialization, as described in Item 1. BusinessManufacturing and Raw Materials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 8, 2021, FDA declined our EUA request,
stating in its letter that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential
risks of its use as a treatment for COVID-19. In addition to raising similar concerns around efficacy, MHRA requested further information
related to clinical, manufacturing and quality processes. Despite these regulatory setbacks, we continue to believe in its potential therapeutic
benefits and remain committed to bringing lenzilumab to patients hospitalized with COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The next anticipated step in our development program
for lenzilumab in COVID-19 is the release of results from the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-5
and Big Effect Trial, in the B arm of the trial (BET-B), referred to as the <span style="color: #201F1E; background-color: white">ACTIV-5/BET-B
trial,</span> which is sponsored and funded by the National Institutes of Health (NIH). This study is evaluating lenzilumab
in combination with remdesivir, compared to placebo and remdesivir, in hospitalized COVID-19 patients, as more fully described below.
We provided lenzilumab for the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A retrospective analysis of the LIVE-AIR study
suggested that patients under the age of 85 and with a baseline CRP below 150 mg/L (the CRP subgroup) appeared to derive
the greatest benefit from lenzilumab, therefore, the ACTIV-5/BET-B study protocol was modified to include baseline CRP below 150 mg/L
as the primary analysis population. The ACTIV-5/BET-B study has reached its target enrollment with over 400 patients enrolled that met
this criterion. Topline results from ACTIV-5/BET-B are expected to be released late in the first quarter or early in the second quarter
of 2022. If confirmatory of the findings of the CRP subgroup from the LIVE-AIR study, we plan to include the results from ACTIV-5/BET-B
in an amendment to EUA submission, and to include these results in a responsive submission to MHRA along with certain performance process
qualification (PPQ) data around drug product batches, in the second quarter of 2022. In addition, as a result of feedback
received from representatives of EMA, if the ACTIV-5/BET-B data are confirmatory of the results of the findings of the CRP subgroup from
the LIVE-AIR study, we intend to submit a Conditional Marketing Authorization (CMA) for lenzilumab with an Accelerated Approval
request to EMA later in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We believe that we have built a strong intellectual
property position in the area of GM-CSF neutralization through multiple approaches and mechanisms, as they pertain to COVID-19, CAR-T,
aGvHD and multiple other oncology/transplantation, inflammation, fibrosis and autoimmune conditions which may be driven by GM-CSF.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Development Programs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in; background-color: white">In addition to our lead
product candidate, lenzilumab, our development portfolio features our other two product candidates, ifabotuzumab and HGEN005, all of which
are Humaneered monoclonal antibodies. Please refer to Item 1. BusinessOur Pipeline for a detailed discussion of our
development programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Critical Accounting Estimates </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our managements discussion and analysis
of our financial condition and results of operations is based on our Consolidated Financial Statements, which have been prepared in accordance
with accounting principles generally accepted in the U.S., or GAAP. The preparation of our financial statements in conformity with GAAP
requires our management to make estimates and assumptions that affect the amounts and disclosures reported in the Consolidated Financial
Statements and accompanying notes. Actual results could differ materially from those estimates. Our management believes judgment is involved
in determining revenue recognition, the fair value-based measurement of stock-based compensation and accruals. Our management evaluates
estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates and assumptions, and those differences could be material to the Consolidated Financial
Statements. If our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also
have a material adverse effect on our statements of operations, liquidity and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While our significant accounting policies are described
in more detail in Note&nbsp;2 to our Consolidated Financial Statements included in Part&nbsp;II,&nbsp;Item 8, Financial Statements
and Supplementary Data&nbsp;of this Annual Report on Form&nbsp;10-K, we believe the following accounting policies to be critical
to the judgments and estimates used in the preparation of our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accrued Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of the process of preparing our Consolidated
Financial Statements, we are required to estimate our accrued research and development expenses. This process involves reviewing contracts
and purchase orders, reviewing the terms of our license agreements, communicating with our applicable personnel to identify services that
have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when
we have not yet been invoiced or otherwise notified of actual cost. Some of our service providers invoice us monthly in arrears for services
performed. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that
time. Examples of estimated accrued research and development expenses include fees to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>contract research organizations and other service providers in connection with clinical studies;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>contract manufacturers in connection with the production of lenzilumab, including cancellation and termination charges and charges for
        product that does not meet specifications; and</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>vendors in connection with preclinical development activities.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We base our expenses related to clinical studies
on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract
research organizations that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to
negotiation, vary from contract to contract, and may result in uneven payment flows and expense recognition. Payments under some of these
contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing
these costs, we estimate the time period over which services will be performed for which we have not been invoiced and the level of effort
to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we
adjust the accrual accordingly. Our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in our reporting changes in estimates in any particular period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our stock-based compensation expense for stock
options is estimated at the grant date based on the awards fair value as calculated by the Black-Scholes option pricing model and
is recognized as expense over the requisite service period. The Black-Scholes option pricing model requires various highly judgmental
assumptions including expected volatility and expected term. The expected volatility is based on the combined historical stock volatilities
of our own common stock and that of several of our publicly listed peers over a period equal to the expected terms of the options as we
do not have a sufficient trading history to rely solely on the volatility of our own common stock. To estimate the expected term, we have
opted to use the simplified method, which is the use of the midpoint of the vesting term and the contractual term. If any of the assumptions
used in the Black-Scholes option pricing model changes significantly, stock-based compensation expense may differ materially in the future
from that recorded in the current period. In addition, we are required to estimate the expected forfeiture rate and only recognize expense
for those shares expected to vest. We estimate the forfeiture rate based on historical experience and our expectations regarding future
pre-vesting termination behavior of employees. To the extent our actual forfeiture rate is different from our estimate, stock-based compensation
expense is adjusted accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our revenue to date has been generated primarily
through license agreements and research and development collaboration agreements. We have recorded revenue from licensing of $3.6 million
and $0.3 million for the years ending December 31, 2021 and 2020, respectively. Commencing January 1, 2018, we recognize revenue in accordance
with Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) (ASC
606). The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or
services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods
and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope
of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations
in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract
and (v) recognize revenue when (or as) each performance obligation is satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Revenue under technology licenses and collaborative
agreements typically consists of nonrefundable and/or guaranteed license fees, collaborative research funding, and various milestone and
future product royalty or profit-sharing payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The fair value of deliverables under the arrangement
may be derived using a best estimate of selling price if vendor specific objective evidence and third-party evidence is not available.
Deliverables under the arrangement will be separate units of accounting if a delivered item has value to the customer on a standalone
basis and if the arrangement includes a general right of return for the delivered item, delivery or performance of the undelivered item
is considered probable and substantially in our control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize upfront license payments as revenue
upon delivery of the license only if the license has standalone value from any undelivered performance obligations and that value can
be determined. The undelivered performance obligations typically include manufacturing or development services or research and/or steering
committee services. If the fair value of the undelivered performance obligations can be determined, then these obligations would be accounted
for separately. If the license is not considered to have standalone value, then the license and other undelivered performance obligations
would be accounted for as a single unit of accounting. In this case, the license payments and payments for performance obligations are
recognized as revenue over the estimated period of when the performance obligations are performed or deferred indefinitely until the undelivered
performance obligation is determined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whenever we determine that an arrangement should
be accounted for as a single unit of accounting, we determine the period over which the performance obligations will be performed, and
revenue will be recognized. Revenue is recognized using a proportional performance or straight-line method. The proportional performance
method is used when the level of effort required to complete performance obligations under an arrangement can be reasonably estimated.
The amount of revenue recognized under the proportional performance method is determined by multiplying the total payments under the contract,
excluding royalties and payments contingent upon achievement of milestones, by the ratio of the level of effort performed to date to the
estimated total level of effort required to complete performance obligations under the arrangement. If we cannot reasonably estimate the
level of effort to complete performance obligations under an arrangement, we recognize revenue under the arrangement on a straight-line
basis over the period we are expected to complete our performance obligations. Significant management judgment is required in determining
the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under
an arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our collaboration agreements typically entitle
us to additional payments upon the achievement of development, regulatory and sales performance-based milestones. If the achievement of
a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration
consideration, such as upfront fees and research funding, in our revenue calculation. Typically, these milestones are not considered probable
at the inception of the collaboration. As such, milestones will typically be recognized in one of two ways depending on the timing of
when the milestone is achieved. If the milestone is achieved during the performance period, then we will only recognize revenue to the
extent of the proportional performance achieved at that date, or the proportion of the straight-line basis achieved at that date, and
the remainder will be recorded as deferred revenue to be amortized over the remaining performance period. If the milestone is achieved
after the performance period has completed and all performance obligations have been delivered, then we will recognize the milestone payment
as revenue in its entirety in the period the milestone was achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A description of recently issued accounting pronouncements
that may potentially impact our financial position and results of operations is set forth in Note 2 to our Consolidated Financial Statements
included in this Annual Report on Form 10-K. We do not believe that the impact of recently issued standards that are not yet effective
will have a material impact on our financial position or results of operations upon adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">At December&nbsp;31, 2021, we had an accumulated
deficit of $611.1 million, primarily as a result of research and development and general and administrative expenses. Since inception,
we have recognized a nominal amount of revenue from payments for license or collaboration fees, $3.6 million of which was recognized in
the year ended December 31, 2021. While we may in the future generate additional revenue from a variety of sources, including license
fees, milestone payments, and research and development payments in connection with strategic partnerships, our product candidates may
never be successfully developed or commercialized and we may therefore never realize revenue from any product sales. Accordingly, we expect
to continue to incur substantial losses from operations for the foreseeable future, and there can be no assurance that we will ever generate
significant revenue or profits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comparison of Years Ended December 31, 2021 and 2020</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">The following table summarizes the results of
our operations for the periods indicated (amounts in thousands, except percentages):&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended December 31,</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Increase/ (Decrease)</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">%</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">Revenue:</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 40%; text-align: left; padding-bottom: 1pt; text-indent: 10pt">License revenue</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3,595</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">312</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3,283</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td>
    <td style="width: 12%; text-align: right">1,052</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt">Total revenue</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">3,595</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">312</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">3,283</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">1,052</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">Operating expenses:</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left; text-indent: 10pt">Research and development</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">213,115</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">72,713</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">140,402</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">193</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">23,252</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">15,797</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">7,455</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">47</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt">Total operating expenses</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">236,367</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">88,510</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">147,857</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">167</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left">Loss from operations</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">(232,772</td>
    <td style="text-align: left">)</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">(88,198</td>
    <td style="text-align: left">)</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">(144,574</td>
    <td style="text-align: left">)</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">164</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left">Other expense:</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; text-indent: 10pt">Interest expense</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">(2,264</td>
    <td style="text-align: left">)</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">(1,336</td>
    <td style="text-align: left">)</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">(928</td>
    <td style="text-align: left">)</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">69</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other expense, net</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1,613</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(1,612</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;* </span></td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">Net loss</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(236,649</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(89,535</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(147,114</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">164</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; white-space: nowrap; width: 28%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
        Percentage is not meaningful</span></td>
    <td style="white-space: nowrap; width: 2%">&nbsp;</td>
    <td style="white-space: nowrap; width: 2%">&nbsp;</td>
    <td style="white-space: nowrap; width: 18%">&nbsp;</td>
    <td style="white-space: nowrap; width: 3%">&nbsp;</td>
    <td style="white-space: nowrap; width: 2%">&nbsp;</td>
    <td style="white-space: nowrap; width: 2%">&nbsp;</td>
    <td style="white-space: nowrap; width: 16%">&nbsp;</td>
    <td style="white-space: nowrap; width: 2%">&nbsp;</td>
    <td style="white-space: nowrap; width: 2%">&nbsp;</td>
    <td style="white-space: nowrap; width: 16%">&nbsp;</td>
    <td style="white-space: nowrap; width: 7%">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">Revenue in
the fiscal years ended December 31, 2021 and 2020 represents license revenue under the license agreement (the South Korea Agreement)
with KPM and its affiliate, Telcon, (together with KPM, the Licensee), described in more detail in Note 3 to the Consolidated
Financial Statements included in this Annual Report on Form 10-K. </span>License revenue increased $3.3 million in 2021 from $0.3 million
for the year ended December 31, 2020 to $3.6 million for the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Conducting research and development is central
to our business model. We expense both internal and external research and development costs as incurred. We track external research and
development costs incurred by project for each of our clinical programs. Our external research and development costs consist primarily
of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"></td>
    <td>expenses incurred under agreements with contract research organizations, investigative sites, and consultants that conduct our clinical
        trials and our pre-clinical activities;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the cost of acquiring and manufacturing clinical trial, pre-commercial
        and other materials, the cost to transfer the manufacturing process for bulk drug substance and fill/finish production, development of
        and periodic performance of a variety of tests and assays for stability, release, comparability and product characterization, costs associated
        with quality management, the preparation of documents and information necessary to file with regulatory authorities, cancellation and
        termination charges and charges for failed batches; and</p></td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"></td>
    <td>other costs associated with development activities, including additional studies.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other research and development costs consist primarily
of internal research and development costs such as salaries and related fringe benefit costs for our employees, stock-based compensation
charges, and travel costs not allocated to one of our clinical programs. Internal research and development costs generally benefit multiple
projects and are not separately tracked per project.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table shows a summary of our research
and development expenses for the years ended December 31, 2021 and 2020 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended December 31,</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">(in&nbsp;thousands)</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">External Costs</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; white-space: nowrap; width: 64%">Lenzilumab</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 15%; text-align: right">210,129</td>
    <td style="width: 1%; text-align: left">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 15%; text-align: right">71,341</td>
    <td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; white-space: nowrap">Ifabotuzumab</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">112</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">225</td>
    <td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt">Internal costs</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">2,874</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,147</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">Total research and development</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">213,115</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">72,713</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses increased by
$140.4 million from $72.7 million for the year ended December 31, 2020 to $213.1 million for the year ended December 31, 2021. The increase
is primarily due to an increase of $143.9 million in lenzilumab manufacturing costs, including consulting fees, and a $1.7 million increase
in internal costs, primarily compensation-related, partially offset by a $5.2 million reduction in clinical trial expenses for lenzilumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our development costs will decrease in
2022 as compared to 2021. We have sought to mitigate our financial commitments while continuing to position lenzilumab for a future authorization
or approval in the U.S., EU and UK. Our mitigation efforts included the amendment or in some cases cancelation of certain of our agreements
with CMOs for future manufacturing work, some of which were contingent on EUA, in an effort to reduce our future spending. We incurred
cancellation fees for several of these modifications. We also have disputed several invoices for cancellation fees and for production
batches for lenzilumab that had been submitted by CMOs that failed to produce BDS within our stated release specifications, but our mitigation
efforts may not be successful to recoup any such loss of lenzilumab BDS or DP. See Item 3. To this Annual Report on Form 10-K and Note
11 to the Consolidated Financial Statements included in this Annual Report on Form 10-K for more information on these disputes. In the
event of authorization by MHRA, EMA, or FDA, we anticipate that the demand for commercial product could exceed the in-process and planned
production of lenzilumab through 2022. We intend to seek additional manufacturing capacity if authorization is obtained. We expect to
use a portion of the revenues generated from commercial sale of lenzilumab following receipt of a regulatory authorization to support
our efforts to expand production capacity in 2023 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses consist principally
of personnel-related costs (including stock-based compensation), professional fees for legal and patent expenses, consulting, audit and
tax services, public, governmental and investor relations costs, and other general operating expenses not otherwise included in research
and development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses increased by
$7.5 million from $15.8 million for the year ended December 31, 2020, to $23.3 million for the year ended December 31, 2021. The increase
for the year ended December 31, 2021, is primarily due to increases in consulting and other professional services fees of $6.4 million,
personnel-related expenses of $2.9 million, including $2.3 million in non-cash stock-based compensation expense, primarily attributable
to new hires since the first quarter of 2020, an increase of $0.8 million in business insurance, and other net increases in general and
administrative expenses of $0.8 million, all in support of our increased operating activities to support the trial for COVID-19 and prepare
for potential commercialization of lenzilumab, partially offset by a decrease in public and investor relations expenses of $3.4 million.
We expect our overall general and administrative costs to decrease in the near-term until and if authorization is received in the UK,
EU, or U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Interest Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Interest expense increased $1.0 million from $1.3
million for the year ended December 31, 2020 to $2.3 million for the year ended December 31, 2021. Interest expense for the year ended
December 31, 2021 primarily related to the Loan and Security Agreement with Hercules Capital as agent for its affiliates serving as lenders
thereunder (the Term Loan). On March 29, 2021, we borrowed $25.0 million under the Term Loan. See Note 5 to the <span style="background-color: white">Consolidated
Financial Statements included in this Annual Report on Form 10-K</span> for additional information on the Term Loan. Interest expense
for the year ended December 31, 2020 primarily related to our previously outstanding debt. In June 2020, we paid off substantially all
of our debt with proceeds from the private placement of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Expense, net</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other expense increased by $1.6 million for the
year ended December 31, 2021 as compared to the year ended December 31, 2020, primarily due to litigation costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Income Taxes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December&nbsp;31, 2021, we had net operating
loss carryforwards of approximately $166.2 million to offset future federal income taxes which expire in the years 2022 through 2037,
and approximately $522.5 million that may offset future state income taxes which expire in the years 2028 through 2041. We also have federal
net operating loss carryforwards generated in the years 2018 through 2021 of $346.9 million that have no expiration date as a result of
the tax law changes signed into law on December 22, 2017. Current federal and state tax laws include substantial restrictions on the utilization
of net operating losses and tax credits in the event of an ownership change. Even if the carryforwards are available, they may be subject
to annual limitations, lack of future taxable income, or future ownership changes that could result in the expiration of the carryforwards
before they are utilized. At December&nbsp;31, 2021, we recorded a 100% valuation allowance against our deferred tax assets of approximately
$150.6&nbsp;million, as at that time our management believed it was uncertain that they would be fully realized. If we determine in the
future that we will be able to realize all or a portion of our deferred tax assets, an adjustment to our valuation allowance would increase
net income in the period in which we make such a determination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our inception, we have financed our operations
primarily through proceeds from the public offerings of our common stock, private placements of our common and preferred stock, debt financings,
interest income earned on cash and cash equivalents, and marketable securities, and borrowings against lines of credit, and more recently,
with the proceeds under the South Korea Agreement. Specifically, under the South Korea Agreement, we received a $6.0 million upfront payment
(or $4.5 million, net of withholding taxes and other fees and royalties) in the fourth quarter of 2020 and the first milestone payment
of $6.0 million (or $4.5 million, net of withholding taxes and other fees and royalties) which was met in the first quarter of 2021 and
received in the second quarter of 2021. In the first quarter of 2021, we borrowed $25.0 million under the Term Loan. In the second quarter
of 2021, we sold an aggregate of 5,427,017 shares of our common stock in connection with an underwritten public offering, raising net
proceeds of approximately $94.2 million after deducting underwriting discounts and offering costs. In the year ended December 31, 2021,
we sold an aggregate of 6,408,087 shares of our common stock in connection with our Controlled Equity Offering<sup>SM</sup> Sales Agreement
(the Sales Agreement) with Cantor Fitzgerald &amp; Co. (Cantor), raising net proceeds of approximately $65.7
million after deducting underwriting discounts and offering costs. At December 31, 2021, we had cash and cash equivalents of $70.0 million.
Subsequent to December 31, 2021 and through the date of this filing, as disclosed in Note 13 <span style="background-color: white">to
the Consolidated Financial Statements included in this Annual Report on Form 10-K</span>, we issued and sold 1,301,548 shares of common
stock pursuant to the Sales Agreement and raised net proceeds of approximately $3.7 million, after deducting fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Primary Sources of and Uses of Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the primary sources
and uses of cash and cash equivalents for each of the periods presented below ($000s):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Twelve Months Ended December
        31,</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">(In thousands)</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td>
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">Net cash (used in) provided by:</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; white-space: nowrap; width: 64%; text-align: left">Operating activities</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 15%; text-align: right">(184,045</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 15%; text-align: right">(69,852</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; text-indent: 10pt">Investing activities</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">(20</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; white-space: nowrap; text-align: left; padding-bottom: 1pt">Financing activities</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">186,324</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">137,466</td>
    <td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">Net increase in cash and cash equivalents</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">2,279</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">67,594</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;Net cash used in operating activities was
$184.0 million and $69.9 million for the years ended December 31, 2021 and 2020, respectively. Cash used in operating activities of $184.0
million for the year ended December 31, 2021, primarily related to our net loss of $236.6 million, adjusted for non-cash items, such as
$5.4 million in stock-based compensation, a net increase in operating assets and liabilities of $46.6 million and other non-cash items
of $0.6 million. Cash used in operating activities in 2020 primarily related to our net loss of $89.5 million, adjusted for non-cash items,
such as $2.1 million in stock-based compensation, changes in operating assets and liabilities of $16.5 million and other non-cash items
of $1.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in investing activities was $0 and
$20 thousand for the years ended December 31, 2021 and 2020, respectively. Cash used in investing activities for the year ended December
31, 2020 consisted of the purchase of website domain names for future use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash provided by financing activities was $186.3
million for the year ended December 31, 2021 and consisted primarily of net proceeds of approximately $94.2 million related to the sale
of 5,427,017 shares of our common stock in connection with an underwritten public offering, $65.7 million received from the issuance of
common stock in connection with the Sales Agreement, $24.4 million in net proceeds received from the Term Loan, and $2.0 million received
from the exercise of stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash provided by financing activities was $137.5
million for the year ended December 31, 2020 and consisted primarily of $67.0 million received from the issuance of common stock in the
2020 Private Placement (as defined below) in June 2020, $72.7 million received from the issuance of common stock in the 2020 Underwritten
Offering (as defined below) in September 2020, $0.5 million received from the issuance of the 2020 Convertible Notes, $0.6 million received
from the exercise of stock options, $0.3 million received from the issuance of the 2020 Bridge Notes and $0.1 million received from the
issuance of common stock under the equity line of credit with Lincoln Park Capital Fund, LLC (Lincoln Park), offset by $0.5
million for the payoff of the 2020 Convertible Notes, $2.4 million for the payoff of the 2019 and 2020 Bridge Notes and $0.8 million for
the payoff of the Notes payable to vendors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Controlled Equity Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.05pt">On December 31, 2020, we entered into the&nbsp;Sales
Agreement with Cantor, under which we could issue and sell shares of our common stock through Cantor, as sales agent. During the period
from January 1, 2021 through December 31, 2021, we issued and sold 6,408,087 shares of our common stock under the Sales Agreement, raising
net proceeds of $65.7 million. See Note 8 to the Consolidated Financial Statements included <span style="background-color: white">in this
Annual Report on Form 10-K</span> for additional information related to the Sales Agreement. <i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>2021 Underwritten Public Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">On March 30, 2021, we entered into an underwriting
agreement with Jefferies LLC, Credit Suisse Securities (USA) LLC and Cantor, as representatives of the several underwriters, in connection
with the public offering of 5,000,000 shares of our common stock. In addition, we granted the underwriters a 30-day option to purchase
an additional 750,000 shares of our common stock. The initial offering closed on April 5, 2021. On May 3, 2021, we closed on the sale
of an additional 427,017 shares of our common stock related to the exercise of the underwriters 30-day option. The aggregate gross
proceeds from the sale of the 5,427,017 shares in the offering, inclusive of the additional shares purchased by the underwriters, were
approximately $100.4 million. The net proceeds from this offering, after deducting underwriting discounts and offering costs, were approximately
$94.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Term Loan with Hercules</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 10, 2021, we entered into the Term Loan
with Hercules which provided us with the ability to draw an initial amount of $25.0 million, which we drew on March 29, 2021. We may become
entitled to draw another $20.0 million under the Term Loan through June 15, 2022, at the discretion of Hercules if we request additional
funding in support of our strategic initiatives, although there can be no assurances that Hercules would agree to provide such additional
funding. See Note 5 to the Consolidated Financial Statements <span style="background-color: white">included in this Annual Report on Form
10-K</span> for additional information on the Term Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>2020 Underwritten Public Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">On September 17, 2020,
we entered into an underwriting agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters,
in connection with the public offering of 8,000,000 million shares of Humanigens common stock (the 2020 Underwritten Offering).
In addition, we granted the underwriters a 30-day option to purchase an additional 1,200,000 shares of common stock,&nbsp;<span style="background-color: white">which
option was exercised in full by the underwriters on September 18, 2020</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">As a result of the pricing
of the public offering, our common stock commenced trading on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">The aggregate gross proceeds
from the sale of the full 9,200,000 shares in the offering were approximately $78.2 million. We used the proceeds from the offering to
support our manufacturing, production and commercial preparation activities relating to lenzilumab as a potential therapy for COVID-19
patients and for working capital and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>2020 Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 1, 2020, we entered into a securities purchase
agreement with certain accredited investors to complete a private placement of our common stock (the Private Placement).
The closing of the Private Placement occurred on June 2, 2020 (the Closing Date). At the closing, we issued and sold 16,505,743
shares of our common stock (the Shares) at a purchase price of $4.35 per share, for aggregate gross proceeds of approximately
$71.8 million. We used a portion of the proceeds to retire the following indebtedness:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>the outstanding principal amount and accrued and unpaid interest on Humanigens convertible promissory notes issued in March 2020,
        which approximated $0.5 million, were repaid in full, and the notes were extinguished;</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>the outstanding principal and accrued and unpaid interest, amounting to approximately $2.4 million, on short-term, secured bridge loans
        made to Humanigen in 2019 and 2020 were repaid in full and the related liens were released; and</td></tr>
  </tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in"></td>
    <td>the remaining outstanding principal and accrued and unpaid interest, amounting to approximately $0.8 million, on certain notes payable
        to vendors in accordance with the bankruptcy plan.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We used the remaining proceeds from the Private
Placement to fund our Phase 3 study of lenzilumab in COVID-19, to secure manufacturing capacity, to progress Chemistry, Manufacturing
and Controls (CMC) work, to prepare for commercialization in the event of approval of lenzilumab for use in COVID-19 patients,
our collaboration agreement with Kite Pharmaceuticals, Inc., and other development programs, as well as for working capital and other
general corporate purposes. See Note 11 to the Consolidated Financial Statements included in this Annual Report on Form 10-K for material
information regarding two complaints filed against us in connection with the Private Placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Liquidity and Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">We continue to advance our efforts in support
of the development of lenzilumab as a therapy for hospitalized COVID-19 patients. As of December 31, 2021, we had cash and cash equivalents
of $70.0 million. On September 8, 2021, FDA declined to approve our EUA for lenzilumab. As more fully described in this Annual Report
on Form 10-K under Item 1. BusinessManufacturing and Raw Materials, we have entered into agreements with several
CMOs to provide manufacturing, fill/finish and packaging services for lenzilumab. While we remain committed to our ongoing efforts seeking
authorization or approval for commercial use of lenzilumab to treat hospitalized COVID-19 patients in the US, EU, UK and other territories,
we have amended, and in some cases canceled, certain of these agreements, some of which were contingent on EUA, in an effort to reduce
our future spending on lenzilumab production until and if authorization is received in the UK, EU, or U.S. (See Note 7 to the Consolidated
Financial Statements included in this Annual Report on Form 10-K). These changes may limit future production of lenzilumab but because
most of our manufacturing agreements required payment of upfront fees upon execution and payments against performance of the services
to be provided, often over a lengthy performance period, the changes are expected to decrease our manufacturing costs beginning in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.05pt">Considering our current cash resources and our
current and expected levels of operating expenses, which includes our combined accounts payable and accrued expenses as of December 31,
2021 of $64.6 million, and our capital commitments of $63.4 million during 2022 related to our manufacturing agreements, as further described
below (see Capital Commitments and Capital Resources),we expect to need additional capital to fund our planned operations
and capital requirements for the next twelve months. We may seek to raise such additional capital through public or private equity offerings,
including under the Sales Agreement with Cantor, grant financing and support from governmental agencies, convertible debt, additional
borrowings under our Term Loan with Hercules at the discretion of Hercules, borrowings under other debt financings, collaborations, strategic
alliances and marketing, supply, distribution, or licensing arrangements. Subsequent to December 31, 2021 and through the date of this
filing, as disclosed in Note 13 to the Consolidated Financial Statements included in this Annual Report on Form 10-K, we issued and sold
1,301,548 shares of common stock pursuant to the Sales Agreement and raised net proceeds of approximately $3.7 million, after deducting
fees and expenses. While we believe these plans to raise additional funds will alleviate the conditions that raise substantial doubt about
our ability to continue as a going concern, these plans are not entirely within our control and cannot be assessed as being probable of
occurring. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are
not available, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs, our
commercialization efforts or our manufacturing commitments and capacity. In addition, if we raise additional funds through collaborations,
strategic alliances or marketing, supply, distribution, or licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.05pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect that the results of the ACTIV-5/BET-B
trial will be important to potential investors in evaluating an investment in our company. Accordingly, our ability to raise capital on
favorable terms in the future is linked closely to the success of that trial, which we cannot assure. Unfavorable results likely would
have a material and adverse impact on our stock price and ability to obtain future financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unsuccessful in our efforts to raise
additional capital, based on our current and expected levels of operating expenses our current capital will not be sufficient to fund
our operations for the next twelve months. These conditions raise substantial doubt about our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Capital Commitments and Capital Resources</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">On September 8, 2021, FDA declined to approve
our application for EUA for the use of lenzilumab for the treatment of COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To support our development efforts for lenzilumab
and potential commercialization upon approval under an EUA, CMA or MAA, we have entered into agreements with several organizations for
contract manufacturing services, as more fully described in this Annual Report on Form 10-K under Item 1. BusinessManufacturing
and Raw Materials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">While we remain committed to completing regulatory
processes underway seeking marketing authorization for lenzilumab to treat hospitalized COVID-19 patients in the U.S., EU, UK and other
territories, subsequent to FDAs decision to decline to approve our application for EUA for the use of lenzilumab we amended, and
in some cases terminated, certain of our manufacturing agreements, some of which were contingent on EUA, in an effort to reduce our future
spending on lenzilumab production until and if authorization is received in the UK, EU, or U.S. These changes will significantly limit
future production of lenzilumab but because most of our manufacturing agreements required payment of upfront fees upon execution and payments
against performance of the services to be provided, often over a lengthy performance period, the changes are expected to decrease our
manufacturing costs beginning in 2022. We intend to seek additional manufacturing capacity if authorization is obtained. As of December
31, 2021, we estimate that our commitments remaining to be incurred under these agreements will amount to approximately $63.4 million
during 2022, $4.6 million during 2023, and $7.4 million thereafter. Certain of these commitments and amounts accrued at year-end are in
dispute and we intend to defer these payments, negotiate lower amounts or seek legal recourse for the amounts in question. If marketing
authorization or approval for lenzilumab were granted, we would expect to be able to satisfy certain of the cash requirements associated
with our future manufacturing commitments from revenues from the commercial sale of lenzilumab, supplemented as necessary with proceeds
from the sale of our equity securities; the incurrence of debt; upfront and milestone payments from licensees; and government funding
or financial support, if offered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Contracts below for additional
information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other significant contractual cash requirements
as of December 31, 2021 include payments for principal and interest on the Term Loan. Our current and long-term obligations related to
the Term Loan are outlined in Note 5 to the Consolidated Financial Statements included in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;<b><i>Other Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Note 5 to the Consolidated Financial Statements
included in this Annual Report on Form 10-K for information regarding our other financings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Contracts</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Eversana Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 10, 2021, we announced that we had entered
into a master services agreement (the Eversana Agreement) with Eversana Life Science Services, LLC (Eversana)
pursuant to which Eversana will provide us with services in connection with the potential launch of lenzilumab.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">On September 21, 2021, we notified Eversana that
due to the EUA status in the U.S., we were terminating the initial statement of work related to commercialization support of lenzilumab
for the treatment of COVID-19 in the United States. Eversana is disputing the termination notice and has requested payment of approximately
$4.0 million it has asserted we owe for services rendered from April 1, 2021 to September 30, 2021. We have disputed this assertion and
are working to resolve this dispute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Manufacturing Agreements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into agreements with several CMOs
to manufacture bulk drug substance (BDS) and fill/finish/drug product (DP) for our lenzilumab clinical trial
activities in COVID-19 as well as to manufacture BDS and DP for a potential launch of lenzilumab in anticipation of an EUA or CMA in 2021.
We have also entered into agreements for packaging of the drug. These agreements represent large commitments, including upfront amounts
prior to commencement of manufacturing and progress payments through the course of the manufacturing process and include payments for
technology transfer. Certain of these CMOs have been unsuccessful in their efforts to manufacture some batches of lenzilumab to our specifications
for various reasons. We are working with one of these CMOs to determine if batches of BDS manufactured by them will be usable in the future
or, if not, whether other financial recompense will be offered to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please see <i>Part I, Item 1A - Risk FactorsRisks
Related to Our Efforts to Develop Lenzilumab for COVID-19 Manufacturing efforts relating to our lenzilumab program in COVID-19
have been extremely costly and inefficient in producing treatments for use in our clinical development program or potential sale.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are obligated to make future payments to third
parties under in-license agreements, including sublicense fees, royalties, and payments that become due and payable on the achievement
of certain development and commercialization milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We record upfront and milestone payments made to
third parties under licensing arrangements as an expense. Upfront payments are recorded when incurred and milestone payments are recorded
when the specific milestone has been achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>License with the Mayo Foundation for Medical Education and Research</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 19, 2019, we entered into the Mayo Agreement
with the Mayo Foundation. Under the Mayo Agreement, we have in-licensed certain technologies that we believe may be used to create CAR-T
cells lacking GM-CSF expression through various gene-editing tools including CRISPR-Cas9. Pursuant to the Mayo Agreement, we were required
to pay $0.2 million to the Mayo Foundation within six months of the effective date of the Mayo Agreement, or upon completion of a qualified
financing, whichever is earlier. We paid the initial payment following completion of the Private Placement. The Mayo Agreement also requires
the payment of milestones and royalties upon the achievement of certain regulatory and commercialization milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>License with the University of Zurich</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 19, 2019, we entered into the Zurich Agreement
with University of Zurich (UZH). Under the Zurich Agreement, we have in-licensed certain technologies that we believe may
be used to prevent GvHD through GM-CSF neutralization. The Zurich Agreement required an initial one-time payment of $0.1 million, which
we paid to UZH on July 29, 2019. The Zurich Agreement also requires the payment of annual license maintenance fees, as well as milestones
and royalties upon the achievement of certain regulatory and commercialization milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Outlicensing Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The South Korea Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On November 3, 2020, we
entered into a License Agreement (the South Korea Agreement) with KPM and Telcon (together, the Licensee).
Pursuant to the South Korea Agreement, among other things, we granted the Licensee a license under certain patents and other intellectual
property to develop and commercialize our lead product candidate, lenzilumab (the Product), for treatment of COVID-19 pneumonia,
in South Korea and the Philippines (the Territory), subject to certain reservations and limitations. The Licensee will be
responsible for gaining regulatory approval for, and subsequent commercialization of, lenzilumab in those territories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">As consideration for the
license, the Licensee has agreed to pay us (i) an up-front license fee of $6.0 million(or $4.5 million net of withholding taxes and other
fees and royalties), payable promptly following the execution of the License Agreement, which was received in the fourth quarter of 2020,
(ii) up to an aggregate of $14.0 million in two payments based on our achievement of two specified milestones in the U.S., of which the
first milestone was met in the first quarter of 2021 and $6.0 million (or $4.5 million net of withholding taxes and other fees and royalties)
was received in the second quarter of 2021,and (iii) subsequent to the receipt by the Licensee of the requisite regulatory approvals,
double-digit royalties on the net sales of lenzilumab in South Korea and the Philippines. The Licensee has agreed to certain development
and commercial performance obligations. It is expected that we will supply lenzilumab to the Licensee for a minimum of 7.5 years at a
cost-plus basis from an existing or future manufacturer. The Licensee has agreed to certain minimum purchases of lenzilumab on an annual
basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the normal course of business, we enter into
contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure
under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. To
date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record
charges in the future as a result of these indemnification obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p2i7a"></span>ITEM 7A.&nbsp;&nbsp;QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We are a smaller reporting
company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, for this reporting period and are not required
to provide the information required under this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p2i8"></span>ITEM 8.&nbsp;&nbsp;FINANCIAL STATEMENTS
AND SUPPLEMENTARY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Consolidated Financial Statements and The Report
of Independent Registered Public Accounting Firm are included in this Annual Report on Form&nbsp;10-K on pages&nbsp;F-1 through F-29.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p2i9"></span>ITEM 9.&nbsp;&nbsp;CHANGES IN AND
DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="p2i9a"></span>ITEM 9A.&nbsp;&nbsp;CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Chief Executive Officer and our Chief Financial
Officer evaluated the effectiveness of our disclosure controls and procedures as of December&nbsp;31, 2021. The term disclosure
controls and procedures, as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures
of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the
Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or
submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial
Officer, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and our Chief
Financial Officer concluded that our disclosure controls and procedures were effective as of December&nbsp;31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Managements Annual Report on Internal Control Over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting (as defined in Rule&nbsp;13a-15(f) and 15d-15(f) under the Exchange
Act). Our Chief Executive Officer and our Chief Financial Officer assessed the effectiveness of our internal control over financial reporting
as of December&nbsp;31, 2021. In making this assessment, our Chief Executive Officer and our Chief Financial Officer used the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in <i>Internal ControlIntegrated Framework</i>.
Based on that assessment and using the COSO criteria, our Chief Executive Officer and our Chief Financial Officer concluded that, as of
December&nbsp;31, 2021, our internal control over financial reporting was effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The Companys independent
registered public accounting firm, HORNE LLP, has issued an audit report on the Companys internal control over financial reporting,
which appears on page F-4 of this Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in Internal Control Over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There was no change in our internal control over
financial reporting that occurred during the quarter ended December 31, 2021 that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Inherent Limitations of Controls</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management does not expect that our disclosure
controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. Controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management
necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of
fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making
can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls
also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes
in conditions, or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p2i9b"></span>ITEM 9B.&nbsp;&nbsp;OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p2i9c"></span>ITEM 9C.&nbsp;&nbsp;DISCLOSURE
REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p3i10"></span>ITEM 10.&nbsp;&nbsp;DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in our definitive proxy
statement for our 2022 annual meeting of stockholders under the captions ELECTION OF DIRECTORS, INFORMATION ABOUT
OUR EXECUTIVE OFFICERS and INFORMATION REGARDING THE BOARD AND CORPORATE GOVERNANCE is hereby incorporated by reference.
Certain other information relating to our Executive Officers appears in Part I of this Annual Report on Form 10-K under the heading Information
about our Executive Officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;<b><span id="p3i11"></span>ITEM 11.&nbsp;&nbsp;EXECUTIVE
COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in our definitive proxy
statement for our 2022 annual meeting of stockholders under the caption EXECUTIVE COMPENSATION is hereby incorporated by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p3i12"></span>ITEM 12.&nbsp;&nbsp;SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in our definitive proxy
statement for our 2022 annual meeting of stockholders under the caption SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
is hereby incorporated by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p3i13"></span>ITEM 13.&nbsp;&nbsp;CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information contained in our definitive proxy statement for our
2022 annual meeting of stockholders under the captions CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS and DIRECTOR
INDEPENDENCE is hereby incorporated by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p3i14"></span>ITEM 14.&nbsp;&nbsp;PRINCIPAL ACCOUNTANT
FEES AND SERVICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information contained in our definitive proxy statement for our
2022 annual meeting of stockholders under the caption RATIFICATION OF HORNE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM is hereby incorporated by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p3i15"></span>ITEM 15.&nbsp;&nbsp;EXHIBITS AND
FINANCIAL STATEMENT SCHEDULES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following
documents are filed as part of this report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in">(1)</td>
    <td>Financial StatementsSee Index to Consolidated Financial Statements at Part I, Item&nbsp;8 on page F-1 of this Annual Report on
        Form&nbsp;10-K.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in">(2)</td>
    <td>All financial statement schedules have been omitted because they are not applicable or not required or because the information is included
        elsewhere in the financial statements or the Notes thereto.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.5in"></td>
    <td style="width: 0.5in">(3)</td>
    <td>See exhibits listed under Part (b) below.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Exhibits</i>:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td colspan="5" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Incorporated
        by Reference</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Filed
        or </b></span></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit No.</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit Description</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Form<sup>+</sup></b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Date</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Furnished
        <br> Herewith</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif"><b>3.1</b></span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 39%"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000114420416111735/v443708_ex3-1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amended
        and Restated Certificate of Incorporation of the Registrant.</span></a></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 6, 2016</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.1</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 9%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>3.1.1</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000121465917004822/ex3_1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Certificate
        of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 7, 2017</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.1</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>3.1.2</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000121465918001642/ex3_1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Certificate
        of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant, as amended.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2018</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.1</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>3.1.3</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465920007809/ex3_1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Certificate
        of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant, as amended</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 11, 2020</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.1</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>3.2</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000121465917004822/ex3_2.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Second
        Amended and Restated Bylaws of the Registrant.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 7, 2017</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.2</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>4.1</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000119312513269107/d558586dex102.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Warrant
        to Purchase Stock, by and between the Registrant and MidCap Financial SBIC, LP, dated as of June 19, 2013.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 24, 2013</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>4.2</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000121465916013792/ex4_1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Common
        Stock Purchase Warrant, dated June 30, 2016, by and between the Registrant and Savant Neglected Diseases, LLC.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 23, 2016</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.1</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>4.3</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000121465918003426/ex4_6.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Registration
        Rights Agreement, dated as of February 27, 2018, by and among the Registrant and Black Horse Capital Master Fund, Black Horse Capital,
        Cheval Holdings, Ltd., and Nomis Bay LTD.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May 8, 2018</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.6</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>4.4</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465920005577/ex10_21.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Registration
        Rights Agreement, dated as of June 2, 2020, by and among the Registrant and the investors party thereto</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-1</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 15, 2020</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.21</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>4.5</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/ex4_5.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Description
        of Securities.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;10-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 10, 2021</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.5</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.1**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000155837015001553/kbio-20150630ex102fde481.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">2012
        Equity Incentive Plan, as amended and restated.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 10, 2015</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.1.1**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000121465916014109/ex10_2.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amendment
        to the 2012 Equity Incentive Plan, dated as of September 13, 2016.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">S-8</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(File No. 333-214110)</p></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 14, 2016</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.1.2**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000121465918002900/ex10_3.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amendment
        to the 2012 Equity Incentive Plan, effective March 9, 2018.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May 8, 2018</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.2**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000119312512268394/d361531dex108.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Form
        of Notice of Grant and Stock Option Agreement under the 2012 Equity Incentive Plan.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10-12G</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(File No. 000-54735)</p></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 12, 2012</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.8</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.3**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000104746914002331/a2218868zex-10_37.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Form
        of Notice of Grant and Stock Option Agreement under the 2012 Equity Incentive Plan (Outside Directors).</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 13, 2014</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.37</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.4**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000110465915030165/a15-9775_1ex10d1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Form
        of Notice of Stock Unit Award under the 2012 Equity Incentive Plan.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">April 24, 2015</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td colspan="5" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Incorporated
        by Reference</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Filed
        or </b></span></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit No.</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit Description</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Form<sup>+</sup></b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Date</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Furnished
        <br> Herewith</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif"><b>10.5**</b></span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 39%"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000119312512268394/d361531dex1011.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Form
        of Director and Officer Indemnification Agreement.</span></a></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;10-K</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;March 10, 2021</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;10.5</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 9%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.6</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000119312512338632/d380427dex1013.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Development
        and License Agreement, dated May 11, 2004, by and between the Registrant and the Ludwig Institute for Cancer Research.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10-12G/A</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(File No. 000-54735)</p></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 7, 2012</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.13</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.7</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000119312512338632/d380427dex1014.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">License
        Agreement, dated April 7, 2006, by and between the Registrant and the Ludwig Institute for Cancer Research.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10-12G/A</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(File No. 000-54735)</p></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 7, 2012</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.14</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.7.1</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000110465914036470/a14-10395_1ex10d8.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amendment
        to License Agreement, dated October 9, 2008, by and between the Registrant and the Ludwig Institute for Cancer Research.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May 8, 2014</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.8</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.7.2</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000110465914036470/a14-10395_1ex10d9.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amendment
        to License Agreement, dated June 8, 2011, by and between the Registrant and the Ludwig Institute for Cancer Research.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">May 8, 2014</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.9</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.8</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1293310/000119312512389324/d409009dex1016.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Non-Exclusive
        License Agreement, dated October 15, 2010, by and between the Registrant, BioWa, Inc. and Lonza Sales AG.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10-12G/A</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(File No. 000-54735)</p></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 12, 2012</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.16</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>10.9</b></span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465920006613/ex10_1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Clinical
        Trial Agreement, dated as of July 24, 2020, by and between the Registrant and The National Institute of Allergy and Infectious Diseases
        (NIAID), part of the National Institutes of Health (NIH), as represented by the Division of Microbiology and Infectious Diseases (DMID).</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 30, 2020</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>10.10**</b></span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465920007809/ex10_1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Humanigen,
        Inc. 2020 Omnibus Incentive Compensation Plan, effective September 11, 2020.</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 11, 2020</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>10.11**</b></span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465920007809/ex10_2.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Form
        of Incentive Stock Option Award Agreement under 2020 Omnibus Incentive Plan</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 12, 2021</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>10.12**</b></span></td>
    <td>&nbsp;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465920007809/ex10_3.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Form
        of Non-qualified Stock Option Award Agreement under 2020 Omnibus Incentive Plan.</span></a></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">August 12, 2021</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.13**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/ex10_14.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amended
        and Restated Employment Agreement, dated as of October 29, 2020, by and between the Registrant and Dr. Cameron Durrant.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;10-K</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 10, 2021</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.14</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.14**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/ex10_15.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Employment
        Agreement dated as of August 1, 2020, by and between the Registrant and Timothy Morris.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-K&nbsp;</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 10, 2021</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.15</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.15**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/ex10_17.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amended
        and Restated Employment Agreement, dated as of September 24, 2020, by and between the Registrant and Dr. Dale Chappell.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;10-K</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 10, 2021</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.17</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.16</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/ex10_18.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">License
        Agreement, dated as of November 3, 2020, by and among the Registrant, KPM Tech Co., Ltd and Telcon RF Pharmaceutical, Inc</span></a><span style="font-family: Times New Roman, Times, Serif">.</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;10-K</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 10, 2021</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.18</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.17</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; padding-left: 1.05pt"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/ex10_19.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Amended
        and Restated Cooperative Research and Development Agreement, dated as of January 21, 2021, by and among the Registrant, Joint Program
        Executive Office for Chemical, Biological, Radiological, and Nuclear Defense and Nuclear Defense and Biomedical Advanced Research and
        Development Authority, Office of the Assistant Secretary for Preparedness and Response</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;10-K</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 10, 2021</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.19</span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif"><b>10.18</b></span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 36%"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921000503/ex10_1.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Master
        Services Agreement effective as of January 8, 2021 between the Registrant and EVERSANA Life Science Services, LLC</span></a></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; width: 15%"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif">January 14, 2021</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="text-align: center; width: 12%">&nbsp;</td></tr>
  </tbody></table>

<p style="margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td colspan="5" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Incorporated
        by Reference</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Filed
        or </b></span></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit No.</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit Description</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Form<sup>+</sup></b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Date</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td>
    <td style="white-space: nowrap; vertical-align: top">&nbsp;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Furnished
        <br> Herewith</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif"><b>10.19</b></span><b></b></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 36%"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465921005311/ex10_3.htm" tabindex="18"><span style="font-family: Times New Roman, Times, Serif">Loan
        and Security Agreement, dated March 10, 2021, by and between the Registrant and Hercules Capital, Inc.</span></a></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; width: 15%"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif">May 13, 2021</span></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif">10.3</span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="text-align: center; width: 12%">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>10.20**</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/ex10_20.htm" tabindex="18">Description of Registrants
        Director Compensation Policy</a></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">X</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>21.1</b></span></td>
    <td>&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/ex21_1.htm" tabindex="18">List of Subsidiaries.</a></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">X</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>23.1</b></span></td>
    <td>&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/ex23_1.htm" tabindex="18">Consent of Horne LLP.</a></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>31.1</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/ex31_1.htm" tabindex="18">Certification of Chief Executive
        Officer pursuant to Rule 13a-14(a)or 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">X</span></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><b>31.2</b></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/ex31_2.htm" tabindex="18">Certification of Chief Financial
        Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">X</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>32.1***</b></span></td>
    <td>&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/ex32_1.htm" tabindex="18">Certification of Chief Executive Officer pursuant to 18
        U.S.C. 1350.</a></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">X</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>32.2***</b></span></td>
    <td>&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/ex32_2.htm" tabindex="18">Certification of Chief Financial Officer pursuant to 18
        U.S.C. 1350.</a></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">X</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 10%"><span style="font-family: Times New Roman, Times, Serif"><b>101.INS</b></span></td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="white-space: nowrap; width: 89%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XBRL Instance DocumentThe instance document
        does not appear in the Interactive Data File because its</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XBRL tags are embedded within the Inline XBRL
        document.</p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>101.SCH</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>101.CAL</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Calculation
        Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>101.DEF</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Definition
        Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>101.LAB</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Label
        Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>101.PRE</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XBRL Taxonomy Extension Presentation
        Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><b>104</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cover Page Interactive Data
        File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">**Indicates management contract or compensatory plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">***The certifications attached as Exhibits&nbsp;32.1
and 32.2 that accompanies this Annual Report on Form&nbsp;10-K are not deemed filed with the Securities and Exchange Commission and are
not to be incorporated by reference into any filing of Registrant under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, whether made before or after the date of this Annual Report on Form&nbsp;10-K, irrespective of any general incorporation
language contained in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">Confidential treatment has been granted with respect
to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">Certain portions of this exhibit have been
omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company will furnish supplementally an unredacted copy of such exhibit
to the Securities and Exchange Commission or its staff upon request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.35pt 0pt 9pt"> Schedules omitted pursuant to Item 601(a)(5) of
Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule upon request by the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0"><b><span id="p3i16"></span>ITEM 16.&nbsp;&nbsp;FORM 10-K SUMMARY.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0; text-align: center"><b><span id="sig"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of Section&nbsp;13
or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized on February 28, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"><b>Humanigen, Inc.</b></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr>
    <td rowspan="2" style="vertical-align: bottom; width: 50%">&nbsp;</td>
    <td rowspan="2" style="white-space: nowrap; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif">/s/ Cameron
        Durrant, M.D., MBA</span></td>
    <td style="width: 12%">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cameron Durrant, M.D., MBA</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer and Chairman of the Board of Directors</p></td>
    <td>&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Signature</b></span></td>
    <td style="width: 3%; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Title</b></span></td>
    <td style="width: 2%; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Cameron Durrant</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Cameron Durrant, M.D., MBA</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chairman of the Board and Chief Executive Officer
        <br> (Principal Executive Officer)</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">/s/ Timothy Morris</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Timothy Morris, CPA</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chief Operating Officer and Chief Financial Officer
        <br> (Principal Financial and Accounting Officer)</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Ronald Barliant</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Ronald Barliant, JD</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Rainer Boehm</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Rainer Boehm, M.D.</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Cheryl Buxton</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Cheryl Buxton</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Dale Chappell</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Dale Chappell, M.D., MBA</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ John Hohneker</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">John Hohneker, M.D.</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Kevin Xie, Ph.D.</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt">Kevin Xie, Ph.D.</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 28, 2022</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: left; width: 100%"><span style="font-size: 10pt"><a href="#toc1" tabindex="18">Table of Contents</a></span></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>
<!-- Field: /Include-Text -->


 </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Index to Consolidated Financial Statements</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Humanigen, Inc.</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Contents</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:0pt; ">
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:94%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; ">&nbsp;</p> </td> <td style="width:6%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:94%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style=""><a href="#d1e521_anchor" tabindex="18">Reports of Independent Registered Public Accounting Firm</a></span></p> </td> <td style="width:6%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="">F-2</span></p> </td> </tr> </tbody> </table> </div> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">(PCAOB ID <span><ix:nonnumeric id="fact-identifier-36" contextref="From2021-01-01to2021-12-31" name="dei:AuditorFirmId" inside-table="true" data-original-id="Fact_0000000000032" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">171</ix:nonnumeric></span>)<span style="padding-left:2pt; "></span></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> </tbody> </table> </div> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:94%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style=""><a href="#d1e666_anchor" tabindex="18">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></p> </td> <td style="width:6%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="">F-5</span></p> </td> </tr> <tr class="even" style=""> <td style="width:94%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style=""><a href="#d1e1660_anchor" tabindex="18">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</a></span></p> </td> <td style="width:6%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="">F-6</span></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:94%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style=""><a href="#d1e2379_anchor" tabindex="18">Consolidated Statements of Stockholders Equity (Deficit) for the years ended December 31, 2021 and 2020</a></span></p> </td> <td style="width:6%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="">F-7</span></p> </td> </tr> <tr class="even" style=""> <td style="width:94%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style=""><a href="#d1e3952_anchor" tabindex="18">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</a></span></p> </td> <td style="width:6%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="">F-8</span></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:94%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style=""><a href="#d1e5416_anchor" tabindex="18">Notes to Consolidated Financial Statements</a></span></p> </td> <td style="width:6%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="">F-9</span></p> </td> </tr> </tbody> </table> </div> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-1</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; " id="d1e521_anchor"><span style="font-weight:bold; ">REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">To Shareholders and the Board of Directors of Humanigen, Inc. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Opinion on the Financial Statements</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We have audited the accompanying consolidated balance sheets of Humanigen, Inc. and its subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders' equity (deficit) and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in <span style="font-style:italic; ">Internal </span><span style="font-style:italic; ">Control  Integrated Framework</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013, and our report dated February 28, 2022 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Going Concern Uncertainty</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and its total liabilities exceed its total assets. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Basis for Opinion</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">These financial statements are the responsibility of the Companys management. Our responsibility is to express an opinion on the Companys financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Critical Audit Matter</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Completeness of Accrual for Contract Manufacturing Costs</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">As disclosed in note 4 to the financial statements, the Company has accrued contract manufacturing costs of $16.2 million as of December 31, 2021. The Companys consolidated statement of operations includes contract manufacturing costs within research and development expenses of $188.8 million for the year ended December 31, 2021. The Companys determination of accrued contract manufacturing costs at each reporting period requires significant judgment by management, as estimates are based on a number of factors, including managements knowledge of the contracts and associated timelines, invoicing to date from third party vendors, and the provisions in the contracts, including cancellation and termination charges and charges for product that does not meet specifications. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-2</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">The completeness of the contract manufacturing cost accrual is subject to risk of estimation uncertainty related to services having been provided where invoices are not received from third party vendors prior to the time the consolidated financial statements are issued. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Auditing the completeness of the Companys accrual for contract manufacturing costs requires significant auditor judgment, subjectivity and effort in performing appropriate procedures to evaluate the completeness and accuracy of the audit evidence management utilizes in these estimates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">To evaluate the completeness of the accrual, our audit procedures included, among others, inspecting the contracts with contract manufacturing organizations (CMOs) and evaluating the underlying data used in the estimates of the services provided. We also corroborated the progress of the contracts with the Companys contract monitors and with confirmations obtained directly from CMOs, as well as tested invoices received from vendors throughout the Companys fiscal year and subsequent to the balance sheet date. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">/s/ HORNE LLP </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We have served as the Company's auditor since 2016. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Ridgeland, Mississippi</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">February 28, 2022 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-3</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">To Shareholders and the Board of Directors of Humanigen, Inc. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Opinion on the Internal Control Over Financial Reporting</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We have audited Humanigen, Inc. and its subsidiaries (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in <span style="font-style:italic; ">Internal Control  Integrated Framework</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in <span style="font-style:italic; ">Internal Control  Integrated Framework</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders equity (deficit) and cash flows for the years then ended, and the related notes and our report dated February 28, 2022 expressed an unqualified opinion. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Basis for Opinion</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">The Companys management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting in the accompanying Managements Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Companys internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Definition and Limitations of Internal Control Over Financial Reporting</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">/s/ <span><ix:nonnumeric id="fact-identifier-37" contextref="From2021-01-01to2021-12-31" name="dei:AuditorName" inside-table="false" data-original-id="Fact_0000000000033" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">HORNE LLP</ix:nonnumeric></span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-38" contextref="From2021-01-01to2021-12-31" name="dei:AuditorLocation" inside-table="false" data-original-id="Fact_0000000000034" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Ridgeland, Mississippi</ix:nonnumeric></span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">February 28, 2022 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-4</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; " id="d1e666_anchor"><span style="font-weight:bold; ">Humanigen, Inc. </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Consolidated Balance Sheets</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(in thousands, except share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:2%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, 2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:2%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, 2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Assets</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Current assets: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Cash and cash equivalents<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-39" contextref="AsOf2021-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000035" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,016</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-40" contextref="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000036" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,737</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Prepaid expenses and other current assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-41" contextref="AsOf2021-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000037" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">955</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-42" contextref="AsOf2020-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000038" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">475</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Total current assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-43" contextref="AsOf2021-12-31" name="us-gaap:AssetsCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000039" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,971</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-44" contextref="AsOf2020-12-31" name="us-gaap:AssetsCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000040" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,212</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Other assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-45" contextref="AsOf2021-12-31" name="us-gaap:OtherAssetsNoncurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000041" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-46" contextref="AsOf2020-12-31" name="us-gaap:OtherAssetsNoncurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000042" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:30pt; margin-bottom:0pt; ">Total assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-47" contextref="AsOf2021-12-31" name="us-gaap:Assets" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000043" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,061</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-48" contextref="AsOf2020-12-31" name="us-gaap:Assets" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000044" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,302</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Liabilities and stockholders equity (deficit)</span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Current liabilities:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Accounts payable<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-49" contextref="AsOf2021-12-31" name="us-gaap:AccountsPayableCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000045" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44,698</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-50" contextref="AsOf2020-12-31" name="us-gaap:AccountsPayableCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000046" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,366</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Accrued expenses<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-51" contextref="AsOf2021-12-31" name="us-gaap:AccruedLiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000047" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,882</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-52" contextref="AsOf2020-12-31" name="us-gaap:AccruedLiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000048" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,175</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Deferred revenue<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-53" contextref="AsOf2021-12-31" name="us-gaap:DeferredRevenueCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000049" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,145</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-54" contextref="AsOf2020-12-31" name="us-gaap:DeferredRevenueCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000050" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,874</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Total current liabilities<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-55" contextref="AsOf2021-12-31" name="us-gaap:LiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000051" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,725</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-56" contextref="AsOf2020-12-31" name="us-gaap:LiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000052" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,415</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Non-current liabilities:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Deferred revenue<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-57" contextref="AsOf2021-12-31" name="us-gaap:DeferredRevenueNoncurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000053" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,018</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-58" contextref="AsOf2020-12-31" name="us-gaap:DeferredRevenueNoncurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000054" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,342</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Long-term debt<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-59" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebtNoncurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000055" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,006</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-60" contextref="AsOf2020-12-31" name="us-gaap:LongTermDebtNoncurrent" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000056" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Total liabilities<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-61" contextref="AsOf2021-12-31" name="us-gaap:Liabilities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000057" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">94,749</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-62" contextref="AsOf2020-12-31" name="us-gaap:Liabilities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000058" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,757</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Commitments and contingencies (Note 7)<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Stockholders equity (deficit):<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:20pt !important; margin-bottom:0pt; ">Common stock, $<span><ix:nonfraction id="fact-identifier-63" contextref="AsOf2021-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000060" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction id="fact-identifier-64" contextref="AsOf2020-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000059" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span> par value: <span><ix:nonfraction id="fact-identifier-65" contextref="AsOf2021-12-31" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000062" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction id="fact-identifier-66" contextref="AsOf2020-12-31" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000061" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">225,000,000</ix:nonfraction></span></ix:nonfraction></span> shares authorized at December 31, 2021 and December 31, 2020; <span><ix:nonfraction id="fact-identifier-67" contextref="AsOf2021-12-31" name="us-gaap:CommonStockSharesOutstanding" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000064" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction id="fact-identifier-68" contextref="AsOf2021-12-31" name="us-gaap:CommonStockSharesIssued" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000063" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64,027,629</ix:nonfraction></span></ix:nonfraction></span> and <span><ix:nonfraction id="fact-identifier-69" contextref="AsOf2020-12-31" name="us-gaap:CommonStockSharesOutstanding" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000066" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction id="fact-identifier-70" contextref="AsOf2020-12-31" name="us-gaap:CommonStockSharesIssued" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000065" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,626,508</ix:nonfraction></span></ix:nonfraction></span> shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-71" contextref="AsOf2021-12-31" name="us-gaap:CommonStockValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000067" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-72" contextref="AsOf2020-12-31" name="us-gaap:CommonStockValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000068" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Additional paid-in capital<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-73" contextref="AsOf2021-12-31" name="us-gaap:AdditionalPaidInCapital" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000069" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">587,327</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-74" contextref="AsOf2020-12-31" name="us-gaap:AdditionalPaidInCapital" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000070" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">419,923</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Accumulated deficit<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-75" contextref="AsOf2021-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000071" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">611,079</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-76" contextref="AsOf2020-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000072" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">374,430</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Total stockholders equity (deficit)<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-77" contextref="AsOf2021-12-31" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000073" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,688</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-78" contextref="AsOf2020-12-31" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000074" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,545</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:30pt; margin-bottom:0pt; ">Total liabilities and stockholders equity (deficit)<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-79" contextref="AsOf2021-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000075" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,061</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-80" contextref="AsOf2020-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000076" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,302</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">See accompanying notes. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-5</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; " id="d1e1660_anchor"><span style="font-weight:bold; ">Humanigen, Inc.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Consolidated Statements of Operations</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(in thousands, except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:2%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Twelve Months Ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:2%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:2%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Revenue: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">License revenue<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-81" contextref="From2021-01-01to2021-12-31_us-gaap_LicenseMember" name="us-gaap:Revenues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000077" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,595</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-82" contextref="From2020-01-01to2020-12-31_us-gaap_LicenseMember" name="us-gaap:Revenues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000078" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">312</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total revenue<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-83" contextref="From2021-01-01to2021-12-31" name="us-gaap:Revenues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000079" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,595</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-84" contextref="From2020-01-01to2020-12-31" name="us-gaap:Revenues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000080" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">312</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Operating expenses:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Research and development<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-85" contextref="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000081" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">213,115</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-86" contextref="From2020-01-01to2020-12-31" name="us-gaap:ResearchAndDevelopmentExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000082" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,713</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">General and administrative<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-87" contextref="From2021-01-01to2021-12-31" name="us-gaap:GeneralAndAdministrativeExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000083" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,252</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-88" contextref="From2020-01-01to2020-12-31" name="us-gaap:GeneralAndAdministrativeExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000084" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,797</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total operating expenses<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-89" contextref="From2021-01-01to2021-12-31" name="us-gaap:OperatingExpenses" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000085" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">236,367</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-90" contextref="From2020-01-01to2020-12-31" name="us-gaap:OperatingExpenses" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000086" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88,510</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Loss from operations<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-91" contextref="From2021-01-01to2021-12-31" name="us-gaap:OperatingIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000087" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">232,772</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-92" contextref="From2020-01-01to2020-12-31" name="us-gaap:OperatingIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000088" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88,198</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Other expense:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Interest expense<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-93" contextref="From2021-01-01to2021-12-31" name="us-gaap:InterestExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000089" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,264</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-94" contextref="From2020-01-01to2020-12-31" name="us-gaap:InterestExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000090" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,336</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Other expense, net<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-95" contextref="From2021-01-01to2021-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000091" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,613</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-96" contextref="From2020-01-01to2020-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000092" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-97" contextref="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000093" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">236,649</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-98" contextref="From2020-01-01to2020-12-31" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000094" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,535</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Basic and diluted net loss per common share<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-99" contextref="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerShareBasicAndDiluted" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000095" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.04</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-100" contextref="From2020-01-01to2020-12-31" name="us-gaap:EarningsPerShareBasicAndDiluted" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000096" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.42</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:10pt !important; margin-bottom:0pt; ">Weighted average common shares outstanding used to calculate basic and diluted net loss per common share<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-101" contextref="From2021-01-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000097" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58,533,637</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-102" contextref="From2020-01-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000098" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,963,030</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">See accompanying notes. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-6</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; " id="d1e2379_anchor"><span style="font-weight:bold; ">Humanigen, Inc.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Consolidated Statements of Stockholders Equity (Deficit)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(in thousands, except share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Total</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Additional</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Stockholders</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Common Stock</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Paid-In</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Accumulated</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Equity</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Shares</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Amount</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Capital</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Deficit</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(Deficit)</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balances at January 1, 2020<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-103" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesOutstanding" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000099" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,806,890</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-104" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-105" contextref="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">270,555</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-106" contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">284,895</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-107" contextref="AsOf2019-12-31" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,318</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Issuance of common stock, net of expenses<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-108" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,745,744</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-109" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-110" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">139,733</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-111" contextref="From2020-01-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">139,760</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Issuance of common stock for conversion of debt<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-112" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,397,916</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-113" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueOther" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-114" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueOther" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,313</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-115" contextref="From2020-01-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueOther" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,316</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:30pt !important; margin-bottom:0pt; ">Issuance of common stock in exchange for services<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-116" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,064</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-117" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">302</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-118" contextref="From2020-01-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">302</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:30pt !important; margin-bottom:0pt; ">Issuance of stock options for payment of compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-119" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">180</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-120" contextref="From2020-01-01to2020-12-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">180</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:30pt !important; margin-bottom:0pt; ">Issuance of common stock for payment of compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-121" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,317</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-122" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-123" contextref="From2020-01-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Issuance of warrant for services<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-124" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="hgen:IssuanceOfWarrantForServices" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,070</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-125" contextref="From2020-01-01to2020-12-31" name="hgen:IssuanceOfWarrantForServices" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,070</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Issuance of common stock upon option exercise<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-126" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="hgen:StockIssuedDuringPeriodSharesStockOptionsExercised1" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">390,668</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-127" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="hgen:StockIssuedDuringPeriodValueStockOptionsExercised1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">572</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-128" contextref="From2020-01-01to2020-12-31" name="hgen:StockIssuedDuringPeriodValueStockOptionsExercised1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">572</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Issuance of common stock upon warrant exercise<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-129" contextref="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="hgen:StockIssuedDuringPeriodSharesStockWarrantsExercised1" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">222,909</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-130" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="hgen:StockIssuedDuringPeriodValueStockWarrantsExercised1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-131" contextref="From2020-01-01to2020-12-31" name="hgen:StockIssuedDuringPeriodValueStockWarrantsExercised1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Stock-based compensation expense<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-132" contextref="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,110</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-133" contextref="From2020-01-01to2020-12-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,110</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Net loss<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-134" contextref="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,535</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-135" contextref="From2020-01-01to2020-12-31" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,535</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balances at December 31, 2020<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-136" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesOutstanding" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,626,508</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-137" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-138" contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">419,923</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-139" contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">374,430</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-140" contextref="AsOf2020-12-31" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,545</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Issuance of common stock, net of expenses<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-141" contextref="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,835,104</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-142" contextref="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-143" contextref="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">159,903</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-144" contextref="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">159,915</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:30pt !important; margin-bottom:0pt; ">Issuance of stock options for payment of compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-145" contextref="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-146" contextref="From2021-01-01to2021-12-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Issuance of common stock upon option exercise<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-147" contextref="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="hgen:StockIssuedDuringPeriodSharesStockOptionsExercised1" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">566,017</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-148" contextref="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="hgen:StockIssuedDuringPeriodValueStockOptionsExercised1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,965</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-149" contextref="From2021-01-01to2021-12-31" name="hgen:StockIssuedDuringPeriodValueStockOptionsExercised1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,965</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Stock-based compensation expense<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-150" contextref="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,368</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-151" contextref="From2021-01-01to2021-12-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,368</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Net loss<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-152" contextref="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">236,649</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-153" contextref="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">236,649</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balances at December 31, 2021<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-154" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesOutstanding" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64,027,629</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-155" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-156" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">587,327</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-157" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">611,079</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:9%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-158" contextref="AsOf2021-12-31" name="us-gaap:StockholdersEquity" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,688</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">) </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">See accompanying notes. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-7</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; " id="d1e3952_anchor"><span style="font-weight:bold; ">Humanigen, Inc.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Consolidated Statements of Cash Flows</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(in thousands)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td colspan="6" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Twelve Months Ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td colspan="2" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td colspan="2" style="width:1%; border-bottom:1pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="odd" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Operating activities:</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-159" contextref="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">236,649</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-160" contextref="From2020-01-01to2020-12-31" name="us-gaap:NetIncomeLoss" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,535</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Adjustments to reconcile net loss to net cash used in operating activities:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Stock based compensation expense<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-161" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensation" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,368</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-162" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensation" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,110</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Non-cash interest expense related to debt financing<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-163" contextref="From2021-01-01to2021-12-31" name="us-gaap:AmortizationOfDebtDiscountPremium" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">562</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-164" contextref="From2020-01-01to2020-12-31" name="us-gaap:AmortizationOfDebtDiscountPremium" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">706</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Issuance of common stock for payment of compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-165" contextref="From2021-01-01to2021-12-31" name="hgen:IssuanceOfCommonStockInLieuOfCashCompensation" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-166" contextref="From2020-01-01to2020-12-31" name="hgen:IssuanceOfCommonStockInLieuOfCashCompensation" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">78</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Issuance of common stock in exchange for services<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-167" contextref="From2021-01-01to2021-12-31" name="hgen:IssuanceOfCommonStockInExchangeForServices" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-168" contextref="From2020-01-01to2020-12-31" name="hgen:IssuanceOfCommonStockInExchangeForServices" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">302</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Changes in operating assets and liabilities:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Prepaid expenses and other assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-169" contextref="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">480</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-170" contextref="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Accounts payable<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-171" contextref="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,332</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-172" contextref="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,032</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Accrued expenses<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-173" contextref="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,875</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-174" contextref="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,405</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">Deferred revenue<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-175" contextref="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">947</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-176" contextref="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,216</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net cash used in operating activities<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-177" contextref="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">184,045</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-178" contextref="From2020-01-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69,852</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Investing activities:</span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Purchase of intangible assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-179" contextref="From2021-01-01to2021-12-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-180" contextref="From2020-01-01to2020-12-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net cash used in investing activities<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-181" contextref="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-182" contextref="From2020-01-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Financing activities:</span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Net proceeds from issuance of common stock<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-183" contextref="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">159,915</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-184" contextref="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">139,760</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Proceeds from exercise of stock options<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-185" contextref="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromStockOptionsExercised" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,965</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-186" contextref="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromStockOptionsExercised" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">572</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Net proceeds from issuance of long-term debt<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-187" contextref="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,444</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-188" contextref="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Net proceeds from issuance of convertible notes<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-189" contextref="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromConvertibleDebt" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-190" contextref="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromConvertibleDebt" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000186" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">467</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Net proceeds from issuance of PPP loan<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-191" contextref="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromOtherDebt" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-192" contextref="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromOtherDebt" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Net proceeds from issuance of bridge notes<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-193" contextref="From2021-01-01to2021-12-31" name="hgen:ProceedsFromBridgeNotes" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-194" contextref="From2020-01-01to2020-12-31" name="hgen:ProceedsFromBridgeNotes" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">350</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Payments on PPP loan<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-195" contextref="From2021-01-01to2021-12-31" name="us-gaap:RepaymentsOfOtherDebt" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-196" contextref="From2020-01-01to2020-12-31" name="us-gaap:RepaymentsOfOtherDebt" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Payments on bridge notes<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-197" contextref="From2021-01-01to2021-12-31" name="hgen:PaymentsOnBridgeNotes" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-198" contextref="From2020-01-01to2020-12-31" name="hgen:PaymentsOnBridgeNotes" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,400</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Payments on convertible notes<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-199" contextref="From2021-01-01to2021-12-31" name="us-gaap:RepaymentsOfConvertibleDebt" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-200" contextref="From2020-01-01to2020-12-31" name="us-gaap:RepaymentsOfConvertibleDebt" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">518</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Payments on notes payable to vendors<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-201" contextref="From2021-01-01to2021-12-31" name="us-gaap:RepaymentsOfNotesPayable" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-202" contextref="From2020-01-01to2020-12-31" name="us-gaap:RepaymentsOfNotesPayable" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">775</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net cash provided by financing activities<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-203" contextref="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">186,324</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-204" contextref="From2020-01-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,466</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net increase in cash and cash equivalents<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-205" contextref="From2021-01-01to2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,279</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-206" contextref="From2020-01-01to2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,594</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cash and cash equivalents, beginning of period<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-207" contextref="AsOf2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,737</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:1pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-208" contextref="AsOf2019-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cash and cash equivalents, end of period<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-209" contextref="AsOf2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,016</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-210" contextref="AsOf2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,737</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Supplemental cash flow disclosure:</span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cash paid for interest<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-211" contextref="From2021-01-01to2021-12-31" name="us-gaap:InterestPaidNet" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,519</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-212" contextref="From2020-01-01to2020-12-31" name="us-gaap:InterestPaidNet" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">672</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Supplemental disclosure of non-cash investing and financing activities:</span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Issuance of stock options in lieu of cash compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-213" contextref="From2021-01-01to2021-12-31" name="hgen:IssuanceInStockOptionsForPaymentOfAccruedCompensation" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">168</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-214" contextref="From2020-01-01to2020-12-31" name="hgen:IssuanceInStockOptionsForPaymentOfAccruedCompensation" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Issuance of warrants for services<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-215" contextref="From2021-01-01to2021-12-31" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-216" contextref="From2020-01-01to2020-12-31" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,070</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:64%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Conversion of notes payable and related accrued interest and fees to common stock<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-217" contextref="From2021-01-01to2021-12-31" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-218" contextref="From2020-01-01to2020-12-31" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,316</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">See accompanying notes. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-8</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; " id="d1e5416_anchor"><span style="font-weight:bold; ">Notes to Consolidated Financial Statements</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">(in thousands unless otherwise indicated, except share and per share data)</span> </p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-219" contextref="From2021-01-01to2021-12-31" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">1. Organization and Description of Business</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Description of the Business</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Humanigen, Inc. (the Company or Humanigen) was incorporated on March 15, 2000 in California and reincorporated as a Delaware corporation in September 2001. Effective August 7, 2017, the Company changed its legal name to Humanigen, Inc.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company is a clinical stage biopharmaceutical company, developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. The Companys proprietary, patented Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Humanigen has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them. The Companys lead product candidate, lenzilumab, and its other two product candidates, ifabotuzumab (iFab) and HGEN005, are Humaneered monoclonal antibodies. The Companys Humaneered antibodies are closer to human antibodies than chimeric or conventionally humanized antibodies and have a high affinity for their target. In addition, the Company believes its Humaneered antibodies offer further important advantages, such as high potency, a slow off-rate and a lower likelihood to induce an inappropriate immune response or infusion related reaction.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">It is focusing its efforts on the development of its lead product candidate, lenzilumab. Lenzilumab is a monoclonal antibody that has been demonstrated to neutralize GM-CSF, a cytokine that the Company believes is of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome (CRS) or cytokine storm, associated with COVID-19, chimeric antigen receptor T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD) associated with bone marrow transplants. The Companys development programs in COVID-19, CAR-T and aGvHD are complementary in that all are focused on preventing or reducing cytokine storm in those disease states. It is possible that results observed from the Phase 3 trials in COVID-19 described below may be predictive of results in these other settings, which are also characterized by cytokine storm.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company has completed a Phase 3 registrational trial with lenzilumab in newly hospitalized COVID-19 patients and announced positive topline data from the study known as LIVE-AIR in March 2021. Following completion of the LIVE-AIR study, the Company commenced a series of efforts to attain authorization to commercialize lenzilumab for use in hospitalized COVID-19 patients in the United States and other territories. The Companys regulatory initiatives have not yet resulted in any commercial authorization.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The next anticipated step in the Companys development program for lenzilumab in COVID-19 is the release of results from the Accelerating COVID-19 Therapeutic Interventions and Vaccines-5 (ACTIV-5) and Big Effect Trial, in the B arm of the trial (BET-B), referred to as the ACTIV-5/BET-B trial, which is sponsored and funded by the National Institutes of Health (NIH). This study is evaluating lenzilumab in combination with remdesivir, compared to placebo and remdesivir, in hospitalized COVID-19 patients, as more fully described below.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">A retrospective analysis of the LIVE-AIR study suggested that patients under the age of 85 and with a baseline C-reactive protein level (CRP) below 150 mg/L (the CRP subgroup) appeared to derive the greatest benefit from lenzilumab; therefore, the ACTIV-5/BET-B study protocol was modified to include baseline CRP below 150 mg/L as the primary analysis population. The ACTIV-5/BET-B study has reached its target enrollment with over 400 patients enrolled that met this criterion. Topline results from ACTIV-5/BET-B are expected to be released late in the first quarter or early in the second quarter of 2022. If confirmatory of the findings of the CRP subgroup from the Companys LIVE-AIR study, the Company plans to include the results from ACTIV-5/BET-B in an amendment to its Emergency Use Authorization (EUA) submission, and to include these results in a responsive submission to Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom along with certain performance process qualification (PPQ) data around drug product batches, in the second quarter of 2022. In addition, as a result of feedback received from representatives of European Medicines Agency (EMA), if the ACTIV-5/BET-B data are confirmatory of the results of the findings of the CRP subgroup from the LIVE-AIR study, the Company intends to submit a Conditional Marketing Authorization (CMA) for lenzilumab with an Accelerated Approval request to EMA later in 2022.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">See Managements Discussion and Analysis of Financial Condition and Results of Operations included in Item 7 of this Annual Report on Form 10-K for additional information regarding the business.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Liquidity and Going Concern</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Consolidated Financial Statements for the years ended December 31, 2021 and 2020 were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. However, the Company has incurred net losses since its inception, and has negative operating cash flows and its total liabilities exceed total assets. These conditions raised substantial doubt about the Companys ability to continue as a going concern.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-9</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company continues to advance its efforts in support of the development of lenzilumab as a therapy for hospitalized COVID-19 patients. As of December 31, 2021, the Company had cash and cash equivalents of $70.0 million. On September 8, 2021, U.S. Food and Drug Administration (FDA) declined to approve the Companys EUA for lenzilumab. As more fully described under Item 1. BusinessManufacturing and Raw Materials. in this Annual Report on Form 10-K, the Company has entered into agreements with several contract manufacturing organizations (CMOs) to provide manufacturing, fill/finish and packaging services for lenzilumab. While the Company remains committed to its ongoing efforts seeking marketing authorization for lenzilumab to treat hospitalized COVID-19 patients in the U.S., UK and other territories, the Company has amended, and in some cases canceled, certain of these agreements, some of which were contingent on EUA, in an effort to reduce its future spending on lenzilumab production until and if authorization is received in the UK, European Union (EU), or U.S. (See Note 7 below). These changes may limit future production of lenzilumab but because most of the Companys manufacturing agreements required payment of upfront fees upon execution and payments against performance of the services to be provided, often over a lengthy performance period, the changes are expected to decrease the Companys manufacturing costs beginning in 2022 Considering the Companys current cash resources and its current and expected levels of operating expenses, which includes combined accounts payable and accrued expenses recorded in the Companys consolidated balance sheets as of December 31, 2021 of $<span><ix:nonfraction id="fact-identifier-220" contextref="AsOf2021-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64.6</ix:nonfraction></span> million, and its capital commitments of $<span><ix:nonfraction id="fact-identifier-221" contextref="AsOf2021-12-31" name="hgen:CapitalCommitments" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">63.4</ix:nonfraction></span> million during 2022 (see Note 7 below),management expects to need additional capital to fund the Companys planned operations for the next twelve months. Management may seek to raise such additional capital through public or private equity offerings, including under the Controlled Equity Offering<sup>SM</sup> Sales Agreement (the Sales Agreement) with Cantor Fitzgerald &amp; Co. (Cantor), grant financing and support from governmental agencies, convertible debt, borrowings under its Loan and Security Agreement with Hercules Capital and other debt financings, collaborations, strategic alliances and marketing, supply, distribution, or licensing arrangements. Subsequent to December 31, 2021 and through the date of this filing, as disclosed in Note 13 below, the Company issued and sold <span><ix:nonfraction id="fact-identifier-222" contextref="From2022-01-01to2022-02-28_custom_ControlledEquityOfferingSmSalesAgreementMember_us-gaap_SubsequentEventMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,301,548</ix:nonfraction></span> shares of common stock pursuant to the Sales Agreement and received net proceeds of approximately $<span><ix:nonfraction id="fact-identifier-223" contextref="From2022-01-01to2022-02-28_custom_ControlledEquityOfferingSmSalesAgreementMember_us-gaap_SubsequentEventMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.7</ix:nonfraction></span> million, after deducting fees and expenses. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Companys ability to continue as a going concern, these plans are not entirely within the Companys control and cannot be assessed as being probable of occurring. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available, the Company may be required to delay or reduce the scope of or eliminate one or more of its research or development programs, its commercialization efforts or its manufacturing commitments and capacity. In addition, if the Company raises additional funds through collaborations, strategic alliances or marketing, supply, distribution, or licensing arrangements with third parties, the Company may have to relinquish valuable rights to its technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to the Company. The Company expects that the results of the ACTIV-5/BET-B trial will be important to potential investors. Accordingly, its ability to raise capital on favorable terms in the future is linked closely to the success of that trial, which cannot be assured. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-224" contextref="From2021-01-01to2021-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">2. Summary of Significant Accounting Policies</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-style:italic; ">Reclassifications</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. Such reclassifications had no effect on prior years net loss or stockholders equity (deficit).</p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-225" contextref="From2021-01-01to2021-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Basis of Presentation and Use of Estimates</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all adjustments necessary for the presentation of the Companys consolidated financial position, results of operations and cash flows for the periods presented. The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. These financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the Consolidated Financial Statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the determination of revenue recognition, the fair value-based measurement of stock-based compensation and accruals. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Consolidated Financial Statements. </p></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-10</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div> <span><ix:nonnumeric id="fact-identifier-226" contextref="From2021-01-01to2021-12-31" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" inside-table="false" data-original-id="Fact_0000000000221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Concentration of Credit Risk</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk in the event of a default by the related financial institution holding the securities, to the extent of the value recorded in the consolidated balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments with lower credit risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-227" contextref="From2021-01-01to2021-12-31" name="us-gaap:InvestmentPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Cash and Cash Equivalents</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing and demand money market accounts. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-228" contextref="From2021-01-01to2021-12-31" name="us-gaap:DebtPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Debt Issuance Costs</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Debt issuance costs related to a recognized debt liability are presented on the consolidated balance sheets as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts and are amortized to interest expense over the term of the related debt using the effective interest method. </p></ix:nonnumeric></span> <span><ix:nonnumeric id="fact-identifier-229" contextref="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" inside-table="false" data-original-id="Fact_0000000000224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Research and Development Expenses</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Development costs incurred in the research and development of new product candidates are expensed as incurred, including expenses that may or may not be reimbursed under research and development collaboration arrangements. Research and development costs include, but are not limited to, salaries, benefits, stock-based compensation, laboratory supplies, allocated overhead, fees for professional service providers and costs associated with product development efforts, including the cost of consultants and contract manufacturing organizations (CMOs) that manufacture drug products for use in our preclinical studies and clinical trials as well as all other expenses associated with preclinical studies and clinical trials.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company records upfront and milestone payments made to third parties under licensing arrangements as an expense. Upfront payments are recorded when incurred and milestone payments are recorded when the specific milestone has been achieved. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-230" contextref="From2021-01-01to2021-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Revenue Recognition</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Companys revenue to date has been generated primarily through license agreements and research and development collaboration agreements. The Company recorded $<span><ix:nonfraction id="fact-identifier-231" contextref="From2021-01-01to2021-12-31_custom_KpmAndTelconMember" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.6</ix:nonfraction></span> million and $<span><ix:nonfraction id="fact-identifier-232" contextref="From2020-01-01to2020-12-31_custom_KpmAndTelconMember" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span> million for the years ending December 31, 2021 and 2020, respectively, related to the November 3, 2020 License Agreement (the South Korea Agreement) with KPM Tech Co., Ltd. (KPM) and its affiliate, Telcon RF Pharmaceutical, Inc. (Telcon), as further described in Note 3. Commencing January 1, 2018, the Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606  <span style="font-style:italic; ">Revenue from Contracts with Customers</span>. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed license fees, collaborative research funding, and various milestone and future product royalty or profit-sharing payments.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The fair value of deliverables under the arrangement may be derived using a best estimate of selling price if vendor specific objective evidence and third-party evidence is not available. Deliverables under the arrangement will be separate units of accounting if a delivered item has value to the customer on a standalone basis and if the arrangement includes a general right of return for the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the Companys control.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-11</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company recognizes upfront license payments as revenue upon delivery of the license only if the license has standalone value from any undelivered performance obligations and that value can be determined. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the fair value of the undelivered performance obligations can be determined, then these obligations would be accounted for separately. If the license is not considered to have standalone value, then the license and other undelivered performance obligations would be accounted for as a single unit of accounting. In this case, the license payments and payments for performance obligations are recognized as revenue over the estimated period of when the performance obligations are performed or deferred indefinitely until the undelivered performance obligation is determined.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Whenever the Company determines that an arrangement should be accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized. Revenue is recognized using a proportional performance or straight-line method. The proportional performance method is used when the level of effort required to complete performance obligations under an arrangement can be reasonably estimated. The amount of revenue recognized under the proportional performance method is determined by multiplying the total payments under the contract, excluding royalties and payments contingent upon achievement of milestones, by the ratio of the level of effort performed to date to the estimated total level of effort required to complete performance obligations under the arrangement. If the Company cannot reasonably estimate the level of effort to complete performance obligations under an arrangement, the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Companys collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales performance-based milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Companys revenue calculation. Typically, these milestones are not considered probable at the inception of the collaboration. As such, milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is achieved during the performance period, then the Company will only recognize revenue to the extent of the proportional performance achieved at that date, or the proportion of the straight-line basis achieved at that date, and the remainder will be recorded as deferred revenue to be amortized over the remaining performance period. If the milestone is achieved after the performance period has completed and all performance obligations have been delivered, then the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved. See Note 3 for information on the South Korea Agreement. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-233" contextref="From2021-01-01to2021-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Leases</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset's economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its operating right-of-use asset and operating lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Rent expense is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company has made an accounting policy election to not recognize short-term leases, or leases that have a lease term of 12 months or less at commencement date, within its consolidated balance sheets and to recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. </p></ix:nonnumeric></span> <span><ix:nonnumeric id="fact-identifier-234" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" inside-table="false" data-original-id="Fact_0000000000229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Stock-Based Compensation Expense</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company measures stock-based compensation expense for stock awards at the grant date, based on the fair value-based measurement of the award, and the expense is recorded over the related service period, generally the vesting period, net of estimated forfeitures. The Company calculates the fair value-based measurement of stock options using the Black-Scholes valuation model and the simplified method and recognizes expense using the straight-line attribution approach. </p></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-12</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-235" contextref="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Income Taxes</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company accounts for income taxes under an asset-and-liability approach. Deferred income taxes reflect the impact of temporary differences between assets and liabilities recognized for tax and financial reporting purposes measured by applying enacted tax rates and laws that will be in effect when the differences are expected to reverse, net operating loss carryforwards and tax credits. Valuation allowances are provided when necessary to reduce net deferred tax assets to an amount that is more likely than not to be realized. The Companys policy is to include interest and penalties related to unrecognized tax benefits within the Companys provision for income taxes. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-236" contextref="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Net Loss Per Common Share</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, stock options, common stock warrants and convertible debt are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Companys potential dilutive securities, which include stock options, warrants and convertible debt have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per common share and be antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented.</p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-237" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> The following shares subject to outstanding potentially dilutive securities have been excluded from the computations of diluted net loss per common share as the effect of including such securities would be antidilutive: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="89.71631205673759%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:70%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">As of December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:70%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:70%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options to purchase common stock<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-238" contextref="From2021-01-01to2021-12-31_custom_EmployeeAndNonemployeeStockOptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,429,906</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-239" contextref="From2020-01-01to2020-12-31_custom_EmployeeAndNonemployeeStockOptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,728,149</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="even" style=""> <td style="width:70%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Warrants to purchase common stock<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-240" contextref="From2021-01-01to2021-12-31_custom_WarrantsToPurchaseCommonStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,238</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-241" contextref="From2020-01-01to2020-12-31_custom_WarrantsToPurchaseCommonStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,238</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:70%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Convertible debt<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-242" contextref="From2021-01-01to2021-12-31_us-gaap_ConvertibleDebtMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">510,986</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-243" contextref="From2020-01-01to2020-12-31_us-gaap_ConvertibleDebtMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="even" style=""> <td style="width:70%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-244" contextref="From2021-01-01to2021-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,972,130</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:12%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-245" contextref="From2020-01-01to2020-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,779,387</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p></td></tr></tbody></table></div></ix:nonnumeric></span></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-246" contextref="From2021-01-01to2021-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Segment Reporting</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company determines its segment reporting based upon the way the business is organized for making operating decisions and assessing performance. The Company operates in only <span><ix:nonfraction id="fact-identifier-247" contextref="From2021-01-01to2021-12-31" name="us-gaap:NumberOfOperatingSegments" unitref="Pure" decimals="INF" scale="0" format="ixt-sec:numwordsen" inside-table="false" data-original-id="Fact_0000000000241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span> segment, which is related to the development of pharmaceutical products. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-248" contextref="From2021-01-01to2021-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; font-style:italic; ">Recent Accounting Pronouncements</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, Simplifying the Accounting for Income Taxes. ASU No. 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU No. 2019-12 on January 1, 2021, which did not have any impact to the Companys Consolidated Financial Statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entitys Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from U.S. GAAP, separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the if-converted method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Companys current accounting treatment under the current guidance. The guidance is effective for the Companys financial statements issued for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company early adopted the new guidance on January 1, 2021, using the modified retrospective approach. The adoption did not have any impact to the Companys Consolidated Financial Statements. </p></ix:nonnumeric></span></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-13</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-249" contextref="From2021-01-01to2021-12-31" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">3. License Revenue</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On November 3, 2020, the Company entered into the South Korea Agreement with KPM and Telcon (together, the Licensee). Pursuant to the South Korea Agreement, among other things, the Company granted the Licensee a license under certain patents and other intellectual property to develop and commercialize the Companys lead product candidate, lenzilumab, for treatment of COVID-19 pneumonia, in South Korea and the Philippines (the Territory), subject to certain reservations and limitations. The Licensee will be responsible for gaining regulatory approval for, and subsequent commercialization of, lenzilumab in the Territory.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">As consideration for the license, the Licensee has agreed to pay the Company (i) an up-front license fee of $<span><ix:nonfraction id="fact-identifier-250" contextref="From2020-10-01to2020-12-31_custom_KpmAndTelconMember_custom_KpmAndTelconMember" name="hgen:UpfrontLicenseFeeAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.0</ix:nonfraction></span> million (or $<span><ix:nonfraction id="fact-identifier-251" contextref="From2020-10-01to2020-12-31_custom_KpmAndTelconMember_custom_KpmAndTelconMember" name="hgen:LicenseAgreementUpfrontPayment" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.5</ix:nonfraction></span> million net of withholding taxes and other fees and royalties), payable promptly following the execution of the License Agreement, which was received in the fourth quarter of 2020, (ii) up to an aggregate of $<span><ix:nonfraction id="fact-identifier-252" contextref="From2021-01-01to2021-03-31_custom_KpmAndTelconMember_custom_KpmAndTelconMember" name="hgen:MilestoneLicensePayments" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14.0</ix:nonfraction></span> million in two payments based on achievement by the Company of two specified milestones in the U.S., of which the first milestone was met in the first quarter of 2021 and $<span><ix:nonfraction id="fact-identifier-253" contextref="From2021-04-01to2021-06-30_custom_KpmAndTelconMember_custom_KpmAndTelconMember" name="hgen:UpfrontLicenseFeeAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.0</ix:nonfraction></span> million (or $<span><ix:nonfraction id="fact-identifier-254" contextref="From2021-04-01to2021-06-30_custom_KpmAndTelconMember_custom_KpmAndTelconMember" name="hgen:LicenseAgreementUpfrontPayment" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.5</ix:nonfraction></span> million net of withholding taxes and other fees and royalties) was received in the second quarter of 2021, and (iii) subsequent to the receipt by the Licensee of the requisite regulatory approvals, double-digit royalties on the net sales of lenzilumab in South Korea and the Philippines. The Licensee has agreed to certain development and commercial performance obligations. It is expected that <span><ix:nonnumeric id="fact-identifier-255" contextref="From2021-01-01to2021-12-31_custom_KpmAndTelconMember" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" inside-table="false" data-original-id="Fact_0000000000250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">the Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.</ix:nonnumeric></span> The Licensee has agreed to certain minimum purchases of lenzilumab on an annual basis.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company assessed the South Korea Agreement in accordance with ASC 606 and ASC 808  <span style="font-style:italic; ">Collaborative Arrangements</span> and determined that its performance obligations under the South Korea agreement include (i) the exclusive, royalty-bearing, sublicensable license to lenzilumab, (ii) the manufacturing supply services to be provided by the Company, (iii) cooperation and assistance to be provided by the Company to the Licensee with regulatory authorities in the Territory and (iv) its obligation to serve on a joint steering committee (Items iii and iv above collectively, the Research and Development Services or the Services). The Company concluded that in the initial period leading up to regulatory approval in the Territory (the Initial Period), the license was not distinct since it was of no benefit to Licensee without the aforementioned Services and that, as such, the license and the Services should be bundled as a single performance obligation. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company has concluded that the nature of its promise is to stand ready to provide Research and Development Services as needed during the Performance Period (as defined below). The Company has further concluded that for all of the increments of time during the Performance Period its promise of standing ready to provide the Services is substantially the same. While the specific tasks performed during each increment of time will vary, the nature of the overall promise to provide the Services remains the same throughout the Performance Period.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Since the provision of the license and the Services are considered a single performance obligation, the $4.5 million upfront payment ($6.0 million net of withholding taxes and other fees and royalties) is being recognized as revenue ratably <span><ix:nonnumeric id="fact-identifier-256" contextref="From2021-01-01to2021-12-31_custom_KpmAndTelconMember" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" inside-table="false" data-original-id="Fact_0000000000251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">over the 29-month period through March of 2023 (the Performance Period), the expected period over which the Company conservatively expects the Services to be performed with approval in the Territory expected by the end of March 2023.</ix:nonnumeric></span> In addition, since the milestone was achieved during the performance period, the Company recognized revenue to the extent of the proportion of the straight-line basis achieved as of the first quarter of 2021, with the remainder recorded as deferred revenue to be amortized over the remaining Performance Period. Therefore, in the years ended December 21, 2021 and 2020, the Company has recognized license revenue totaling approximately $<span><ix:nonfraction id="fact-identifier-257" contextref="From2021-01-01to2021-12-31_custom_KpmAndTelconMember" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.6</ix:nonfraction></span> million and $<span><ix:nonfraction id="fact-identifier-258" contextref="From2020-01-01to2020-12-31_custom_KpmAndTelconMember" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span> million, respectively.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Licensees purchases of lenzilumab for development purposes or for commercial requirements, represent options under the agreement and revenues will therefore be recognized when control of the product is transferred to Licensee.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Contract Liabilities</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">A contract liability of $5.2 million was recorded on the Consolidated Balance Sheets as deferred revenue as of December 31, 2021 related to the South Korea agreement. There were no contract asset or deferred contract acquisition costs as of December 31, 2021 associated with the South Korea agreement.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-14</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-259" contextref="From2021-01-01to2021-12-31" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> The following table presents changes in the Companys contract liability for the years ended December 31, 2021 and 2020 (in thousands): </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance at January 1, 2020<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-260" contextref="AsOf2019-12-31" name="us-gaap:ContractWithCustomerLiability" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Additions<sup>(1)</sup><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-261" contextref="From2020-01-01to2020-12-31" name="hgen:ContractWithCustomerLiabilityRevenueRecognized1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,528</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Deductions for performance obligations satisfied:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">In current period<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-262" contextref="From2020-01-01to2020-12-31" name="hgen:ContractWithCustomerPerformanceObligationSatisfiedInCurrentPeriod" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">312</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance at December 31, 2020<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-263" contextref="AsOf2020-12-31" name="us-gaap:ContractWithCustomerLiability" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,216</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Additions<sup>(2)</sup><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-264" contextref="From2021-01-01to2021-12-31" name="hgen:ContractWithCustomerLiabilityRevenueRecognized1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,542</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Deductions for performance obligations satisfied:<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">In current period<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-265" contextref="From2021-01-01to2021-12-31" name="hgen:ContractWithCustomerPerformanceObligationSatisfiedInCurrentPeriod" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,721</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:20pt; margin-bottom:0pt; ">In prior period<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-266" contextref="From2021-01-01to2021-12-31" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,874</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance at December 31, 2021<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-267" contextref="AsOf2021-12-31" name="us-gaap:ContractWithCustomerLiability" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,163</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td colspan="5" style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">_______________<span style="padding-left:2pt; "></span></p> </td> </tr> <tr class="odd" style=""> <td colspan="5" style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:10pt !important; margin-bottom:0pt; "><sup>(1)</sup> <ix:footnote id="FN_621627d1c1256b3ad4a9b49f" footnoterole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Up-front license fee of $6.0 million (or $4.5 million net of withholding taxes and other fees and royalties).</ix:footnote><span style="padding-left:2pt; "></span></p> </td> </tr> <tr class="even" style=""> <td colspan="5" style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> </tr> <tr class="odd" style=""> <td colspan="5" style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-10pt !important; padding-left:10pt !important; margin-bottom:0pt; "><sup>(2)</sup> <ix:footnote id="FN_621627d1c1256b3ad4a9b49d" footnoterole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Milestone payment of $6.0 million (or $4.5 million net of withholding taxes and other fees and royalties).</ix:footnote> <span style="padding-left:2pt; "></span></p></td></tr></tbody></table></div></ix:nonnumeric></span></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-268" contextref="From2021-01-01to2021-12-31" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:14pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">4. </span><span style="font-weight:bold; ">Accrued Expenses</span></p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-269" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> Accrued expenses consist of the following (in thousands): </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="7" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">As of December 31,</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued contract manufacturing-related<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-270" contextref="AsOf2021-12-31" name="hgen:AccruedContractManufacturingRelated" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">16,174</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-271" contextref="AsOf2020-12-31" name="hgen:AccruedContractManufacturingRelated" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued milestone and royalties<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-272" contextref="AsOf2021-12-31" name="hgen:AccruedMilestoneAndRoyaltiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,736</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-273" contextref="AsOf2020-12-31" name="hgen:AccruedMilestoneAndRoyaltiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,368</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued clinical trial-related<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-274" contextref="AsOf2021-12-31" name="hgen:AccruedClinicalTrialRelatedCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">160</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-275" contextref="AsOf2020-12-31" name="hgen:AccruedClinicalTrialRelatedCurrent" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued compensation-related<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-276" contextref="AsOf2021-12-31" name="us-gaap:DeferredCompensationLiabilityCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-277" contextref="AsOf2020-12-31" name="us-gaap:DeferredCompensationLiabilityCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">530</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued other<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-278" contextref="AsOf2021-12-31" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">768</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-279" contextref="AsOf2020-12-31" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">277</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-280" contextref="AsOf2021-12-31" name="us-gaap:AccruedLiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,882</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-281" contextref="AsOf2020-12-31" name="us-gaap:AccruedLiabilitiesCurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,175</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonnumeric></span></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-282" contextref="From2021-01-01to2021-12-31" name="us-gaap:DebtDisclosureTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:14pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">5. Debt</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Secured Term Loan Facility</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On March 10, 2021, the Company executed a Loan and Security Agreement with Hercules Capital as agent for its affiliates serving as lenders thereunder (the Term Loan). The Term Loan provides a loan in the aggregate principal amount of up to $<span><ix:nonfraction id="fact-identifier-283" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80.0</ix:nonfraction></span> million, in three tranches. On March 29, 2021, the Company drew the initial $<span><ix:nonfraction id="fact-identifier-284" contextref="AsOf2021-03-29_custom_SecuredTermLoanFacilityMember" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.0</ix:nonfraction></span> million tranche under the Term Loan. After giving effect to payment of fees and expenses associated with the draw, the Company received net proceeds of approximately $<span><ix:nonfraction id="fact-identifier-285" contextref="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember" name="us-gaap:ProceedsFromLinesOfCredit" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24.4</ix:nonfraction></span> million. The Company is no longer entitled to draw the second tranche, which was to be in the amount of $<span><ix:nonfraction id="fact-identifier-286" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember_custom_SecondTrancheMember_srt_MaximumMember" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35.0</ix:nonfraction></span> million or $<span><ix:nonfraction id="fact-identifier-287" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember_custom_SecondTrancheMember_srt_MinimumMember" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.0</ix:nonfraction></span> million, as it did not receive EUA for lenzilumab for the treatment of hospitalized patients with COVID-19 pneumonia by September 15, 2021. The Company may become entitled to draw another $<span><ix:nonfraction id="fact-identifier-288" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember_custom_ThirdTrancheMember" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.0</ix:nonfraction></span> million under the Term Loan through June 15, 2022, at the discretion of Hercules if the Company requests additional funding in support of the Companys strategic initiatives, although there can be no assurances that Hercules would agree to provide such additional funding.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company will be required to repay amounts borrowed by March 1, 2025, subject to a one-year extension option that it may exercise if it has received FDA approval of a BLA for the use of lenzilumab for the treatment of hospitalized patients with COVID-19 pneumonia, and the FDA-authorized label for lenzilumab is generally consistent with that sought in the Companys BLA filing, and the Company has paid Hercules certain fees and expenses associated with the extension.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Amounts drawn bear interest at a floating rate equal to the greater of either (i) <span><ix:nonfraction id="fact-identifier-289" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.75</ix:nonfraction></span>% plus the prime rate as reported in The Wall Street Journal minus <span><ix:nonfraction id="fact-identifier-290" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="hgen:DebtInstrumentInterestRateFloatingRateDeduction" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.25</ix:nonfraction></span>%, or (ii) 8.75% (such greater amount, the Base Interest Rate). Subject to there not having occurred any default or event of default under the loan agreement, the Base Interest Rate will be reduced by <span><ix:nonfraction id="fact-identifier-291" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="hgen:BaseInterestRateReductionBasisPoints" unitref="Pure" decimals="INF" scale="-4" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25</ix:nonfraction></span> basis points upon the occurrence of each of the first three of the four following events to occur:</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:57pt; margin-bottom:0pt; ">if the Company achieves the protocol-specified primary efficacy endpoint for the pivotal Phase 3 study of lenzilumab for COVID-19, (clinicaltrials.gov identifier NCT04351152), and receives EUA for the use of lenzilumab for the treatment of hospitalized patients with COVID-19 pneumonia;</p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-15</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:57pt; margin-bottom:0pt; ">if the Company achieves product revenue from lenzilumab that is invoiced and/or recognized as revenue (as determined in accordance with GAAP) solely from the sale of lenzilumab (Net Lenzilumab Product Revenue) of at least $<span><ix:nonfraction id="fact-identifier-292" contextref="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember" name="hgen:NetLenzilumabProductRevenue" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100.0</ix:nonfraction></span> million; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; ">if the Company achieves Net Lenzilumab Product Revenue of at least $<span><ix:nonfraction id="fact-identifier-293" contextref="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember_srt_MinimumMember" name="hgen:NetLenzilumabProductRevenue" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">250.0</ix:nonfraction></span> million; and </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; ">if the Company achieves Net Lenzilumab Product Revenue of at least $<span><ix:nonfraction id="fact-identifier-294" contextref="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember_srt_MaximumMember" name="hgen:NetLenzilumabProductRevenue" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">350.0</ix:nonfraction></span> million. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">No principal payments will be due during an interest-only period, commencing on the initial borrowing date and continuing to April 1, 2023, subject to extension to April 1, 2024, and potentially October 1, 2024, under certain conditions. Following the interest-only period, the outstanding balance of the loan will be required to be repaid monthly, continuing through the maturity date.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company may prepay amounts drawn under the agreement in full prior to the maturity date then in effect, subject to payment of prepayment charges equal to:</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-295" contextref="AsOf2021-12-31_custom_SecuredTermLoanFacilityMember" name="hgen:PrepaymentPercentageChargeIfPaidBeforeDateOne" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span>% of the amounts borrowed, if the prepayment occurs on or prior to March 29, 2022; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-296" contextref="AsOf2021-12-31_custom_SecuredTermLoanFacilityMember" name="hgen:PrepaymentPercentageChargeIfPaidBeforeDateTwo" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.5</ix:nonfraction></span>% of the amounts borrowed, if the prepayment occurs after March 29, 2022 and before March 29, 2023; and </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-297" contextref="AsOf2021-12-31_custom_SecuredTermLoanFacilityMember" name="hgen:PrepaymentPercentageChargeIfPaidBeforeDateThree" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span>% of the amounts borrowed, if the prepayment occurs after March 29, 2023 and before March 29, 2024. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">In addition, on the earliest to occur of (i) the maturity date, (ii) the date the Company prepays the outstanding principal amount of the Term Loan, or (iii) the date the outstanding principal amount of the Term Loan otherwise becomes due, the Company will owe Hercules an end of term (EOT) charge equal to <span><ix:nonfraction id="fact-identifier-298" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="hgen:EndOfTermFeePercentage" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.75</ix:nonfraction></span>% of the aggregate amount of the Term Loan funded by Hercules.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">As a condition to obtaining the Term Loan, the Company granted Hercules a security interest in substantially all of its assets and personal property not otherwise subject to existing or permitted liens. In addition, the Term Loan contains customary representations and warranties and events of default for a term loan facility of this size and type. Under the Term Loan, the Company also agreed to comply with certain customary affirmative and negative covenants that become effective upon the initial draw of the first tranche, including covenants to:</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; ">maintain $<span><ix:nonfraction id="fact-identifier-299" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="hgen:UnrestrictedCash" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span> million unrestricted cash; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:57pt; margin-bottom:0pt; ">comply with certain requirements to provide Hercules with financial information and other rights to inspect the Companys books and records and the collateral for the Term Loan; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:57pt; margin-bottom:0pt; ">refrain from incurring debt that is not expressly subordinated to the Term Loan; Rule 144A-style convertible notes in aggregate principal amount up to $<span><ix:nonfraction id="fact-identifier-300" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="us-gaap:ConvertibleNotesPayable" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250.0</ix:nonfraction></span> million; and other permitted indebtedness; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:57pt; margin-bottom:0pt; ">refrain from granting (or permitting to exist) liens on the Companys assets and properties, other than certain permitted liens, including in respect of its patents and other intellectual property; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; ">refrain from making certain investments, other than permitted acquisitions and certain other permitted investments; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; ">refrain from repurchasing the Companys stock or paying dividends, subject to limited exceptions; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; ">refrain from transferring any material portion of its assets; and </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:36pt; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:57pt; margin-bottom:0pt; ">refrain from entering into any merger or consolidation in which the Company is not the surviving entity. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">All of these covenants will not apply upon repayment of any borrowings under the Term Loan.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Certain of the baskets for permitted investments and other exceptions to the covenants described above have increased because the Company has raised more than $<span><ix:nonfraction id="fact-identifier-301" contextref="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember" name="hgen:UnrestrictedNetCashProceeds" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100.0</ix:nonfraction></span> million in unrestricted net cash proceeds from one or more bona fide equity financings prior to March 31, 2022. (See Note 8 below for information relating to the Companys equity financings in 2021 in this regard.) Further, the covenants in the Term Loan will not prohibit the Company from pursuing its strategy of entering into out-bound license agreements for lenzilumab that may be exclusive as to specific geographic regions outside the U.S., nor will the covenants prohibit the Company from entering into co-development or co-promotion or commercialization agreements relating to lenzilumab, so long as such agreements generally are negotiated on arms length and commercially reasonable terms.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">While the Term Loan is outstanding, the lenders will have the right to convert a portion of the principal amount outstanding under the Term Loan (ranging from $<span><ix:nonfraction id="fact-identifier-302" contextref="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember_srt_MinimumMember" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span> million to $<span><ix:nonfraction id="fact-identifier-303" contextref="From2021-03-01to2021-03-10_custom_SecuredTermLoanFacilityMember_srt_MaximumMember" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.0</ix:nonfraction></span> million in the aggregate) into shares of the Companys common stock at a conversion price equal to $<span><ix:nonfraction id="fact-identifier-304" contextref="AsOf2021-03-10_custom_SecuredTermLoanFacilityMember" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19.57</ix:nonfraction></span> per share, subject to customary anti-dilution adjustments.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-16</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-305" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> The following table summarizes the outstanding future payments of principal and interest associated with the Companys Term Loan as of December 31, 2021 (in thousands): </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2022<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-306" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,218</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2023<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-307" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,800</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2024<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-308" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,671</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2025<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-309" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,153</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total payments<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-310" contextref="AsOf2021-12-31" name="hgen:LongTermDebtMaturitiesRepaymentsOfPrincipal" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">31,842</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less amount representing interest<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-311" contextref="AsOf2021-12-31" name="hgen:LongTermDebtMaturitiesRepaymentsOfInterest" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,155</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Notes payable, gross<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-312" contextref="AsOf2021-12-31" name="us-gaap:NotesPayable" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,687</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less: Unamortized portion of EOT charge<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-313" contextref="AsOf2021-12-31" name="hgen:UnamortizedPortionOfEotCharge" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,264</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less: Unamortized discount on notes payable<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-314" contextref="AsOf2021-12-31" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">159</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less: Unamortized debt issuance costs<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-315" contextref="AsOf2021-12-31" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">258</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Long-term debt<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-316" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebtNoncurrent" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,006</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less current portion<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-317" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebtCurrent" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:82%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Long-term debt, net of current portion<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-318" contextref="AsOf2021-12-31" name="us-gaap:LongTermDebt" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,006</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; text-indent:36pt; margin-bottom:0pt; ">Interest expense related to the Term Loan, for the year ended December 31, 2021 was approximately $<span><ix:nonfraction id="fact-identifier-319" contextref="From2021-01-01to2021-12-31_custom_SecuredTermLoanFacilityMember" name="us-gaap:InterestExpenseDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span> million and the effective interest rate was <span><ix:nonfraction id="fact-identifier-320" contextref="AsOf2021-12-31_custom_SecuredTermLoanFacilityMember" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.0</ix:nonfraction></span>%.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Notes Payable to Vendors</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On June 30, 2016, the Company issued promissory notes in an aggregate principal amount of approximately $<span><ix:nonfraction id="fact-identifier-321" contextref="AsOf2016-06-30_us-gaap_NotesPayableOtherPayablesMember" name="us-gaap:LongTermNotesPayable" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span> million to certain claimants in accordance with the Companys Plan of Reorganization (the Plan) filed with the United States Bankruptcy Court for the District of Delaware (the Bankruptcy Court) (Case No. 15-12628 (LSS) (the Bankruptcy Case) which became effective June 30, 2016, at which time the Company emerged from its Chapter 11 bankruptcy proceedings. The notes were unsecured, accrued interest at <span><ix:nonfraction id="fact-identifier-322" contextref="AsOf2016-06-30_us-gaap_NotesPayableOtherPayablesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span>% per annum and became due and payable in full, including principal and accrued interest on June 30, 2019. In July and August, 2019, following the receipt of proceeds from the 2019 Bridge Notes, the Company used approximately $<span><ix:nonfraction id="fact-identifier-323" contextref="AsOf2019-08-31_us-gaap_NotesPayableOtherPayablesMember_custom_BridgeNotesMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span> million of the proceeds to retire a portion of these notes, including accrued interest. In June and July 2020, the Company used the proceeds from the Private Placement (as defined below) to repay the remaining outstanding principal including accrued and unpaid interest on these notes and the notes were extinguished. As of December 31, 2020, all the notes had been repaid.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Convertible Notes</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-style:italic; ">2018 Convertible Notes</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Commencing September 19, 2018, the Company delivered a series of convertible promissory notes (the 2018 Notes) evidencing an aggregate of $<span><ix:nonfraction id="fact-identifier-324" contextref="AsOf2018-09-19_custom_ConvertiblePromissoryNoteMember_custom_BlackHorseCapitalLPMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.5</ix:nonfraction></span> million of loans made to the Company by six different lenders, including an affiliate of Black Horse Capital, L.P. (BHC), the Companys controlling stockholder at the time. The 2018 Notes accrued interest at a rate of <span><ix:nonfraction id="fact-identifier-325" contextref="From2018-09-01to2018-09-19_custom_ConvertiblePromissoryNoteMember_custom_BlackHorseCapitalLPMember" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span>% per annum and, in general, were set to mature twenty-four months from the date the 2018 Notes were signed. The Company used the proceeds from the 2018 Notes for working capital.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The 2018 Notes were convertible into equity securities of the Company in three different scenarios, including if the Company sold its equity securities on or before the date of repayment of the 2018 Notes in any financing transaction that resulted in gross proceeds to the Company of less than $<span><ix:nonfraction id="fact-identifier-326" contextref="From2018-09-20to2020-06-30_us-gaap_ConvertibleNotesPayableMember_custom_NonQualifiedFinancingMember" name="us-gaap:ProceedsFromConvertibleDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.0</ix:nonfraction></span> million (a Non-Qualified Financing). In connection with a Non-Qualified Financing, the noteholders were able to convert their remaining 2018 Notes into either (i) such equity securities as the noteholder would acquire if the principal and accrued but unpaid interest thereon (the Conversion Amount) were invested directly in the financing on the same terms and conditions as given to the financing investors in the Non-Qualified Financing, or (ii) common stock at a conversion price equal to $<span><ix:nonfraction id="fact-identifier-327" contextref="AsOf2020-04-30_us-gaap_ConvertibleNotesPayableMember_custom_NonQualifiedFinancingMember" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.25</ix:nonfraction></span> per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Notes).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Companys sales of shares pursuant to the ELOC Purchase Agreement with Lincoln Park constituted a Non-Qualified Financing. Commencing on April 2, 2020, the holders of the 2018 Notes notified the Company of their exercise of their conversion rights under the 2018 Notes. See 2019 Convertible Notes for additional information regarding the conversion of 2018 Notes by the holders.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Interest expense recorded during the year ended December 31, 2020 related to the 2018 Notes was approximately $<span><ix:nonfraction id="fact-identifier-328" contextref="From2020-01-01to2020-12-31_us-gaap_NotesPayableOtherPayablesMember_us-gaap_ConvertibleNotesPayableMember" name="us-gaap:InterestExpenseDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.8</ix:nonfraction></span> million.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-17</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-style:italic; ">2019 Convertible Notes</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Commencing on April 23, 2019, the Company delivered a series of convertible promissory notes (the 2019 Notes and together with the 2018 Notes, the Convertible Notes) evidencing an aggregate of $<span><ix:nonfraction id="fact-identifier-329" contextref="AsOf2019-04-23_custom_ConvertibleNotesPayableTwoMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span> million of loans made to the Company. The 2019 Notes accrued interest at a rate of <span><ix:nonfraction id="fact-identifier-330" contextref="From2019-04-24to2020-04-30_custom_ConvertibleNotesPayableTwoMember" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.5</ix:nonfraction></span>% per annum and, in general, were set to mature twenty-four months from the date the 2019 Notes were signed. The Company used the proceeds from the 2019 Notes for working capital.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The 2019 Notes were convertible into equity securities of the Company in four different scenarios, including if the Company sold its equity securities on or before the date of repayment of the 2019 Notes in any financing transaction that resulted in gross proceeds to the Company of less than $<span><ix:nonfraction id="fact-identifier-331" contextref="From2019-04-24to2020-04-30_custom_ConvertibleNotesPayableTwoMember_custom_NonQualifiedFinancingMember" name="us-gaap:ProceedsFromConvertibleDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.0</ix:nonfraction></span> million (a Non-Qualified Financing). In connection with a Non-Qualified Financing, the noteholders were able to convert their remaining 2019 Notes into either (i) such equity securities as the noteholder would acquire if the Conversion Amount were invested directly in the financing on the same terms and conditions as given to the financing investors in the Non-Qualified Financing, or (ii) common stock at a conversion price equal to $<span><ix:nonfraction id="fact-identifier-332" contextref="AsOf2020-04-30_custom_ConvertibleNotesPayableTwoMember_custom_NonQualifiedFinancingMember" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.25</ix:nonfraction></span> per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the 2019 Notes).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Companys sales of shares pursuant to the ELOC Purchase Agreement with LPC constituted a Non-Qualified Financing. Commencing on April 2, 2020, holders of the Convertible Notes, including Cheval, an affiliate of BHC, the Companys controlling stockholder at the time, notified the Company of their exercise of their conversion rights under the Convertible Notes. Pursuant to the exemption from registration afforded by Section 3(a)(9) under the Securities Act, the Company issued an aggregate of <span><ix:nonfraction id="fact-identifier-333" contextref="From2020-04-01to2020-04-02_custom_ConvertibleNotesPayableTwoMember" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,397,916</ix:nonfraction></span> shares of its common stock upon the conversion of $<span><ix:nonfraction id="fact-identifier-334" contextref="From2020-04-01to2020-04-02_custom_ConvertibleNotesPayableTwoMember" name="us-gaap:ProceedsFromConvertibleDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.3</ix:nonfraction></span> million in aggregate principal and interest on the Convertible Notes that were converted, which obligations were retired. Of these, the Company issued <span><ix:nonfraction id="fact-identifier-335" contextref="From2020-04-01to2020-04-02_custom_ConvertibleNotesPayableTwoMember_custom_ChevalDrDaleChappellMember" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316,666</ix:nonfraction></span> shares to Cheval. Dr. Dale Chappell, who was serving as the Companys ex-officio chief scientific officer at the time and currently serves as its Chief Scientific Officer, controls BHC and reports beneficial ownership of all shares held by it and its affiliates, including Cheval. After giving effect to the shares issued upon such conversions, no convertible notes issued in 2018 or 2019 were outstanding as of December 31, 2020.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Interest expense related to the 2019 Notes, recorded during the year ended December 31, 2020, was approximately $<span><ix:nonfraction id="fact-identifier-336" contextref="From2020-01-01to2020-12-31_custom_ConvertibleNotesPayableTwoMember" name="us-gaap:InterestExpenseDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Advance Notes, the 2018 Notes and the 2019 Notes had an optional voluntary conversion feature in which the holder could convert the notes in the Companys common stock at maturity at a conversion rate of $<span><ix:nonfraction id="fact-identifier-337" contextref="From2020-04-01to2020-04-30_custom_AdvanceNotesMember_custom_ConvertibleNotesPayables2018Member" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.25</ix:nonfraction></span> per share for the Advance Notes and the 2018 Notes and at a conversion rate of $<span><ix:nonfraction id="fact-identifier-338" contextref="From2020-04-01to2020-04-30_custom_AdvanceNotesMember_custom_ConvertibleNotesPayableTwoMember" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.25</ix:nonfraction></span> for the 2019 Notes. The intrinsic value of this beneficial conversion feature was $<span><ix:nonfraction id="fact-identifier-339" contextref="From2020-04-01to2020-04-30_custom_AdvanceNotesMember_custom_ConvertibleNotesPayables2018Member" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.8</ix:nonfraction></span> million upon the issuance of the Advance Notes, the 2018 Notes and the 2019 Notes and was recorded as additional paid-in capital and as a debt discount which was accreted to interest expense over the term of the Advance Notes, the 2018 Notes and the 2019 Notes. Interest expense included debt discount amortization of $<span><ix:nonfraction id="fact-identifier-340" contextref="From2020-01-01to2020-12-31_custom_AdvanceNotesMember" name="us-gaap:AmortizationOfDebtDiscountPremium" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.8</ix:nonfraction></span> million for the year ended December 31, 2020.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company evaluated the embedded features within the Advance Notes, the 2018 Notes and the 2019 Notes to determine if the embedded features are required to be bifurcated and recognized as derivative instruments. The Company determined that the Advance Notes, the 2018 Notes and the 2019 Notes contain contingent beneficial conversion features (CBCF) that allow or require the holder to convert the Advance Notes, the 2018 Notes and the 2019 Notes, as applicable, to Company common stock at a conversion rate of $2.25 per share for the Advance Notes and the 2018 Notes and $6.25 for the 2019 Notes, but did not contain embedded features requiring bifurcation and recognition as derivative instruments. Upon the occurrence of a CBCF that results in conversion of the Advance Notes, the 2018 Notes or the 2019 Notes to Company common stock, the remaining unamortized discount will be charged to interest expense. Upon conversion of the Advance Notes on May 30, 2019, the remaining unamortized discount was charged to interest expense. Upon the conversion of the Convertible Notes in April 2020, the remaining related unamortized discount was charged to interest expense.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-style:italic; ">2020 Convertible Redeemable Notes</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On March 13, 2020 and March 19, 2020 (the Issuance Dates), the Company delivered two convertible redeemable promissory notes (the 2020 Notes) evidencing loans with an aggregate principal amount of $<span><ix:nonfraction id="fact-identifier-341" contextref="AsOf2020-03-19_custom_ConvertibleNotesPayableThreeMember" name="us-gaap:LongTermNotesPayable" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">518,333</ix:nonfraction></span> made to the Company.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The 2020 Notes accrued interest at a rate of <span><ix:nonfraction id="fact-identifier-342" contextref="From2020-03-14to2020-06-30_custom_ConvertibleNotesPayableThreeMember" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span>% per annum and were set to mature on <span><ix:nonnumeric id="fact-identifier-343" contextref="From2020-03-01to2020-03-13_custom_ConvertibleNotesPayableThreeMember_custom_TrancheOneMember" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen" inside-table="false" data-original-id="Fact_0000000000338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March 13, 2021</ix:nonnumeric></span> and <span><ix:nonnumeric id="fact-identifier-344" contextref="From2020-03-01to2020-03-19_custom_ConvertibleNotesPayableThreeMember_custom_TrancheTwoMember" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen" inside-table="false" data-original-id="Fact_0000000000339" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March 19, 2021</ix:nonnumeric></span>, respectively. The 2020 Notes contained an original issue discount of $<span><ix:nonfraction id="fact-identifier-345" contextref="AsOf2020-03-13_custom_ConvertibleNotesPayableThreeMember_custom_TrancheOneMember" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,000</ix:nonfraction></span> and $<span><ix:nonfraction id="fact-identifier-346" contextref="AsOf2020-03-19_custom_ConvertibleNotesPayableThreeMember_custom_TrancheTwoMember" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,833</ix:nonfraction></span>, respectively. The Company used the proceeds from the 2020 Notes for working capital.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-347" contextref="From2021-01-01to2021-12-31_custom_ConvertibleNotesPayableThreeMember" name="us-gaap:DebtInstrumentRedemptionDescription" inside-table="false" data-original-id="Fact_0000000000342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The notes could be redeemed by the Company at any time before the 270<sup>th</sup> day following issuance, at a redemption price equal to the principal and accrued but unpaid interest on the notes to the date of redemption, plus a premium that increases on day 61 and day 121 from the issuance date. Accordingly, the notes were repaid in June 2020 with proceeds from the Private Placement, and the notes were extinguished.</ix:nonnumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-18</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company evaluated the embedded features within the 2020 Notes and determined that the embedded features are required to be bifurcated and recognized as stand-alone derivative instruments. The variable-share settlement features within the 2020 Notes qualify as redemption features and meet the net settlement criterion for qualification as a stand-alone derivative. In determining the fair value of the bifurcated derivative, the Company evaluated the likelihood of conversion of the 2020 Notes to Company stock. As the Company believed it would have adequate funding prior to the six-month anniversary of the 2020 Notes, the first conversion option for the holders of the 2020 Notes, and it had the intent to either begin making amortizing payments or to pay off the 2020 Notes in their entirety prior to that date, the fair value was determined to be $<span><ix:nonfraction id="fact-identifier-348" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableThreeMember" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitref="Usd" decimals="-3" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>. The original issue discount was accreted to interest expense and the remaining balance was charged to interest expense upon payoff.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Interest expense related to the 2020 Notes, recorded during the year ended December 31, 2020, was approximately $<span><ix:nonfraction id="fact-identifier-349" contextref="From2020-01-01to2020-12-31_custom_ConvertibleNotesPayableThreeMember" name="us-gaap:InterestExpenseDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million. Interest expense includes the original issue discount amortization of approximately $<span><ix:nonfraction id="fact-identifier-350" contextref="From2020-01-01to2020-12-31_custom_ConvertibleNotesPayableThreeMember" name="us-gaap:AmortizationOfDebtDiscountPremium" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million for the year ended December 31, 2020.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-style:italic; ">Bridge Notes</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On June 28, 2019, the Company issued three short-term, secured bridge notes (the June Bridge Notes) evidencing an aggregate of $<span><ix:nonfraction id="fact-identifier-351" contextref="AsOf2019-06-28_custom_BridgeNotesMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.7</ix:nonfraction></span> million of loans made to the Company by three parties: Cheval, an affiliate of BHC, the Companys controlling stockholder at the time, lent $<span><ix:nonfraction id="fact-identifier-352" contextref="AsOf2019-06-28_custom_BridgeNotesMember_custom_CameronDurrantMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-4" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span> million; Nomis Bay LTD, the Companys second largest stockholder, lent $<span><ix:nonfraction id="fact-identifier-353" contextref="AsOf2019-06-28_custom_BridgeNotesMember_custom_NomisBayLtdMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-4" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span> million; and Dr. Cameron Durrant, the Companys Chief Executive Officer and Chairman of the Board of Directors (the Board), lent $<span><ix:nonfraction id="fact-identifier-354" contextref="AsOf2019-06-28_custom_BridgeNotesMember_srt_ChiefExecutiveOfficerMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million. The proceeds from the June Bridge Notes were used to satisfy a portion of the unsecured obligations incurred in connection with the Companys emergence from bankruptcy in 2016 and for working capital and general corporate purposes.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The June Bridge Notes accrued interest at a rate of <span><ix:nonfraction id="fact-identifier-355" contextref="From2020-01-01to2020-12-31_custom_BridgeNotesMember" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span>% per annum and after giving effect to multiple extensions, were set to mature on December 31, 2020. The June Bridge Notes could become due and payable at such earlier time as the Company raised more than $<span><ix:nonfraction id="fact-identifier-356" contextref="From2020-06-01to2020-06-30_custom_BridgeNotesMember_custom_BonaFideFinancingTransactionMember" name="us-gaap:ProceedsFromNotesPayable" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.0</ix:nonfraction></span> million in a bona fide financing transaction or upon a change in control. Accordingly, the June Bridge Notes were repaid in June 2020 with proceeds from the Private Placement, and the June Bridge Notes were extinguished.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On November 12, 2019, the Company issued two short-term, secured bridge notes (the November Bridge Notes and together with the June Bridge Notes, the 2019 Bridge Notes) evidencing an aggregate of $<span><ix:nonfraction id="fact-identifier-357" contextref="AsOf2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-4" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.35</ix:nonfraction></span> million of loans made to the Company by two parties: Cheval, an affiliate of BHC, the Companys controlling stockholder at the time, lent $<span><ix:nonfraction id="fact-identifier-358" contextref="AsOf2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_ChevalHoldingsMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-4" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span> million; and Dr. Cameron Durrant, the Companys Chief Executive Officer and Chairman of its Board, lent $<span><ix:nonfraction id="fact-identifier-359" contextref="AsOf2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_CameronDurrantMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million. The proceeds from the November Bridge Notes were used for working capital and general corporate purposes.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The November Bridge Notes ranked on par with the June Bridge Notes and possessed other terms and conditions substantially consistent with those notes. The November Bridge Notes accrued interest at a rate of <span><ix:nonfraction id="fact-identifier-360" contextref="AsOf2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span>% per annum and after giving effect to multiple extensions, were set to mature on <span><ix:nonnumeric id="fact-identifier-361" contextref="From2019-11-01to2019-11-12_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen" inside-table="false" data-original-id="Fact_0000000000356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31, 2020</ix:nonnumeric></span>. The November Bridge Notes could become due and payable at such earlier time as the Company raised more than $3.0 million in a bona fide financing transaction or upon a change in control. Accordingly, the November Bridge Notes were repaid in June 2020 with proceeds from the Private Placement.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">In April 2020, the Company issued two short-term, secured bridge notes (the April Bridge Notes and together with the June Bridge Notes and the November Bridge Notes, the Bridge Notes) evidencing an aggregate of $<span><ix:nonfraction id="fact-identifier-362" contextref="AsOf2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-4" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.35</ix:nonfraction></span> million of loans made to the Company: Cheval, an affiliate of BHC, the Companys controlling stockholder at the time, loaned $<span><ix:nonfraction id="fact-identifier-363" contextref="AsOf2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_ChevalMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million, and Nomis Bay, the Companys second largest stockholder, loaned $<span><ix:nonfraction id="fact-identifier-364" contextref="AsOf2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember_custom_NomisBayMember" name="us-gaap:DebtInstrumentFaceAmount" unitref="Usd" decimals="-4" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span> million. The proceeds from the April Bridge Notes were used for working capital and general corporate purposes.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The April Bridge Notes ranked on par with the June Bridge Notes and the November Bridge Notes and possessed other terms and conditions substantially consistent with them. The notes accrued interest at a rate of <span><ix:nonfraction id="fact-identifier-365" contextref="AsOf2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span>% per annum and were set to mature on <span><ix:nonnumeric id="fact-identifier-366" contextref="From2020-04-01to2020-04-30_custom_BridgeNotesMember_custom_NovemberBridgeNotesMember" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen" inside-table="false" data-original-id="Fact_0000000000361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31, 2020</ix:nonnumeric></span>. The April Bridge Notes could become due and payable at such earlier time as the Company raised more than $<span><ix:nonfraction id="fact-identifier-367" contextref="From2018-09-20to2020-04-30_custom_BridgeNotesMember_custom_BonaFideFinancingMember" name="us-gaap:ProceedsFromNotesPayable" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.0</ix:nonfraction></span> million in a bona fide financing transaction or upon a change in control. Accordingly, these April Bridge Notes were repaid in June 2020 with proceeds from the Private Placement, and these bridge notes were extinguished.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Bridge Notes were secured by a lien on substantially all the Companys assets, which liens have been released.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Interest expense related to the Bridge Notes, recorded during the year ended December 31, 2020, was approximately $<span><ix:nonfraction id="fact-identifier-368" contextref="From2020-01-01to2020-12-31_custom_BridgeNotesMember" name="us-gaap:InterestExpenseDebt" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-369" contextref="From2021-01-01to2021-12-31" name="hgen:WarrantsToPurchaseCommonStockTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">6. Warrants to Purchase Common Stock</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On June 19, 2013, the Company issued a warrant to purchase up to an aggregate of <span><ix:nonfraction id="fact-identifier-370" contextref="AsOf2013-06-19_us-gaap_WarrantMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,238</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction id="fact-identifier-371" contextref="AsOf2013-06-19_us-gaap_WarrantMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">484.80</ix:nonfraction></span> per share. The warrant expires on the tenth anniversary of its issuance date. As of December 31, 2021, these warrants were fully vested and unexercised. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On December 4, 2015, the Company issued a warrant to purchase up to an aggregate of <span><ix:nonfraction id="fact-identifier-372" contextref="AsOf2015-12-04_us-gaap_WarrantMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction id="fact-identifier-373" contextref="AsOf2015-12-04_us-gaap_WarrantMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146.60</ix:nonfraction></span> per share. The warrant expired on December 4, 2020. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-19</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On June 30, 2016, the Company and Savant Neglected Diseases, LLC (Savant) entered into an Agreement for the Manufacture, Development and Commercialization of Benznidazole for Human Use (the MDC Agreement), pursuant to which the Company acquired certain worldwide rights relating to benznidazole. In connection with the MDC Agreement, also on June 30, 2016, the Company issued to Savant a <span><ix:nonnumeric id="fact-identifier-374" contextref="From2016-06-01to2016-06-30_custom_SavantWarrantMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five-year </ix:nonnumeric></span>warrant (the Savant Warrant) to purchase <span><ix:nonfraction id="fact-identifier-375" contextref="AsOf2016-06-30_custom_SavantWarrantMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span> shares of the Companys Common Stock, at an exercise price of $<span><ix:nonfraction id="fact-identifier-376" contextref="AsOf2016-06-30_custom_SavantWarrantMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.25</ix:nonfraction></span> per share, subject to adjustment. The Savant Warrant was exercisable for <span><ix:nonfraction id="fact-identifier-377" contextref="From2016-06-01to2016-06-30_custom_SavantWarrantMember" name="hgen:PercentageOfWarrantExercisable" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25</ix:nonfraction></span>% of the shares immediately and exercisable for the remaining shares upon reaching certain regulatory related milestones. In addition, pursuant to the MDC Agreement, the Company had granted Savant certain piggyback registration rights for the shares issuable under the Savant Warrant. On June 30, 2020, Savant exercised <span><ix:nonfraction id="fact-identifier-378" contextref="From2021-06-01to2021-06-30_custom_SavantWarrantMember_us-gaap_SubsequentEventMember" name="hgen:NumberOfWarrantsExercisedDuringPeriod" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,000</ix:nonfraction></span> warrants in a cashless exercise resulting in <span><ix:nonfraction id="fact-identifier-379" contextref="AsOf2020-07-30_custom_SavantWarrantMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,909</ix:nonfraction></span> shares being issued to Savant in July 2020. The remaining unvested warrants for an aggregate of up to 20,000 shares expired on June 30, 2021. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On April 22, 2020, in connection with investor relation services, the Company issued two warrants to purchase up to an aggregate of <span><ix:nonfraction id="fact-identifier-380" contextref="AsOf2020-04-22_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,000</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction id="fact-identifier-381" contextref="AsOf2020-04-22_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span> per share. The warrants were to vest upon either a change of control, as defined in the warrant agreement, an uplisting to a national securities exchange, or <span><ix:nonnumeric id="fact-identifier-382" contextref="From2020-04-01to2020-04-22_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">eight years</ix:nonnumeric></span> from the issuance date and were to expire <span><ix:nonnumeric id="fact-identifier-383" contextref="From2020-04-01to2020-04-22_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">two years</ix:nonnumeric></span> after full vesting. On September 18, 2020, the Companys common stock commenced trading on the Nasdaq Capital Market and on the same day the warrants became vested and were exercised for proceeds of $<span><ix:nonfraction id="fact-identifier-384" contextref="From2020-04-01to2020-04-22_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ProceedsFromWarrantExercises" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400</ix:nonfraction></span>. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On May 20, 2020, in connection with investor relation services, the Company issued a warrant to purchase up to an aggregate of <span><ix:nonfraction id="fact-identifier-385" contextref="AsOf2020-05-20_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,000</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction id="fact-identifier-386" contextref="AsOf2020-05-20_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span> per share. The warrants were to vest upon either a change of control, as defined in the warrant agreement, an uplisting to a national securities exchange, or <span><ix:nonnumeric id="fact-identifier-387" contextref="From2020-05-01to2020-05-20_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">eight years</ix:nonnumeric></span> from the issuance date and were to expire <span><ix:nonnumeric id="fact-identifier-388" contextref="From2020-05-01to2020-05-20_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">two years</ix:nonnumeric></span> after full vesting. On September 18, 2020, the Companys common stock commenced trading on the Nasdaq Capital Market and on the same day the warrants became vested and were exercised for proceeds of $<span><ix:nonfraction id="fact-identifier-389" contextref="From2020-05-01to2020-05-20_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ProceedsFromWarrantExercises" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200</ix:nonfraction></span>. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On May 20, 2020, in connection with manufacturing consulting services, the Company issued a warrant to purchase up to an aggregate of <span><ix:nonfraction id="fact-identifier-390" contextref="AsOf2020-05-20_us-gaap_WarrantMember_custom_ManufacturingConsultingServicesMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,000</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction id="fact-identifier-391" contextref="AsOf2020-05-20_us-gaap_WarrantMember_custom_ManufacturingConsultingServicesMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.30</ix:nonfraction></span> per share. The warrants were fully vested on the date of issue and expire <span><ix:nonnumeric id="fact-identifier-392" contextref="From2020-05-01to2020-05-20_us-gaap_WarrantMember_custom_ManufacturingConsultingServicesMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ten years</ix:nonnumeric></span> from the issuance date. These warrants remained unexercised as of December 31, 2021. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On September 14, 2020, in connection with investor relation services, the Company issued three warrants to purchase up to an aggregate of <span><ix:nonfraction id="fact-identifier-393" contextref="AsOf2020-09-14_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span> shares of common stock at an exercise price of $<span><ix:nonfraction id="fact-identifier-394" contextref="AsOf2020-09-14_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span> per share. The warrants were to vest upon either a change of control, as defined in the warrant agreement, an uplisting to a national securities exchange, or <span><ix:nonnumeric id="fact-identifier-395" contextref="From2020-09-01to2020-09-14_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">eight years</ix:nonnumeric></span> from the issuance date and were to expire <span><ix:nonnumeric id="fact-identifier-396" contextref="From2020-09-01to2020-09-14_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">two years</ix:nonnumeric></span> after full vesting. On September 18, 2020, the Companys common stock commenced trading on the Nasdaq Capital Market and on the same day the warrants became vested and were exercised for proceeds of $<span><ix:nonfraction id="fact-identifier-397" contextref="From2020-09-01to2020-09-14_us-gaap_WarrantMember_custom_InvestorRelationServicesMember" name="us-gaap:ProceedsFromWarrantExercises" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000</ix:nonfraction></span>. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-398" contextref="From2021-01-01to2021-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">7. Commitments and Contingencies</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Eversana Agreement</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On January 10, 2021, the Company announced that it had entered into a master services agreement (the Eversana Agreement) with Eversana Life Science Services, LLC (Eversana) pursuant to which Eversana will provide the Company multiple services from its integrated commercial platform in preparation for the potential commercialization of lenzilumab.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Under the Eversana Agreement, Eversana will provide the Company with services in connection with the potential launch of lenzilumab. Eversana services during 2021 have comprised marketing, market access, consulting, field solutions, field operations, health economics and medical affairs. Additional services may be negotiated by the parties and set forth in statements of work delivered in accordance with the Eversana Agreement.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On September 21, 2021, the Company notified Eversana that due to the EUA status in the U.S., it was terminating the initial statement of work related to commercialization support of lenzilumab for the treatment of COVID-19 in the United States. Eversana is disputing the termination notice and has requested payment of approximately $<span><ix:nonfraction id="fact-identifier-399" contextref="From2021-04-01to2021-09-30_custom_EversanaAgreementMember" name="us-gaap:LossContingencyDamagesSoughtValue" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.0</ix:nonfraction></span> million it has asserted the Company owes for services rendered from April 1, 2021 to September 30, 2021. The Company has disputed this assertion and is working to resolve this dispute.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Eversana Agreement provides for a one-year term and will renew for subsequent one-year terms unless either party provides a notice of non-renewal. After the first year, the Company may terminate the Eversana Agreement upon advance written notice to Eversana. The Eversana Agreement contains customary provisions allowing either party to terminate the Eversana Agreement as a result of certain changes in law and material breaches and certain insolvency events by or relating to the other party.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Eversana Agreement imposes customary mutual obligations on the parties to protect and not disclose the confidential information and intellectual property of the other, and contains insurance, non-solicitation, indemnification and limitation of liability provisions customary for service contracts of this type.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-20</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Manufacturing Agreements</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company has entered into agreements with several CMOs to manufacture bulk drug substance (BDS) and fill/finish/drug product (DP) for lenzilumab for a potential launch of lenzilumab in anticipation of an EUA or CMA in 2021. The Company has also entered into agreements for packaging of the drug. These agreements represent large commitments, including upfront amounts prior to commencement of manufacturing and progress payments through the course of the manufacturing process and include payments for technology transfer. Since September 9, 2021, the Company has amended, and in some cases canceled, certain of these agreements, some of which were contingent on EUA, in an effort to reduce its future spending on lenzilumab production until and if authorization is received in the UK, EU, or U.S. These changes may limit future production of lenzilumab but because most of the Companys manufacturing agreements required payment of upfront fees upon execution and payments against performance of the services to be provided, often over a lengthy performance period, the changes are expected to decrease the Companys manufacturing costs beginning in 2022. In addition, certain of the Companys CMOs have been unsuccessful in their efforts to manufacture some batches of lenzilumab to the Companys specifications for various reasons. The Company is working with these CMOs to determine if batches of BDS manufactured by them will be usable in the future or, if not, whether other financial recompense will be offered to the Company. As of December 31, 2021, the Company estimates that its commitments remaining to be incurred under these agreements are approximately $<span><ix:nonfraction id="fact-identifier-400" contextref="AsOf2021-12-31" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63.4</ix:nonfraction></span> million for 2022, $<span><ix:nonfraction id="fact-identifier-401" contextref="AsOf2021-12-31" name="us-gaap:OtherCommitmentDueInSecondYear" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.6</ix:nonfraction></span> million for 2023, and $<span><ix:nonfraction id="fact-identifier-402" contextref="AsOf2021-12-31" name="hgen:OtherCommitmentDueAfterTwoYear" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.4</ix:nonfraction></span> million thereafter. Certain of these commitments and amounts accrued at year-end are in dispute and the Company intends to defer these payments, negotiate lower amounts or seek legal recourse for the amounts in question.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Operating Leases</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">During a portion of 2020, the Company sub-leased office space under a short-term lease in Burlingame, California. The sub-lease initial term expired on March 31, 2020 and was renewed until September 1, 2020. On September 1, 2020, the Company entered into a one-year lease for a small office in the same building in Burlingame, California for $<span><ix:nonfraction id="fact-identifier-403" contextref="From2020-09-01to2020-09-30" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200</ix:nonfraction></span> per month which expired on <span><ix:nonnumeric id="fact-identifier-404" contextref="From2021-09-01to2021-09-30" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen" inside-table="false" data-original-id="Fact_0000000000399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">August 31, 2021</ix:nonnumeric></span>. On September 1, 2021, the Company entered into a new one-year lease with one-month free rent for a small office in the same building in Burlingame, California for $<span><ix:nonfraction id="fact-identifier-405" contextref="From2021-09-01to2021-09-30" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200</ix:nonfraction></span> per month which will expire on <span><ix:nonnumeric id="fact-identifier-406" contextref="From2020-09-01to2020-09-30" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen" inside-table="false" data-original-id="Fact_0000000000401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">September 30, 2022</ix:nonnumeric></span>. Management determined the lease term for each of the subleases and leases to be less than 12 months, including renewals, and therefore did not record a right-of-use asset and corresponding liability under the short-term lease recognition exemption.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Lease costs for the years ended December 31, 2021 and 2020 totaled approximately $<span><ix:nonfraction id="fact-identifier-407" contextref="From2021-01-01to2021-12-31" name="us-gaap:LeaseCost" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14</ix:nonfraction></span> thousand and $<span><ix:nonfraction id="fact-identifier-408" contextref="From2020-01-01to2020-12-31" name="us-gaap:LeaseCost" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span> thousand, respectively, and are included in the Consolidated Statements of Operations. As of December 31, 2021, the Company had future minimum lease payments of approximately $<span><ix:nonfraction id="fact-identifier-409" contextref="AsOf2021-12-31" name="hgen:OperatingLeasesFutureMinimumPayments" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11</ix:nonfraction></span> thousand. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Indemnification</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-410" contextref="From2021-01-01to2021-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000550" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">8. Stockholders Equity</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Reverse Stock Split</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Effective as of 4:30 p.m. Eastern Time on September 11, 2020 (the Effective Time), the Company amended its charter to effect a reverse stock split at a ratio of <span><ix:nonnumeric id="fact-identifier-411" contextref="From2020-01-01to2020-09-11_custom_EquityPlan2020Member" name="us-gaap:StockholdersEquityReverseStockSplit" inside-table="false" data-original-id="Fact_0000000000406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1-for-5</ix:nonnumeric></span> (the Split Ratio). No fractional shares were issued in connection with the reverse stock split. Stockholders of record otherwise entitled to receive fractional shares of common stock received cash (without interest or deduction) in lieu of such fractional share interests. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The reverse stock split reduced the total number of shares of the Companys common stock outstanding as of the Effective Time from approximately <span><ix:nonfraction id="fact-identifier-412" contextref="AsOf2020-09-11_srt_MaximumMember" name="us-gaap:CommonStockSharesOutstanding" unitref="Shares" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">210.9</ix:nonfraction></span> million shares to approximately <span><ix:nonfraction id="fact-identifier-413" contextref="AsOf2020-09-11_srt_MinimumMember" name="us-gaap:CommonStockSharesOutstanding" unitref="Shares" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42.2</ix:nonfraction></span> million shares. The par value per share and other terms of the Companys common stock were not affected by the reverse stock split, and the number of authorized shares of the Companys common stock remained at <span><ix:nonfraction id="fact-identifier-414" contextref="AsOf2020-09-11" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">225,000,000</ix:nonfraction></span>. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The reverse stock split resulted in a proportionate adjustment in the number of shares reserved for issuance under the 2020 Equity Plan, such that a total of <span><ix:nonfraction id="fact-identifier-415" contextref="AsOf2020-09-11_custom_EquityPlan2020Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,000,000</ix:nonfraction></span> shares of the Companys common stock were reserved for issuance under the 2020 Equity Plan following the Effective Time. In addition, proportionate adjustments were made to the number of shares covered by, and the exercise price applicable to, each outstanding stock option award under the 2012 Equity Plan and outstanding warrants issued by the Company, in each case to give effect to the Split Ratio and the reverse stock split. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-21</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The reverse stock split was accounted for retroactively and is reflected in the Companys common stock, stock option and warrant activity as of and during the year ended December 31, 2020. Unless stated otherwise, all share data and per share data in this Annual Report on Form 10-K have been adjusted, as appropriate, to reflect the reverse stock split. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">2020 Private Placement</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On June 1, 2020, the Company entered into a securities purchase agreement (the Purchase Agreement) with certain accredited investors (the Investors) to complete a private placement of the Companys common stock (the Private Placement). The closing of the Private Placement occurred on June 2, 2020 (the Closing Date). At the closing, the Company issued and sold <span><ix:nonfraction id="fact-identifier-416" contextref="From2020-06-01to2020-06-30_us-gaap_PrivatePlacementMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,505,743</ix:nonfraction></span> shares of its common stock (the Shares) at a purchase price of $<span><ix:nonfraction id="fact-identifier-417" contextref="AsOf2020-06-02_us-gaap_PrivatePlacementMember" name="us-gaap:CommonStockParOrStatedValuePerShare" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.35</ix:nonfraction></span> per share, for aggregate gross proceeds of approximately $<span><ix:nonfraction id="fact-identifier-418" contextref="From2020-06-01to2020-06-30_us-gaap_PrivatePlacementMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71.8</ix:nonfraction></span> million. The Company used a portion of the proceeds to retire certain indebtedness, as further described in Note 5. See Note 11 for information regarding two complaints filed against the Company in connection with the Private Placement. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On the Closing Date, the Company and the Investors also entered into a registration rights agreement (the Registration Rights Agreement) pursuant to which the Company agreed to prepare and file a registration statement (the Resale Registration Statement) for the resale of the Shares with the Securities and Exchange Commission. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Subject to certain limitations and an overall cap, the Company may be required to pay liquidated damages to the investors at a rate of 2% of the invested capital for each occurrence (and continuation for 30 consecutive days thereafter) of a breach by the Company of certain of its obligations under the Registration Rights Agreement. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Purchase Agreement also required that the Company use its commercially reasonable efforts to achieve a listing of the Common Stock on a national securities exchange, subject to certain limitations set forth in the Purchase Agreement. On July 6, 2020, the Company applied to have its common stock approved for listing on the Nasdaq Capital Market. On September 18, 2020, the Companys common stock commenced trading on the Nasdaq Capital Market under the symbol HGEN. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">2020 Underwritten Public Offering</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On September 17, 2020, the Company entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters, in connection with the public offering of <span><ix:nonfraction id="fact-identifier-419" contextref="From2020-09-01to2020-09-17_custom_UnderwrittenPublicOffering2020Member_custom_JPMorganSecuritiesLlcAndJefferiesLlcMember" name="hgen:SharesIssuedInPublicOffering" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8,000,000</ix:nonfraction></span> of the Companys shares of common stock. Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option to purchase an additional <span><ix:nonfraction id="fact-identifier-420" contextref="From2020-09-01to2020-09-17_custom_UnderwrittenPublicOffering2020Member_custom_JPMorganSecuritiesLlcAndJefferiesLlcMember" name="hgen:SharesIssuedToUnderwriters" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,200,000</ix:nonfraction></span> shares of common stock, which option was exercised in full by the underwriters on September 18, 2020. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">As a result of the pricing of the public offering, the Companys common stock commenced trading on the Nasdaq Capital Market under the symbol HGEN. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The aggregate gross proceeds from the sale of the full <span><ix:nonfraction id="fact-identifier-421" contextref="From2020-09-01to2020-09-17_custom_PartialUnderwrittenPublicOffering2020Member" name="hgen:SharesIssuedInPublicOffering" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9,200,000</ix:nonfraction></span> shares in the offering were approximately $<span><ix:nonfraction id="fact-identifier-422" contextref="From2020-09-01to2020-09-17_custom_PartialUnderwrittenPublicOffering2020Member" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78.2</ix:nonfraction></span> million. The Company expects to use the proceeds from the offering to support its manufacturing, production and commercial preparation activities relating to lenzilumab as a potential therapy for COVID-19 patients and for working capital and other general corporate purposes. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">2021 Underwritten Public Offering</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On March 30, 2021, we entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC, Credit Suisse Securities (USA) LLC and Cantor, as representatives of the several underwriters, in connection with the public offering of <span><ix:nonfraction id="fact-identifier-423" contextref="From2021-03-01to2021-03-30_custom_UnderwrittenPublicOffering2021Member_custom_JefferiesLlcMember" name="hgen:SharesIssuedInPublicOffering" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,000,000</ix:nonfraction></span> shares of our common stock. In addition, we granted the underwriters a 30-day option to purchase an additional <span><ix:nonfraction id="fact-identifier-424" contextref="From2021-03-01to2021-03-30_custom_UnderwrittenPublicOffering2021Member_custom_JefferiesLlcMember" name="hgen:TotalNumberOfSharesOfferedToUnderwriters" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">750,000</ix:nonfraction></span> shares of our common stock. The initial offering closed on April 5, 2021. On May 3, 2021, we closed on the sale of an additional <span><ix:nonfraction id="fact-identifier-425" contextref="From2021-05-01to2021-05-03_custom_UnderwrittenPublicOffering2021Member" name="hgen:SharesIssuedToUnderwriters" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">427,017</ix:nonfraction></span> shares of our common stock related to the exercise of the underwriters 30-day option. The aggregate gross proceeds from the sale of the <span><ix:nonfraction id="fact-identifier-426" contextref="From2021-03-01to2021-05-03_custom_UnderwrittenPublicOffering2021Member" name="hgen:SharesIssuedInPublicOffering" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,427,017</ix:nonfraction></span> shares in the offering, inclusive of the additional shares purchased by the underwriters, were approximately $<span><ix:nonfraction id="fact-identifier-427" contextref="From2021-03-01to2021-05-03_custom_UnderwrittenPublicOffering2021Member" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100.4</ix:nonfraction></span> million. The net proceeds from this offering, after deducting underwriting discounts and offering costs, were approximately $<span><ix:nonfraction id="fact-identifier-428" contextref="From2021-03-01to2021-05-03_custom_UnderwrittenPublicOffering2021Member" name="hgen:SaleOfStockConsiderationReceivedOnTransactionAfterOfferingCosts" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">94.2</ix:nonfraction></span> million. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-22</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-429" contextref="From2021-01-01to2021-12-31" name="hgen:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> The Company has reserved the following shares of common stock for issuance as of December 31, 2021: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="70.0354609929078%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:78%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Warrants to purchase common stock<span style="padding-left:2pt; "></span></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-430" contextref="AsOf2021-12-31" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,238</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="even" style=""> <td style="width:78%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options:<span style="padding-left:2pt; "></span></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:78%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Outstanding under the 2020 Equity Incentive Plan<span style="padding-left:2pt; "></span></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-431" contextref="AsOf2021-12-31_custom_EquityIncentivePlanTwentyTwentyMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,962,489</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="even" style=""> <td style="width:78%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Outstanding under the 2012 Equity Incentive Plan<span style="padding-left:2pt; "></span></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-432" contextref="AsOf2021-12-31_custom_EquityIncentivePlanTwentyTwelveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,467,417</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:78%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Available for future grants under the 2020 Equity Incentive Plan<span style="padding-left:2pt; "></span></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-433" contextref="From2021-01-01to2021-12-31_custom_EquityIncentivePlanTwentyTwentyMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,004,035</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="even" style=""> <td style="width:78%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:15%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-434" contextref="AsOf2021-12-31" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,465,179</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p></td></tr></tbody></table></div></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Controlled Equity Offering</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On December 31, 2020, the Company entered into the Sales Agreement with Cantor, under which the Company could issue and sell from time-to-time shares of the Companys common stock, having an aggregate gross sales price of up to $<span><ix:nonfraction id="fact-identifier-435" contextref="From2021-01-01to2021-12-31_custom_ControlledEquityOfferingSmSalesAgreementMember_custom_CantorFitzgeraldAndCoMember_srt_MaximumMember" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100.0</ix:nonfraction></span> million through Cantor, as sales agent. During the year ended December 31, 2021, the Company issued and sold <span><ix:nonfraction id="fact-identifier-436" contextref="From2021-01-01to2021-12-31_custom_ControlledEquityOfferingSmSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,408,087</ix:nonfraction></span> shares of common stock pursuant to the Sales Agreement, and received net proceeds of approximately $<span><ix:nonfraction id="fact-identifier-437" contextref="From2021-01-01to2021-12-31_custom_ControlledEquityOfferingSmSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65.7</ix:nonfraction></span> million, after deducting fees and expenses. As of December 31, 2021, the Company had the ability to offer and sell shares of common stock having an aggregate offering price of up to $<span><ix:nonfraction id="fact-identifier-438" contextref="AsOf2021-12-31_custom_ControlledEquityOfferingSmSalesAgreementMember_custom_CantorFitzgeraldAndCoMember_srt_MaximumMember" name="hgen:RemainingAvailableForSale" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">32.3</ix:nonfraction></span> million under the prospectus supplement dated August 13, 2021 to the Companys prospectus dated September 14, 2020 filed in respect of the Sales Agreement. See Note 13 below for additional information related to the Sales Agreement. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">2020 Equity Plan</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On July 27, 2020, the Board unanimously approved, and recommended that the Companys stockholders approve, the 2020 Equity Plan, to ensure that the Board and its compensation committee (the Compensation Committee) will be able to make the types of awards, and covering the number of shares, as necessary to meet the Companys compensatory needs. On July 29, 2020, the 2020 Equity Plan was approved by the holders of approximately <span><ix:nonfraction id="fact-identifier-439" contextref="AsOf2020-07-27_custom_EquityPlan2020Member" name="hgen:PercentageOfOutstandingSharesApprovedEquityPlan" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">63</ix:nonfraction></span>% of the Companys outstanding shares of common stock on that date. The 2020 Equity Plan became effective on September 11, 2020 following the Effective Time of the reverse stock split. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Immediately following the Effective Time, a total of <span><ix:nonfraction id="fact-identifier-440" contextref="AsOf2020-07-27_custom_EquityPlan2020Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,000,000</ix:nonfraction></span> shares of the Companys common stock were reserved for issuance under the 2020 Equity Plan. The Board or Compensation Committee may grant the following types of awards under the 2020 Equity Plan: stock options, stock appreciation rights, restricted stock, stock awards, restricted stock units, performance shares, performance units, cash-based awards and substitute awards. The 2020 Equity Plan will remain in effect until the tenth anniversary of its effective date, unless terminated earlier by the Board. For options, the per share exercise price may not be less than the fair market value of a Company common share on the date of grant. Options generally vest and become exercisable over <span><ix:nonnumeric id="fact-identifier-441" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" inside-table="false" data-original-id="Fact_0000000000436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three years</ix:nonnumeric></span> and expire <span><ix:nonnumeric id="fact-identifier-442" contextref="From2021-01-01to2021-12-31_custom_EquityIncentivePlanTwentyTwentyMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" inside-table="false" data-original-id="Fact_0000000000437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonnumeric></span> years from the date of grant. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">As of December 31, 2021, there were <span><ix:nonfraction id="fact-identifier-443" contextref="AsOf2021-12-31_custom_EquityPlan2020Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,004,035</ix:nonfraction></span> shares available for grant under the 2020 Equity Incentive Plan. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">2012 Equity Plan</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The 2020 Equity Plan replaced the 2012 Equity Plan, under which no further grants will be made. However, any outstanding awards under the 2012 Equity Plan will continue in accordance with the terms of the 2012 Equity Plan and any award agreement executed in connection with such outstanding awards. At the Effective Time of the reverse stock split, proportionate adjustments were made to the number of shares covered by, and the exercise price applicable to, each outstanding stock option award under the 2012 Equity Plan to give effect to the Split Ratio and the reverse stock split. Under the 2012 Equity Plan, the Company could grant shares, stock units, stock appreciation rights, performance cash awards and/or options to employees, directors, consultants, and other service providers. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">As of December 31, 2021, there were no shares available for grant under the 2012 Equity Incentive Plan. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-23</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Stock Option Activity</span> </p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-444" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> The following table summarizes stock option activity for the years ended December 31, 2021 and 2020: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Number of</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Shares</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Average</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Exercise</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Price (per</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">share)(1)</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted-</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Average</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Remaining</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Contractual</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Term </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(in years)</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Aggregate</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Intrinsic</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Value</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">($000's)(2)</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Outstanding at January 1, 2020<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-445" contextref="AsOf2019-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000439" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,176,336</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-446" contextref="AsOf2019-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.75</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Granted<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-447" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">985,164</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-448" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.35</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Exercised<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-449" contextref="From2020-01-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">429,330</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-450" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.55</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Cancelled (expired)<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-451" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-452" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58.40</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Outstanding at December 31, 2020<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-453" contextref="AsOf2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,732,149</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-454" contextref="AsOf2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.57</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Granted<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-455" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,444,176</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-456" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.58</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Exercised<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-457" contextref="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">582,936</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-458" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000452" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.98</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Cancelled (forfeited)<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-459" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,711</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-460" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000454" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.09</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Cancelled (expired)<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-461" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,772</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-462" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.71</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Outstanding at December 31, 2021<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-463" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,429,906</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-464" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.89</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-465" contextref="From2021-01-01to2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.4</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-466" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,087</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Options vested and expected to vest<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-467" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000461" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,281,658</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-468" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.77</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-469" contextref="From2021-01-01to2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.3</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-470" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,084</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:37%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Exercisable<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-471" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,951,257</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-472" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.08</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:12%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-473" contextref="From2021-01-01to2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.7</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-474" contextref="AsOf2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,017</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-3pt; margin-bottom:0pt; ">&nbsp; </p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td colspan="2" style="width:4%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">______________________ </p> </td> </tr> <tr class="even" style=""> <td style="width:4%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:12pt; margin-bottom:0pt; ">(1) </p> </td> <td style="width:96%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:12pt; margin-bottom:0pt; "><ix:footnote id="FN_619b843e2c08a27c7fd81efc" footnoterole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The weighted average price per share is determined using exercise price per share for stock options.</ix:footnote> </p> </td> </tr> <tr class="odd" style=""> <td style="width:4%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> <td style="width:96%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp; </p> </td> </tr> <tr class="even" style=""> <td style="width:4%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">(2) </p> </td> <td style="width:96%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><ix:footnote id="FN_621627d1c1256b3ad4a9b4a2" footnoterole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the option and the fair value of the Companys common stock for in-the-money options at December 31, 2021.</ix:footnote> </p></td></tr></tbody></table></div></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-475" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; text-indent:36pt; margin-bottom:0pt; "> The stock options outstanding and exercisable by exercise price at December 31, 2021 are as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="89.71631205673759%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Stock Options Outstanding</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Stock Options Exercisable</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted-</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Average </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Remaining</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted-</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Average</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted-</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Average</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Contractual</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Exercise</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Exercise</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Number</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Life</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Price</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Number of</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Price</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:33%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Range of Exercise Prices</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">of Shares</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">In Years</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Per Share</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Shares</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Per Share</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$<span><ix:nonfraction id="fact-identifier-476" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.90</ix:nonfraction></span> - $<span><ix:nonfraction id="fact-identifier-477" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.25</ix:nonfraction></span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-478" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">216,795</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-479" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.00</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-480" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.16</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-481" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">169,069</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-482" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars1.90To2.25Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.14</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$<span><ix:nonfraction id="fact-identifier-483" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars3.33Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.33</ix:nonfraction></span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-484" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars3.33Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000478" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,894,168</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-485" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars3.33Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.18</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-486" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars3.33Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.33</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-487" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars3.33Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000481" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,894,168</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-488" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars3.33Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.33</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$<span><ix:nonfraction id="fact-identifier-489" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.50</ix:nonfraction></span> - $<span><ix:nonfraction id="fact-identifier-490" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.65</ix:nonfraction></span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-491" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">987,674</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-492" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000486" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.04</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-493" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000487" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.92</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-494" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000488" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">328,349</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-495" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars3.50To9.65Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.33</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$<span><ix:nonfraction id="fact-identifier-496" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.64</ix:nonfraction></span> - $<span><ix:nonfraction id="fact-identifier-497" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.90</ix:nonfraction></span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-498" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">274,425</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-499" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.17</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-500" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000494" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14.22</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-501" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113,174</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-502" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To16.90Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000496" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.86</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$<span><ix:nonfraction id="fact-identifier-503" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars16.07Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000497" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.07</ix:nonfraction></span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-504" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars16.07Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000498" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">733,240</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-505" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars16.07Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000499" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.21</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-506" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars16.07Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.07</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-507" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars16.07Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">183,310</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-508" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars16.07Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.07</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$<span><ix:nonfraction id="fact-identifier-509" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.90</ix:nonfraction></span> - $<span><ix:nonfraction id="fact-identifier-510" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000504" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.00</ix:nonfraction></span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-511" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">293,604</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-512" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000506" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.40</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-513" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17.19</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-514" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">258,187</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-515" contextref="AsOf2021-12-31_custom_ExercisePriceRangeFromDollars16.90To20.00Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000509" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.96</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$<span><ix:nonfraction id="fact-identifier-516" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars20.68Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.68</ix:nonfraction></span><span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-517" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars20.68Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000511" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,000</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-518" contextref="From2021-01-01to2021-12-31_custom_ExercisePriceRangeDollars20.68Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.43</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-519" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars20.68Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.68</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-520" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars20.68Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-521" contextref="AsOf2021-12-31_custom_ExercisePriceRangeDollars20.68Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.68</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:33%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-522" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000516" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,429,906</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-523" contextref="From2021-01-01to2021-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.40</ix:nonnumeric></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-524" contextref="AsOf2021-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.89</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-525" contextref="AsOf2021-12-31" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000519" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,951,257</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:11%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-526" contextref="AsOf2021-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.08</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; text-indent:36pt; margin-bottom:0pt; ">The total fair value of options vested for the years ended December 31, 2021 and 2020 was $<span><ix:nonfraction id="fact-identifier-527" contextref="From2021-01-01to2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span> million and $<span><ix:nonfraction id="fact-identifier-528" contextref="From2020-01-01to2020-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000523" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.2</ix:nonfraction></span> million, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-24</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Stock-Based Compensation</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Companys stock-based compensation expense for stock options is estimated at the grant date based on the awards fair value as calculated by the Black-Scholes option pricing model and is recognized as expense over the requisite service period. The Black-Scholes option pricing model requires various highly judgmental assumptions including expected volatility and expected term. The expected volatility is based on the combined historical stock volatilities of the Companys own common stock and that of its publicly listed peers over a period equal to the expected terms of the options as the Company does not have a sufficient trading history to rely solely on the volatility of its own common stock. To estimate the expected term, the Company has opted to use the simplified method, which is the use of the midpoint of the vesting term and the contractual term. If any of the assumptions used in the Black-Scholes option pricing model changes significantly, stock-based compensation expense may differ materially in the future from that recorded in the current period. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.</p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-529" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> The weighted-average fair value-based measurement of stock options granted under the Companys stock plans in the years ended December 31, 2021 and 2020 was $<span><ix:nonfraction id="fact-identifier-530" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.32</ix:nonfraction></span> and $<span><ix:nonfraction id="fact-identifier-531" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitref="Usdpershares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.35</ix:nonfraction></span> per share, respectively. The fair value-based measurement of stock options granted under the Companys stock plans was estimated at the date of grant using the Black-Scholes model with the following assumptions: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="3" style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year Ended December 31,</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:15%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected term<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-532" contextref="From2021-01-01to2021-12-31_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span> - <span><ix:nonnumeric id="fact-identifier-533" contextref="From2021-01-01to2021-12-31_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonnumeric></span> years </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonnumeric id="fact-identifier-534" contextref="From2020-01-01to2020-12-31_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span> - <span><ix:nonnumeric id="fact-identifier-535" contextref="From2020-01-01to2020-12-31_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" inside-table="true" data-original-id="Fact_0000000000529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonnumeric></span> years </p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected volatility<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-536" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104</ix:nonfraction></span>% - <span><ix:nonfraction id="fact-identifier-537" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">109</ix:nonfraction></span>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-538" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">95</ix:nonfraction></span>% - <span><ix:nonfraction id="fact-identifier-539" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">111</ix:nonfraction></span>% </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-540" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.98</ix:nonfraction></span>% - <span><ix:nonfraction id="fact-identifier-541" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000535" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.35</ix:nonfraction></span>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-542" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.28</ix:nonfraction></span>% - <span><ix:nonfraction id="fact-identifier-543" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000537" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.57</ix:nonfraction></span>% </p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected dividend yield<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-544" contextref="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000538" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:15%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-545" contextref="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>% </p></td></tr></tbody></table></div></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-546" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; text-indent:36pt; margin-bottom:0pt; "> Total expense for stock option grants recognized was as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year Ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">General and administrative<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-547" contextref="From2021-01-01to2021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000541" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,028</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-548" contextref="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000542" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,773</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-549" contextref="From2021-01-01to2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,340</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-550" contextref="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">337</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total stock-based compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-551" contextref="From2021-01-01to2021-12-31" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000545" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,368</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-552" contextref="From2020-01-01to2020-12-31" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,110</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; text-indent:36pt; margin-bottom:0pt; ">At December 31, 2021, the Company had $<span><ix:nonfraction id="fact-identifier-553" contextref="AsOf2021-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.2</ix:nonfraction></span> million of total unrecognized compensation expense, net of estimated forfeitures, related to outstanding stock options that will be recognized over a weighted-average period of <span><ix:nonnumeric id="fact-identifier-554" contextref="From2021-01-01to2021-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" inside-table="false" data-original-id="Fact_0000000000549" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonnumeric></span> years. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-555" contextref="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000604" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">9. Income Taxes</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">No provision for federal income taxes has been recorded for the years ended December 31, 2021 and 2020 due to net losses and the valuation allowance established.</p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-556" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryovers and the temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">As of December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Deferred tax assets: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Net operating losses<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-557" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000551" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,732</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-558" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,149</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Research and other credits<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-559" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,178</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-560" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,178</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Stock based compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-561" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,354</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-562" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,256</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">In-Process research and development<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-563" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,132</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-564" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000558" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,193</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:10pt; margin-bottom:0pt; ">Other<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-565" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsOther" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">230</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-566" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsOther" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">665</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total deferred tax assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-567" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsGross" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,626</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-568" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsGross" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000562" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,441</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&nbsp;<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Valuation allowance<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-569" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,626</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-570" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,441</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:68%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net deferred tax assets<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-571" contextref="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000565" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-572" contextref="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-25</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-573" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 2021 and 2020 is as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:66%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year Ended December 31,</span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:66%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:2%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:2%; border-bottom:0.7pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:66%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Statutory rate<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-574" contextref="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000568" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-575" contextref="From2020-01-01to2020-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000569" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> </tr> <tr class="even" style=""> <td style="width:66%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Valuation allowance<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-576" contextref="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28.5</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<span><ix:nonfraction id="fact-identifier-577" contextref="From2020-01-01to2020-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" sign="-" inside-table="true" data-original-id="Fact_0000000000571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27.9</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)% </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:66%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Nondeductible stock compensation<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-578" contextref="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-579" contextref="From2020-01-01to2020-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitref="Pure" scale="-2" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000573" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> </tr> <tr class="even" style=""> <td style="width:66%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Other<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-580" contextref="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.1</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:0.7pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-581" contextref="From2020-01-01to2020-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.9</ix:nonfraction></span> </p> </td> <td style="width:2%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:66%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Effective tax rate<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-582" contextref="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitref="Pure" scale="-2" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000576" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-583" contextref="From2020-01-01to2020-12-31" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitref="Pure" scale="-2" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; ">% </p></td></tr></tbody></table></div></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; text-indent:36pt; margin-bottom:0pt; ">On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act tax reform legislation. This legislation makes significant change in U.S. tax law including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate tax rate from <span><ix:nonfraction id="fact-identifier-584" contextref="From2021-01-01to2021-12-31_srt_MaximumMember" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35</ix:nonfraction></span>% to <span><ix:nonfraction id="fact-identifier-585" contextref="From2021-01-01to2021-12-31_srt_MinimumMember" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21</ix:nonfraction></span>%. As a result of the enacted law, the Company was required to revalue deferred tax assets and liabilities at the 21% for the year ended December 31, 2017. This revaluation resulted in additional income tax expense of $<span><ix:nonfraction id="fact-identifier-586" contextref="From2021-01-01to2021-12-31" name="us-gaap:ResultsOfOperationsIncomeTaxExpense" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000581" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.6</ix:nonfraction></span> million in continuing operations, a corresponding reduction in the net deferred tax asset, an additional income tax benefit of $<span><ix:nonfraction id="fact-identifier-587" contextref="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxExpenseBenefit" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000582" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.6</ix:nonfraction></span> million, and a corresponding reduction in the valuation allowance on net deferred tax assets. The other provisions of the Tax Cuts and Jobs Act did not have a material impact on the 2017, 2018 or 2019 consolidated financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $<span><ix:nonfraction id="fact-identifier-588" contextref="From2021-01-01to2021-12-31" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68.2</ix:nonfraction></span> million during 2021 and increased by $<span><ix:nonfraction id="fact-identifier-589" contextref="From2020-01-01to2020-12-31" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000584" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.0</ix:nonfraction></span> million during 2020.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">At December 31, 2021, the Company had federal net operating loss carryforwards of approximately $<span><ix:nonfraction id="fact-identifier-590" contextref="AsOf2021-12-31_us-gaap_InternalRevenueServiceIRSMember" name="us-gaap:OperatingLossCarryforwards" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000585" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166.2</ix:nonfraction></span> million, which expire in the years <span style="-sec-ix-hidden:Fact_0000000000586"><span><ix:nonnumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextref="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MinimumMember" id="fact-identifier-591" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="Fact_0000000000586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2022</ix:nonnumeric></span></span> through <span style="-sec-ix-hidden:Fact_0000000000587"><span><ix:nonnumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextref="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MaximumMember" id="fact-identifier-592" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="Fact_0000000000587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2037</ix:nonnumeric></span></span>, and state net operating loss carryforwards of approximately $<span><ix:nonfraction id="fact-identifier-593" contextref="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember" name="us-gaap:OperatingLossCarryforwards" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">522.5</ix:nonfraction></span> million, which expire in the years <span style="-sec-ix-hidden:Fact_0000000000589"><span><ix:nonnumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextref="From2021-01-01to2021-12-31_us-gaap_StateAndLocalJurisdictionMember_srt_MinimumMember" id="fact-identifier-594" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="Fact_0000000000589" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2028</ix:nonnumeric></span></span> through <span style="-sec-ix-hidden:Fact_0000000000590"><span><ix:nonnumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextref="From2021-01-01to2021-12-31_us-gaap_StateAndLocalJurisdictionMember_srt_MaximumMember" id="fact-identifier-595" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="Fact_0000000000590" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2041</ix:nonnumeric></span></span>. The Company also has federal net operating loss carryforwards generated in the years 2018 through 2021 of $<span><ix:nonfraction id="fact-identifier-596" contextref="AsOf2018-12-31_us-gaap_InternalRevenueServiceIRSMember" name="us-gaap:OperatingLossCarryforwards" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000591" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">346.9</ix:nonfraction></span> million that have no expiration date as a result of the December 22, 2017 tax law changes discussed above.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">At December 31, 2021, the Company had federal research and development credit carryforwards of approximately $<span><ix:nonfraction id="fact-identifier-597" contextref="AsOf2021-12-31_us-gaap_InternalRevenueServiceIRSMember_us-gaap_ResearchMember" name="us-gaap:TaxCreditCarryforwardAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000592" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span> million, which expire in the years <span style="-sec-ix-hidden:Fact_0000000000593"><span><ix:nonnumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextref="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_us-gaap_ResearchMember_srt_MinimumMember" id="fact-identifier-598" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="Fact_0000000000593" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2022</ix:nonnumeric></span></span> through <span style="-sec-ix-hidden:Fact_0000000000594"><span><ix:nonnumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextref="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_us-gaap_ResearchMember_srt_MaximumMember" id="fact-identifier-599" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="Fact_0000000000594" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2035</ix:nonnumeric></span></span> and state research and development credit carryforwards of approximately $<span><ix:nonfraction id="fact-identifier-600" contextref="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember" name="us-gaap:TaxCreditCarryforwardAmount" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.2</ix:nonfraction></span> million. The state research and development credit carryforwards can be carried forward indefinitely.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">During 2013, the Company completed a Section 382 study in accordance with the Internal Revenue Code of 1986, as amended, and similar state provisions. The study concluded that the Company has experienced several ownership changes since inception. This causes the Company's utilization of its net operating loss and tax credit carryforwards to be subject to substantial annual limitations. These results are reflected in the above carryforward amounts and deferred tax assets. The Company's ability to utilize its net operating loss and tax credit carryforwards are further limited as a result of subsequent ownership changes. All such limitations could result in the expiration of carryforwards before they are utilized. An ownership change may have occurred during 2015 or 2016 or 2017 or 2018, or all four years and in connection with the Restructuring Transactions that occurred in 2018. As a result, tax attributes such as net operating losses and research and development credits may be subject to further limitation.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">FASB ASC 740 requires that the Company recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination.</p> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-601" contextref="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000603" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; "> A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="79.7872340425532%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:84%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance at December 31, 2019<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-602" contextref="AsOf2019-12-31" name="us-gaap:UnrecognizedTaxBenefits" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000596" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,060</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:84%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Additions based on tax positions related to prior year<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-603" contextref="From2020-01-01to2020-12-31" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:84%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Additions based on tax positions related to current year<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-604" contextref="From2020-01-01to2020-12-31" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:84%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance at December 31, 2020<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-605" contextref="AsOf2021-12-31" name="us-gaap:UnrecognizedTaxBenefits" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,060</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:84%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Additions based on tax positions related to prior year<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-606" contextref="From2021-01-01to2021-12-31" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:84%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Additions based on tax positions related to current year<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:0.7pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-607" contextref="From2021-01-01to2021-12-31" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitref="Usd" xsi:nil="true" inside-table="true" data-original-id="Fact_0000000000601" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:84%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance at December 31, 2021<span style="padding-left:2pt; "></span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:13%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><span><ix:nonfraction id="fact-identifier-608" contextref="AsOf2020-12-31" name="us-gaap:UnrecognizedTaxBenefits" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="true" data-original-id="Fact_0000000000602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,060</ix:nonfraction></span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; text-indent:36pt; margin-bottom:0pt; ">There were no interest or penalties related to unrecognized tax benefits. Substantially all of the unrecognized tax benefit, if recognized to offset future taxable income would affect the Companys tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. Because of net operating loss carryforwards, substantially all of the Companys tax years remain open to federal tax and state tax examination.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-26</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company files income tax returns in the U.S. federal jurisdiction, California and Florida. Federal and California corporation income tax returns beginning with the 2001 tax year remain subject to examination by the Internal Revenue Service and the California Franchise Tax Board and the Florida corporate income tax returns beginning with 2018 remain subject to examination by the Florida Department of Revenue, respectively. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-609" contextref="From2021-01-01to2021-12-31" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000606" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">10. Employee Benefit Plan</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company has established a 401(k) tax-deferred savings plan (the 401(k) Plan), which permits participants to make contributions by salary deduction pursuant to Section 401(k) of the Internal Revenue Code. The Company is responsible for administrative costs of the 401(k) Plan. The Company may, at its discretion, make matching contributions to the 401(k) Plan. The Company contributed $<span><ix:nonfraction id="fact-identifier-610" contextref="From2021-01-01to2021-12-31" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitref="Usd" decimals="-3" scale="3" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,000</ix:nonfraction></span> in matching contributions to the 401(k) Plan for the year ended December 31, 2021. No employer contribution was made to the plan for the year ended December 31, 2020. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-611" contextref="From2021-01-01to2021-12-31" name="us-gaap:LegalMattersAndContingenciesTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">11. Litigation</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Avid Arbitration</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On December 17, 2021, Avid Bioservices, Inc. (Avid) filed a Demand for Arbitration claiming more than $<span><ix:nonfraction id="fact-identifier-612" contextref="From2021-12-01to2021-12-17_custom_AvidArbitrationMember" name="us-gaap:LossContingencyDamagesSoughtValue" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000607" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.5</ix:nonfraction></span> million in damages against the Company with the American Arbitration Association entitled, <span style="font-style:italic; ">Avid Bioservices, Inc. v. Humanigen, Inc.</span> (AAA Case No. 01-21-0018-0523). The Demand contains three claims for: (1) Breach of Contract concerning the Process Development and Manufacturing Master Services Agreement; (2) Anticipatory Breach of Contract concerning the Capacity Expansion and Contribution/Commitment letter; and (3) Trade Libel and Commercial Disparagement relating to their inability to perform. Avid claims that the Company cancelled the contract after Avid was unable to successfully produce any full batches of lenzilumab BDS, but that the Company still owes the full amount due under the contract for all batches never produced. Avid blamed its failed attempts on a subcontractor. To date, the Company has paid Avid $<span><ix:nonfraction id="fact-identifier-613" contextref="From2021-12-01to2021-12-17_custom_AvidArbitrationMember" name="us-gaap:LossContingencyDamagesPaidValue" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000608" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.6</ix:nonfraction></span> million, despite Avid not being able to produce any full BDS batches. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On January 6, 2022, the Company filed an Answer to Avids Demand, denying the allegations and asserting affirmative defenses. An Arbitration Hearing date has not yet been scheduled.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company will vigorously defend itself, assert all available claims against Avid, and seek all available remedies.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Savant Litigation</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">The Company is currently involved in litigation with Savant in an action captioned Humanigen, Inc. v. Savant Neglected Diseases, LLC, C.A. No. N17C-07-068-PRW [CCLD]. In this litigation, the Company filed a complaint against Savant in the Superior Court of the State of Delaware, New Castle County (the Superior Court). The Company asserted breach of contract, declaratory judgment and fraudulent inducement claims against Savant arising under the MDC Agreement.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Subsequently, Savant filed a complaint against the Company and Madison Joint Venture LLC (Madison) in the Delaware Court of Chancery (the Chancery Action) seeking to recover as damages amounts owed to it under the MDC Agreement, and to reclaim Savants intellectual property, among other things. This action was subsequently consolidated with the Superior Court action.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On July 9, 2021, the Court issued a memorandum opinion resolving various summary judgment motions. In the opinion, the Court granted the Companys motion for summary judgment on certain of Savants claims. Accordingly, Savants claims are now limited to breach of contract and fraudulent transfer claims. Savants summary judgment motion was denied in its entirety leaving Humanigens fraud and contract claims against Savant for trial.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On November 22, 2021, the Court held a scheduling conference regarding the trial date. Subsequently, on December 15, 2021, the Court scheduled a five-day jury for the week of September 12, 2022, with a pre-trial conference scheduled for August 12, 2022. The Company is prepared to defend itself vigorously and pursue all remedies available against Savant for breach of contract and fraud.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Private Placement Litigation</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On June 15, 2020, a complaint was filed against the Company and Dr. Durrant in the Commercial Division of the Supreme Court of the State of New York. The case caption is <span style="font-style:italic; ">Alliance Texas Holdings, LLC et al. v. Humanigen, Inc. et al.</span>, Index No. 652490/2020 (Alliance Texas Holdings Case). Dr. Durrant has been dismissed as an individual defendant in the case. The plaintiffs in the Alliance Texas Holdings Case comprise a group of prospective investors introduced to Humanigen by Noble Capital Markets, Inc. (Noble), which had been engaged by the Company as a non-exclusive placement agent in connection with a private placement of its common stock (the Private Placement). The plaintiffs had indicated interest in purchasing shares of common stock in the Private Placement but, due to the strength of demand for shares from other prospective investors, the plaintiffs were not allocated any investment amount. The plaintiffs allege that the Company breached a contractual obligation to deliver shares of common stock to the plaintiffs. The plaintiffs seek to recover for losses due to the Companys alleged failure to deliver shares to them and seek equitable relief in the form of specific performance. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-27</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On April 19, 2021, the Company and Noble entered into a confidential settlement agreement in respect of a separate lawsuit brought by Noble related to the Private Placement (the Noble Case) captioned Noble Capital Markets, Inc. v. Humanigen, Inc., Case No. 9:20-CV-81131-WPD, pursuant to which the Noble Case was dismissed with prejudice.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On <span><ix:nonnumeric id="fact-identifier-614" contextref="From2022-02-01to2022-02-24_custom_AllianceTexasHoldingCaseMember_custom_TwoPlaintiffsMember_us-gaap_SubsequentEventMember" name="us-gaap:LossContingencySettlementAgreementDate" inside-table="false" data-original-id="Fact_0000000000609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">February 24, 2022</ix:nonnumeric></span>, the Company entered into a confidential settlement agreement and release with respect to the claims raised in the Alliance Texas Holding Case, pursuant to which the Alliance Texas Holding Case has been discontinued with prejudice, except as to two Plaintiffs whose claims comprised less than <span><ix:nonfraction id="fact-identifier-615" contextref="From2022-02-01to2022-02-24_custom_AllianceTexasHoldingCaseMember_srt_MinimumMember_custom_TwoPlaintiffsMember_us-gaap_SubsequentEventMember" name="hgen:LossContingencySettlementAgreementPercentage" unitref="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span>% of the total alleged investments, as to whom the case will be discontinued without prejudice. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-616" contextref="From2021-01-01to2021-12-31" name="hgen:LicenseAndCollaborationAgreementsTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">12. License and Collaboration Agreements</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Kite Agreement</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On May 30, 2019, the Company entered into a collaboration agreement (the Kite Agreement) with Kite Pharmaceuticals, Inc. (Kite), pursuant to which the Company and Kite are conducting a multi-center Phase 1b/2 study of lenzilumab with Kites Yescarta in patients with relapsed or refractory B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL). On April 19, 2021, the Company announced positive preliminary data from this study. As a result of this positive preliminary data and the conclusion of the Phase 1b portion of the study, the Company elected to terminate the clinical collaboration agreement with Kite. Enrollment in the Phase 1b portion of the study is closed and the study itself shall be closed by the fourth quarter of 2021. The effective date of termination of the clinical collaboration with Kite was December 31, 2021. Until the Phase 1b portion of the study is terminated and the last subject transitioned onto the Kite long term follow up protocol, Humanigen and Kite will cooperate to ensure the orderly wind down of study activities. The Company is preparing to initiate a Company-sponsored Phase 3 study with commercially available CD19 CAR-T therapies in non-Hodgkin lymphoma in 2022 and met with FDA in December 2021 to discuss the study protocol. The Company currently plans to enroll more than 150 patients in the study. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">During the years ended December 31, 2021 and 2020, the Company paid $<span><ix:nonfraction id="fact-identifier-617" contextref="From2021-01-01to2021-12-31_custom_KiteAgreementMember" name="hgen:AmountPaidInLicenseAgreement" unitref="Usd" decimals="-5" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0</ix:nonfraction></span> and $<span><ix:nonfraction id="fact-identifier-618" contextref="From2020-01-01to2020-12-31_custom_KiteAgreementMember" name="hgen:AmountPaidInLicenseAgreement" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span> million, respectively, to Kite towards its contribution for the study, which payments were recorded as Research and development expense. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Mayo Agreement</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On June 19, 2019, the Company entered into an exclusive worldwide license agreement (the Mayo Agreement) with the Mayo Foundation for Medical Education and Research (Mayo) for certain technologies used to create CAR-T cells lacking GM-CSF expression through various gene-editing tools including CRISPR-Cas9 (GM-CSF<sup>KO</sup> CAR-T). The license covers various patent applications and know-how developed by Mayo in collaboration with the Company. These licensed technologies complement and broaden the Companys position in the GM-CSF neutralization space and expand the Companys discovery platform aimed at improving CAR-T to include gene-edited CAR-T cells. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Pursuant to the Mayo Agreement, the Company paid $<span><ix:nonfraction id="fact-identifier-619" contextref="From2020-01-01to2020-06-30_custom_MayoAgreementMember" name="hgen:AmountPaidInLicenseAgreement" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span> million to Mayo in June 2020, which payment was accrued as Research and development expense in June 2019. The Mayo Agreement also requires the payment of milestones and royalties upon the achievement of certain regulatory and commercialization milestones. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Zurich Agreement</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On July 19, 2019, the Company entered into an exclusive worldwide license agreement (the Zurich Agreement) with the University of Zurich (UZH) for technology used to prevent or treat GvHD through GM-CSF neutralization. The Zurich Agreement covers various patent applications filed by UZH which complement and broaden the Companys position in the application of GM-CSF and expands the Companys development platform to include improving allogeneic Hematopoietic Stem Cell Transplantation (HSCT). The Zurich Agreement requires the payment of nominal annual maintenance fees and milestones and royalties upon the achievement of certain regulatory and commercialization milestones. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On July 24, 2020, the Company entered into a clinical trial agreement (the ACTIV-5 Clinical Trial Agreement) with the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, which is part of the U.S. Government Department of Health and Human Services, as represented by the Division of Microbiology and Infectious Diseases. Pursuant to the ACTIV-5 Clinical Trial Agreement, lenzilumab is being evaluated in the NIAID-sponsored ACTIV-5/BET-B in hospitalized patients with COVID-19. The ACTIV-5/BET-B study protocol was modified to include baseline CRP below 150 mg/L (the CRP subgroup) as the primary analysis population. The ACTIV-5/BET-B study has reached its target enrollment with over 400 patients enrolled that met this criterion and the Company anticipates top-line data in late first quarter or early second quarter of 2022. See Note 1 above for further information regarding ACTIV-5/BET-B. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-28</p> </div><hr style="border-top:1.5pt solid #000000;"><div style="page-break-after:always;"></div>
<p style="font-size:10pt;"><a href="#toc" tabindex="18">Table of Contents</a></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Pursuant to the ACTIV-5 Clinical Trial Agreement, NIAID will serve as sponsor and is responsible for funding, supervising and overseeing ACTIV-5/BET-B. The Company will be responsible for providing lenzilumab to NIAID without charge and in quantities to ensure a sufficient supply of lenzilumab. The ACTIV-5 Clinical Trial Agreement imposes additional obligations on the Company that are reasonable and customary for clinical trial agreements of this nature, including in respect of compliance with data privacy laws and potential indemnification obligations. The Company will have access to data from ACTIV-5/BET-B once concluded. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; font-style:italic; ">CRADA</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On November 5, 2020, the Company and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND or JPEO) entered into a Cooperative Research and Development Agreement (CRADA) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), in support of Operation Warp Speed (OWS), to assist in the development of lenzilumab, in connection with a potential EUA for COVID-19. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Pursuant to the CRADA, the Company has been provided access to a full-scale, integrated team of OWS manufacturing, and regulatory subject matter experts, leading decision makers and statistical support in its efforts to apply for EUA for lenzilumab as a potential treatment for COVID-19. </p></ix:nonnumeric></span> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric id="fact-identifier-620" contextref="From2021-01-01to2021-12-31" name="us-gaap:SubsequentEventsTextBlock" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="Fact_0000000000618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">13. Subsequent Events</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">Subsequent to December 31, 2021 and through the date of this filing, the Company issued and sold <span><ix:nonfraction id="fact-identifier-621" contextref="From2022-01-01to2022-02-28_custom_ControlledEquityOfferingSmSalesAgreementMember_us-gaap_SubsequentEventMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitref="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,301,548</ix:nonfraction></span> shares of common stock under the Sales Agreement for net proceeds of $<span><ix:nonfraction id="fact-identifier-622" contextref="From2022-01-01to2022-02-28_custom_ControlledEquityOfferingSmSalesAgreementMember_us-gaap_SubsequentEventMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="Usd" decimals="-5" scale="6" format="ixt:numdotdecimal" inside-table="false" data-original-id="Fact_0000000000617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.7</ix:nonfraction></span> million.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">On February 24, 2022, the Company entered into a confidential settlement agreement and release with respect to the claims raised in the Alliance Texas Holding Case. See Note 11 above for further information. </p></ix:nonnumeric></span>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:36pt; margin-bottom:0pt; ">&nbsp;</p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F-29</p> </div><hr style="border-top:1.5pt solid #000000;"> </div> </div>
  


</body>
</html>